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Abstract 
Intensified efforts to promote protective T cell-based immunity in vaccines and 
immunotherapies have created a compelling need to expand our understanding of human 
T cell function and maintenance beyond its characterization in peripheral blood. The 
paradigm that memory T lymphocytes are continuously circulating through the body in 
search of their cognate antigen has been recently challenged by the discovery of memory 
T cells residing in a variety of tissues, including the bone marrow (BM). However, the 
division of labor and lifestyle of circulating versus tissue resident memory T cells remains 
poorly understood. 
Previous work of our group has shown that the human BM is home to a great number of 
memory T cells. Despite of CD69 expression, BM memory T cells are resting in terms of 
transcription profile, proliferation and migration. Moreover, BM memory CD4+ T cells 
contain a wide array of antigen specificities, and show high protective potential, being 
mostly polyfunctional. Interestingly, memory CD4+ T cells specific for systemic childhood 
antigens, like measles, mumps or rubella have been found in the BM of elderly humans, 
even when they were no longer detectable in peripheral blood (PB) circulation. From these 
results, we hypothesized that BM memory T cells are resident, resting and maintain long-
term memory to systemic antigens. The survival mechanisms involved in the maintenance 
of circulating and BM resident memory T cells; as well as the capacities of tissue resident 
memory T cells to be reactivated and mobilized into blood circulation after systemic 
antigen re-challenge to confer us with immune protection remains to be elucidated. 
In this doctoral thesis, I have shown that PB and BM memory T cells have different 
survival capacities, as well as identified the role of soluble factors and direct contact with 
stromal cells in their maintenance, and the molecular mechanisms underlying. Moreover, 
using flow cytometric and sequencing analysis of the TCRβ repertoire, I have determined 
that PB and BM memory T cells are separated cell populations, highly compartmentalized 
in their respective tissues. Finally, by tracking the dynamics of antigen-specific memory 
CD4+ T cells after systemic MMR re-vaccination I could show that TRM CD4+ T cells 
specific for systemic antigens can be rapidly mobilized into blood circulation and contribute 
to the immune response. Taken together, these studies provide a more comprehensive 
understanding of the function and maintenance of immunological memory in humans. 
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Zusammenfassung 
Verstärkte Anstrengungen zur Förderung der T-Zell-basierten Immunität in Impfstoffen und 
Therapien haben eine zwingende Notwendigkeit für unser Verständnis der menschlichen 
T-Zell-Funktion und -Erhaltung, die über eine Charakterisierung in peripheren Blut 
hinausgehen, geschaffen. Das Paradigma, dass Gedächtnis-T-Lymphozyten kontinuierlich 
auf der Suche nach ihrem Antigen durch den Körper zirkulieren wurde vor kurzem durch 
die Entdeckung der Gedächtnis-T-Zellen, die in einer Vielzahl von Geweben, 
einschließlich des Knochenmarks (BM) angesiedelt sind, herausgefordert. Allerdings bleibt 
der Unterschied zwischen Funktionsweise und Lebensstil von zirkulierenden und 
gewebeansässigen Gedächtnis-T-Zellen nur unzulänglich verstanden. 
Vorhergehende Arbeiten unserer Gruppe haben gezeigt, dass das menschliche 
Knochenmark die Heimat für eine große Anzahl Gedächtnis-T-Zellen ist. Gedächtnis-T-
Zellen im Knochenmark sind trotz CD69 Expression hinsichtlich ihres Transkriptionsprofils, 
der Proliferation und Migration ruhend. Zusätzlich beinhalten CD4+ Gedächtnis-T-Zellen 
aus dem Knochenmark ein breites Spektrum an Antigenspezifitäten und ein hohes 
protektives Potential, da sie größtenteils polyfunktional sind. Interessanterweise wurden 
CD4+ Gedächtnis-T-Zellen spezifisch für systemische Kindheitsantigene wie Masern, 
Mumps oder Röteln im Knochenmark von älteren Menschen gefunden, auch wenn sie 
nicht mehr in der peripheren Blutzirkulation nachgewiesen werden konnten. Aus diesen 
Ergebnissen ziehen wir die Hypothese, dass Gedächtnis-T-Zellen aus dem Knochenmark 
sesshaft und ruhend sind und das Langzeitgedächtnis gegen systemische Antigene 
erhalten. Sowohl der Überlebensmechanismus, der den Erhalt von zirkulierenden und 
knochenmarksansässigen Gedächtnis-T-Zellen ermöglicht, als auch die Kapazität von 
gewebsansässigen Gedächtnis-T-Zellen nach einer systemischen Herausforderung mit 
Antigen reaktiviert und in die Blutzirkulation mobilisiert zu werden, um uns Immunschutz 
zu verleihen, sind bisher nur unzureichend geklärt. 
In dieser Dissertation habe ich gezeigt, dass Gedächtnis-T-Zellen aus dem peripheren Blut 
und Knochenmark unterschiedliche Überlebensfähigkeiten haben. Weiterhin habe ich die 
Rolle von löslichen Faktoren und dem direkten Kontakt zu Stroma Zellen in ihrer Erhaltung 
sowie die zugrundeliegenden molekularen Mechanismen identifiziert. Zudem habe ich 
mittels Durchflusszytometrie und Sequenzanalysen des TCRβ Repertoires bestimmt, dass 
Gedächtnis-T-Zellen aus dem peripheren Blut und Knochenmark unterschiedliche 
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Zellpopulationen sind, die stark in ihren jeweiligen Geweben getrennt sind. Schließlich 
konnte ich durch Verfolgen der Dynamik von antigenspezifischen CD4+ Gedächtnis          
T-Zellen nach Auffrischen der systemischen MMR Impfung zeigen, dass sesshafte 
Gedächtnis-T-Zellen, die spezifisch für systemische Antigene sind, schnell in die 
Blutzirkulation mobilisiert werden und dort zu der Immunreaktion beitragen. 
Zusammenfassend bieten diese Studien ein umfassenderes Verständnis der Funktion und 
des Erhalts des immunologischen Gedächtnisses in Menschen. 
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1 Introduction 
1.1  Adaptive T cell immune responses 
The immune system is the collection of cells, tissues and molecules that protect the body from 
numerous pathogens present in our environment. The mammalian immune system can be 
divided in two main arms: innate and adaptive immunity. The cells and receptors of the innate 
immune system are critical for the rapid recognition of the infectious agent and initiating a 
proinflammatory response. The inflammation generated by innate immune cells (neutrophils, 
macrophages, monocytes, natural killer cells (NKs), dendritic cells (DCs), etc.) is important for 
the initial containment of the infection, but also for directing the expansion and differentiation of 
the adaptive immune cells. In response to the inflammatory environment created by the innate 
immune response, cells from the adaptive immune system (B and T cells) are stimulated to 
expand in number and to differentiate into lineages of cells with a range of functions needed for 
the immunological challenge1. 
The activation and programming of T cells from their naïve state to an effector state is critical to 
almost all functions of the adaptive immune response. The primary mediator of T cell activation 
is the T cell receptor (TCR). The TCR is generated by recombination of genomic DNA 
sequences during T cell development in the thymus, and each TCR is essentially unique and is 
responsible for the specificity of each T cell 2. Successful recombination of a functional TCR and 
emergence from the thymus results in a resting “naïve” T cell capable of migrating through the 
secondary lymphoid tissues and PB circulation, but yet incapable of producing any kind of 
immune response. Producing a T cell that is capable of mediating immune protection requires 
the activation of the naïve T cell via coordinated interactions between a number of molecules 
present on the T cell and the antigen-presenting cell (APC). APCs are cells that bear an 
antigenic peptide derived from the infectious agent bound to a major histocompatibility complex 
(MCH) class I or class II molecule. The most important APCs are the highly specialized dendritic 
cells, who ingest the antigen at the sites of infection and migrate to secondary lymphoid organs, 
where they present the antigen to T cells3. A part from dendritic cells, other cell types, such as 
macrophages and B cells can also act as professional APCs, although they are less powerful 
than dendritic cells at activating naïve T cells. 
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1.1.1 TCR formation and selection  
TCRs are highly diverse heterodimers, consisting of a combination of α and β chains (αβ TCR) 
expressed by the majority of T cells, or γδ chains (γδ TCR) expressed in a small fraction of        
T cells in PB (1-5%) and T cells from mucosal sites4. The variable region of TCRα and δ chains 
is encoded by a number of variable (V) and joining (J) genes, while TCR β and γ chains are 
additionally encoded by diversity (D) genes5,6. During VDJ recombination, one random allele of 
each gene segment is recombined with the others to form a functional variable region       
(Figure 1.1). Recombination of the variable region with a constant gene segment results in a 
functional TCR chain transcript. Moreover, random nucleotides are added and/or deleted at the 
junction sites between the gene segments. This process leads to strong combinatorial and 
junctional diversity, resulting in a large and variable TCR repertoire, which will ensure the 
identification of a plethora of antigens. 
Each TCR chain contains three hypervariable loops in its structure, termed complementary 
determining regions (CDR1-3). CDR3 region is encoded by the junctional region between the V 
and J or D and J regions, being therefore highly variable. It plays an essential role in the 
interaction of the TCR with the peptide-MHC complex, as it is the region of the TCR in direct 
contact with the peptide antigen. For this reason, CDR3 is often used as the region of interest to 
determine T cell clonotypes, as it is very unlikely that two T cells will express the same CDR3 
nucleotide sequence, unless they have derived from the same clonally expanded T cell6,7. 
The sum of all TCRs by the T cells of one individual is termed the TCR repertoire. In T cells, the 
protective immune response relies on the presence of a T cell population that is poised to 
respond to peptides derived from pathogens, bound to self-MHC molecules. As the organism 
cannot predict the precise pathogen-derived antigens that will be encountered, the immune 
system relies on the generation and maintenance of a diverse T cell receptor (TCR) repertoire. 
Therefore, the size and diversity of the available T cell repertoire are crucial in shaping the 
immune response to a given antigen. The maximal theoretical diversity of TCR chain´s amino 
acid sequences in humans is estimated between 5 x 1011 8 and 1014 9. However, whole TCR 
chain repertoire size in a single human organism is estimated at 1-5 x 106    8,10,11.   
The large diversity of TCR means that there will usually be at least a few that can bind to any 
given foreign antigen. However, as each lymphocyte has a different receptor, the numbers of 
lymphocytes that can bind and respond to any given antigen is very small. In order to generate 
sufficient antigen-specific effector lymphocytes to fight an infection, lymphocytes with 
appropriate receptor specificity must be activated to proliferate and differentiate into effector 
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cells.  Lymphocyte activation and proliferation is initiated in the draining lymphoid tissues, where 
naïve lymphocytes and activated APCs come together. Here, antigens are presented to the 
naïve circulating lymphocytes which migrate through the lymphoid tissue before returning to the 
bloodstream.  
 
 
 
Figure 1-1: Gene rearrangements at the TCR loci. (A) Functional TCRs are heterodimers consisting of an -chain 
and a -chain that are generated by somatic gene recombination of variable (V), diversity (D) and junctional (J) gene 
segments for the -chain, and V and J gene segments for the -chain. During T-cell development, gene segments 
recombine and are spliced together with the constant region (C) to form the functional  TCR, with each T cell 
expressing only one type of recombined receptor complex. (B) The hypervariable complementary regions CDR1 and 
CDR2 are encoded on the V regions, while the most variable CDR3 region is created by the juxtaposition of different 
V (D) J germline segments after somatic recombination, with the diversity of the naïve TCR repertoire increased 
further by a lack of precision during V (D) J gene rearrangement and by the addition of non-template-encoded 
nucleotides (N) at the V (D) J junctions. Adapted from: Laydon DJ, Bangham CRM, Asquith B. 2015 Estimating T-cell 
repertoire diversity: limitations of classical estimators and a new approach.Phil. Trans. R. Soc. B 370: 20140291.  
 
1.1.2 T cell lineages and differentiation 
T cell support of immune responses comes into two categories: generation of “helper” CD4+       
T cells and generation of “cytotoxic” CD8+ T cells. CD4+ T cell responses support the immune 
system by the robust generation of cytokines and chemokines that either activate neighboring 
cells to perform specific functions (cytokines) or recruit new immune cell subsets to the site of 
pathogen encounter (chemokines).On the other hand, the function of CD8+ T cells is largely 
A B
 
 
Hypervariable 
region CDR3 
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focused on the elimination of pathogen-infected cells by cytotoxic means, although they can also 
produce a diverse array of cytokines. 
Due to the diverse spectrum of pathogens encountered (viruses, bacteria and parasites); the 
host produces an array of specialized T cells to fight the invading pathogen. Naïve T cells retain 
their specificity by the expression of their unique TCR but remain uncommitted to their helper 
fate until engagement of their TCR is accompanied by the integration of molecular signals 
downstream of their cytokine receptors. In response to the specific cytokine environment 
(cytokine milieu), antigen-stimulated T cells will be transcriptionally programmed into a variety of 
potential subsets that possess effector mechanisms appropriate for eliminating the pathogen. 
Helper T cell responses are thus classified into multiple T helper (Th) subsets, with the major 
ones designated as Th1, Th2, Th17, Th9,T follicular helper (Tfh) and T regulatory (Tregs)12.  
Interferon (IFN)-α/β and interleukin 12 (IL-12) generated in response to intracellular pathogens 
stimulate responding T cells to induce the expression of the transcription factor T-bet13, 
promoting their differentiation into the Th1 subset14. The Th1 subset mediates defense against 
intracellular pathogens, and is characterized by the major production of IFNγ and TNFα12,15,16. 
Th2 cells are characterized by the production of IL-4, IL-5 and IL-1315, and are generated after 
activation in the presence of IL-4 produced by a variety of innate cell types in response to 
parasites17. Cytokines produced by Th2 cells activate neighboring eosinophils, mast cells and 
basophils, which are specialized in the elimination of parasites18. Interactions with other 
parasites that generate milieu rich in IL-4 and transforming growth factor (TGF)-β result in the 
generation of the Th9 cell subset19,20, which mainly produces IL-921. Both Th2 and Th9 subsets 
up-regulate the transcription factor GATA-322, which results in their unique helper characteristics. 
In response to extracellular bacteria and fungi23, innate immune cells generate high amounts of 
TGF-β and IL-624, which together with the presence of IL-21 and IL-23 stimulation results in the 
generation of Th17 helper cells25. Those cells are regulated by the retinoic-acid-receptor-related 
orphan nuclear receptor gamma (RORγT)26, and mainly produce IL-17 and IL-2127. They are 
important in activating neutrophils and recruiting them to the site of fungal and bacterial 
invasion28. 
Even though the inflammatory environment is strongly influenced by the specific nature of the 
invading pathogen, not all T cell differentiation is pathogen-specific. Some T cell differentiation 
occurs to support immune functions common to all infection responses. For instance, IL-21 and 
IL-27 stimulation are generated in response to a variety of pathogens and serve to polarize 
naïve T cells to Tfh subset, via the induction of B-cell lymphoma 6 protein (Bcl-6)29. Those cells 
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specifically home to B cell follicles in secondary lymphoid organs and assist in germinal center 
reaction of B cells, promoting the robust generation of high-affinity antibodies30.  
Naïve CD4+ T cells can also differentiate into suppressive Treg cells. These cells produce IL-10 
and/or TGF-β, and their differentiation and function is driven by the expression of forkhead helix 
transcription factor (FOXP3)31.The effects of Treg cells are the suppression of T cell proliferation 
and cytokine production from T cells via different mechanisms, such as production of IL-1032. 
Similarly to CD4+ T cell lineages, Type 1, 2 and 17 cytotoxic CD8+ T cells have been identified 
(Tc1, Tc2 and Tc17), and are also generated depending on the cytokine environment33. 
 
 Figure 1-2: Together with TCR signaling, milieu cytokines 
promote differentiation of naïve T helper cells to one of a 
variety T cell subsets, programmed by transcription factors 
to specifically respond to the spectrum of pathogens. Upon 
differentiation, T cells themselves produce cytokines, which 
feed back into the cellular milieu, amplifying and balancing 
the immune response to promote specific pathogen 
clearance. Adapted from Nathan P. N. et al., (2013). T cell 
responses: Naïve to memory and everything in between. 
Adv Physiol Educ 37: 273–283  
 
 
 
 
 
 
1.2 Immunological memory 
The concept of immunological memory refers to the capacity of the immune system to 
“remember” previously encountered antigens and mount accelerated and enhanced response 
upon secondary re-challenges.   
Already in 1781, in the remote Faroe Islands, a measles outbreak provided an insight into the 
mechanism of long-term protective immunity against infectious diseases. After this first outbreak, 
the Faroes remained measles-free for 65 years, until a major outbreak in 1846 that affected    
75-95% of the population. The Danish physician Ludwig Panum made the observation that none 
of the elderly people who were infected with measles in 1781 had the disease for the second 
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time. Moreover, he also noticed that all the elderly people who had not suffered from measles in 
earlier life were attacked when they were re-exposed to infection. Panum´s study made two 
points: first, that immunity to measles was long-lived and second, that re-exposure to the virus 
was not essential for maintaining this long-term protective immunity34. 
In vaccinia virus-specific responses in mice, the kinetics and duration of T cell responses 
showed strong CD8+ responses at day 7 post-infection, followed by a decline and stabilization at 
day 30 until day 300 after infection. Vaccinia-specific CD4+ T cell responses in mice also peaked 
at 1 week after infection, reaching their maximum from 1 to 7 months after initial exposure 35. 
Moreover, vaccinia-specific memory B cells can make up to 1% of circulating IgG memory         
B cells from 1 to 6 months after vaccination, followed by a decline of ~90% after the first year 
and a stabilization, being vaccinia-specific memory B cells maintained for more than 50 years 36. 
Studies performed in humans also demonstrated the persistence of immune memory. For 
example, antigen specific CD4+ and CD8+ T cells can be identified 60 years following 
vaccination against smallpox, even when the virus was already eliminated and antigenic re-
encounter was excluded 37, and immunity to smallpox vaccination has been proved to last at 
least for 35 years38. Moreover, studies performed using measles vaccination showed that even 
decades after acute measles and in the absence of demonstrable persisting virus, both CD4+ 
and CD8+ T cell pools still contain measurable levels of measles-specific memory T cells39. 
These data supports the idea that immune memory is long-lasting.  
Several studies have shown that the induction of memory T cells, memory B cells and long-lived 
plasma cells are major components of the success of vaccines and protection against re-
infection with previously encountered pathogens40,41. Plasma cells provide protection by constant 
antibody production, whereas memory B and T cells are endowed with unique properties that 
allow more vigorous and specific responses upon reinfection42.  
 
1.2.1  Generation of memory T cells 
Memory B cells, plasma cells, and memory T cells play central roles in immunological memory 
but to date, the pathways that give rise to memory cells and how are they maintained for such 
long-periods remains poorly understood. 
The generation of memory T cells is usually divided in three different phases. The initial one, 
defined as an activation phase, is characterized by the expansion of antigen-reactive T cells. In 
this phase, antigen-specific T lymphocytes undergo a clonal expansion, reaching an increase in 
numbers up to 5000-fold. This massive T cell proliferation is critical to long-term immunity 
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because the magnitude of the initial clonal burst typically determines memory T cell numbers 43. 
Moreover, they acquire cytotoxic activity, up-regulate the secretion of effector cytokines and/or 
express peripheral tissue homing receptors, which will allow them to be recruited to the site of 
infection. Effector T cells migrate to the sites of infection and eliminate the pathogen by killing 
infected cells, producing cytokines, and/or recruiting other leukocytes via chemokine production.  
Once the antigen has been cleared, sustained effector function could result in harmful immune 
inflammation. For this reason, most effector cells die during a second phase of contraction, 
characterized by a rapid decline in the frequencies of antigen-specific T cells that die by 
apoptosis via activation-induced cell death 44 or by neglect due to growth factor withdrawal 45. A 
small proportion of antigen-specific T cell survives to this phase of contraction and constitutes a 
pool of memory T cells, maintaining then T cell oligoclonal specificities that were successful in 
controlling dissemination of the specific pathogen. Finally, in the third phase called the memory 
phase, antigen-specific T cells that survived the phase of contraction (typically 5-20%) develop 
into specialized memory T cells, generating a long-lived and stable pool of memory T cells 46,47. 
Memory T cells persist in an antigen-independent, but apparently cytokine dependent manner48. 
Different models have been developed to study the generation of memory T cells after antigen 
encounter. The first model, known as linear model, suggests that naïve CD4+ T cells, after 
activation by cognate antigen-MHC complexes, differentiate into effector cells and then into 
memory cells49. A linear differentiation pathway was also proposed for CD8+ T cells50. A second 
model, known as divergent model, proposes that memory T cells are directly generated from 
naïve T cells after antigen recognition, without going through the effector stage51. Recently, an 
asymmetric division model was proposed, in which effector and memory cells are formed 
simultaneously upon the first cell division of naïve progenitor T cells 52.  
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Figure 1-3: Formation of memory T cells following T cell responses. Upon infection, naïve T cells become 
activated and proliferate and differentiate into a heterogeneous population of effector T cells. Most of the effector T 
cells terminally differentiate into effector cells (blue cells) that protect against the current infection, but have no 
potential to develop into memory T cells. A smaller subset of effector T cells persists to develop into different types of 
memory T cells. Memory T cells form a potent defense system. Adapted from: Cui W and Kaesch SM., (2012). 
Transcriptional control of effector and memory CD8 T cell differentiation. Nat Rev Immunol 12:749-61  
 
1.2.2  Functional characteristics of memory T cells 
A central feature of the adaptive immune system is the capacity of memory T cells to mediate 
faster, stronger and more effective responses to secondary pathogen challenge than naïve        
T cells 53,54. Memory T cells are thought to have an increased sensitivity to the antigen compared 
to primary responding cells 55–57, probably due to the selection of the repertoire for higher affinity 
TCR clones dominating secondary responses. The ability of memory T cells to respond to lower 
doses of antigens may also be due to alterations in the levels of TCR and/or downstream 
signaling molecules. Kumar and colleagues found that CD3 molecules were more likely to form 
distinct clusters on the cell surface of memory compared with naïve T cells, allowing more 
efficient TCR triggering 58.  
Moreover, memory T cells are mainly polyfunctional in terms of cytokine secretion59. Numerous 
studies in the past have evaluated the frequencies of antiviral CD4+ T cells producing different 
cytokines as a measure of the magnitude and the quality of specific responses, which are critical 
for the control of viral responses. In human studies analyzing CD4+ specific responses to viral 
antigens, multiple-cytokine-producing cells are functionally superior to single-cytokine-producing 
cells, having a major content of cytokine per cell, and showing a higher expression of CD154, 
which provides a better co-stimulation to CD8+ T cells and B cells 60.  
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1.2.3  Heterogeneity of circulating memory T cells in terms of function and 
location 
Naïve T cells are characterized by the expression of the lymph node homing CC-receptor 7 
(CCR7), reflecting their major residence in secondary lymphoid tissues. Memory T cells in 
humans are classically distinguished by the expression of the CD45RO isoform and the lack of 
expression of the CD45RA isoform. However, CD54RO+CD45RA- T cells are now known to 
comprise heterogeneous populations of memory T cell subsets. In 1999, Sallusto, Lanzavecchia 
and colleagues described the heterogeneity in human memory T cells from PB by the 
expression of CCR7, effector functions and proliferative capacity 61. Based on this, memory       
T cells can be divided into CD45RA-CCR7+ central memory T cells (TCM) and CD45RA-CCR7- 
effector memory T cells (TEM). TCM cells are characterized by their ability to traffic to lymphoid 
tissues, proliferate upon activation, provide help to antigen presenting cells (APCs) via CD154, 
and secrete high amounts of IL-2. On the other hand, TEM can migrate to peripheral tissues and 
are able to produce more effector cytokines like IFNγ. Interestingly, TCM cells have the capacity 
to differentiate into TEM cells upon secondary stimulation, with immediate effector functions 61. 
The existence of TCM and TEM cell subsets in lymphoid and peripheral tissues was also confirmed 
in mouse models 62,63.  
Most recently, additional memory cell subgroups have been described, suggesting further 
heterogeneity of memory T cells. Memory stem cells (TSCM) are defined by the expression of 
naïve (CD45RA+ and CCR7+) and memory (CXCR3+ and CD95+) markers, and represent the 
most stable memory subset 64–66. Transcriptional analysis of human CD4+ T cell populations 
positioned TSCM cells as a distinct population with a transcriptional profile between naïve and TCM 
cells 67. Memory stem T cells have also been described in non-human primates, where they 
were found in PB, secondary lymphoid organs and the BM 68. 
 
1.3 Tissue resident memory T cells (TRM) 
In addition to circulating memory T cells, mouse studies have also established the existence of a 
non-circulating TRM subset as a non-circulating subset that resides in peripheral tissue sites and 
elicits rapid in situ protective responses69. Memory T lymphocytes persisting in different tissues 
have attracted increasing interest because their considerable contribution to the long-live 
memory T cell pool70. However, limited access to human tissue samples and the limitations of 
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current methods to dissociate memory T cells in peripheral organs, limits our current 
understanding on the presence and activities of these cells71. 
In humans, only a small proportion of T cells can be found in blood circulation (5-10 x 109 cells), 
in contrast with other tissues, where the T cell numbers are much higher. Estimates of T cell 
numbers in human tissues are 2 x 1010 in the skin 72,73, 1 x 1010 in the lungs 74, 3 x 1010 in the gut 
75, 15 x 1010  in lymph nodes, 3 x 1010 in spleen, and 2,5 x 1010 in BM 76. These observations 
demonstrate that both lymphoid and non-lymphoid tissues are important when investigating 
memory T cell formation and maintenance. In particular, several studies have demonstrated the 
presence of TRM cells in a variety of tissues, such as BM, gut, skin, lungs, brain and           
thymus 59,62,72,74,77–82. Moreover, animal studies performed in skin and vaginal mucosa indicated 
that T cell-mediated memory responses are highly compartmentalized in tissue sites, and that 
TRM cells mediate responses with a higher protective capacity compared to circulating TCM 
cells79,82–84. 
 
 
 
Figure 1-4: Schematic view of blood and tissue compartmentalization of memory T cells. The distribution of 
different memory T cell populations is shown in the figure, including central memory T cells (TCM), effector memory      
T cells (TEM), stem cell memory T cells (TSCM) and tissue resident memory T cells (TRM). Distinct populations of 
memory T cells have the capabilities to circulate through the blood (red), lymphoid organs (grey) or peripheral tissues 
(yellow). Figure modified from: Donna L Farber et al., Human memory T cells: Generation, compartmentalization and 
homeostasis.  Nature Reviews Immunology. 2013; doi:10.1038/nri3567. 
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1.3.1  Generation of TRM cells 
During the acute phase of an infection, recently activated effector T cells enter the inflamed 
tissue in order to clear the pathogen. Heterogeneous populations of effector T cells have 
different potential to become memory T cells depending on the expression of transcription 
factors and cell surface molecules. Moreover, external factors like T cell receptor (TCR) signal 
strength, and the presence of inflammatory cytokines can also influence the effector and 
memory T cell differentiation and fate85,86. The molecular mechanisms required to control TRM 
differentiation are still poorly understood. It is possible that TRM cell development involves 
several checkpoints, such as tissue entrance, local retention and TRM formation and survival.  
The ability of effector T cells to migrate into non-lymphoid tissues, may be a key for subsequent 
TRM cell differentiation. T cells that lack CCR7 expression show enhanced local conversion to the 
TRM cell phenotype in the skin87. Moreover, CD69-deficient CD8+ T cells show defective TRM cell 
development in the skin 88 and the lungs 89 and BM90, suggesting that CD69 is a critical tissue 
retention marker. 
The cytokine transforming growth factor-β (TGFβ) was shown to have a role in the development 
of CD69+CD103+ TRM cells in the skin, gut and lungs 87,91,92. Moreover, the cytokines interleukin-
33 (IL-33) and tumor necrosis factor (TNF) in combination with TGFβ can induce a TRM like 
phenotype (CD69+CD103+) 93. The homeostatic cytokine IL-15 may also be a decisive factor in 
TRM differentiation and survival. For example, in the absence of IL-15, CD8+ TRM cells do not 
persist in the skin after HSV infection 87. 
 
1.3.2  Phenotype and migratory properties of TRM cells 
The majority of TRM cells in lymphoid and non-lymphoid tissues express two surface cell 
markers: the trans membrane C-type lectin CD69 and the integrin α-E CD103. CD103 can bind 
to E-cadherin94, which may have a role in the retention of T lymphocytes into tissues. Indeed, 
CD8+ T cells genetically deficient in CD103 are able to migrate to the small intestine epithelium, 
brain and skin epidermis, but are not retained 81,87,93. However, some evidence indicates that the 
majority of putative TRM cells in many tissues do not express CD103 69,93, suggesting that it is 
very likely that many TRM cells do not depend, or do not even express CD103. Other integrins 
that bind extracellular matrix proteins in the lamina propria or basement membrane might also 
retain TRM cells in different tissues. For instance, the integrin α1β1 (VLA-1) binds laminins and 
collagens and is highly expressed on CD8+ TRM cells from the brain, small intestine, lung and 
skin79,87,95,96.  
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In addition, TRM cells have elevated expression of the C-type lectin CD69. Functionally, CD69 
has been shown to induce G-protein coupled sphingosine-1-phosphate receptor1 (S1PR1) 
down-regulation. S1PR1 mediates T cell egress from lymph nodes by inducing chemotaxis to 
sphingosine-1-phosphate (S1P) present in efferent lymph 97. Thus, inhibiting S1P 
responsiveness might represent an important checkpoint for the generation of TRM. CD69 is 
induced on TRM after they migrate to the sites of residence 87,98,99. However, it remains to be 
determined whether all TRM require CD69, or whether other means of S1PR1 inhibition are 
sufficient for TRM maintenance. Notably, transcriptional regulation of S1PR1 is driven by the 
Kruppel-like factor 2 (KLF2). TGF β, IL-33 and TNF present in the tissues induce                
down-regulation of KLF2 expression and consequently suppress S1PR1 expression 99. 
Interestingly, KLF2 was also shown to directly promote the expression of CD62L100 and had 
increased correlation to CD69 expression99. Therefore, the down-regulation of KLF2 and S1PR1 
and the up-regulation of CD69 might both play functional roles in the development and retention 
of TRM cells.  
Two studies performed in humans examined naïve and memory T cell subsets from several 
tissues obtained from organ donors, showing that substantial numbers of both CD4+ and CD8+ 
memory T cells in spleen, lymph nodes, lungs and intestines expressed the marker CD69 101,102. 
Moreover, the expression of CD69 has also been detected in memory T cells from human BM 59. 
To conclude, CD103 and CD69 seem to be important for the generation and maintenance of TRM 
cells, but there might be other factors that promote residence and recirculation.  
 
1.3.3  Maintenance and functional capacity of TRM cells 
An important feature of TRM cell populations in non-lymphoid tissues is their long-term 
persistence. In mice, TRM cell populations can remain numerically stable in skin for several 
months79,82,83. Moreover, studies performed in humans have shown the existence of memory 
CD4+ T cells specific for childhood antigens in BM of elderly patients, even though when they 
were no longer detectable in blood circulation 59. Until now, it is not clear whether TRM cell 
populations can be replenished in the steady state from recirculating memory T cells or whether 
and how they are maintained as a stable population. More experiments need to be performed in 
order to address the question about TRM persistence. As TRM cells in lymphoid organs do not 
recirculate, they have limited access to blood-derived signals, so the local availability of nutrients 
may also influence TRM cell maintenance and functions. Moreover, as the space in different 
tissues may limit the number of T cells that persist locally, there is the possibility of competition 
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between TRM cell populations of different specificities. Such competition does not seem to affect 
circulating memory T cells, as populations of TEM can increase in size after immunization without 
affecting the naïve T cell pool 103. IL-15, TGF, TNF and IL-33 have all been implicated in the 
generation and maintenance of TRM cells 87,99. TGF, TNF and IL-33 have been shown to have a 
role in induction of CD103 expression and acquisition of a TRM phenotype, although their role in 
maintaining these cells in specific tissues for long-time periods has still to be proven. 
Upon re-exposure to a pathogen, circulating memory T cells (mostly TCM) are re-stimulated in 
draining lymph nodes where they proliferate and generate large numbers of effector T cells, 
which will migrate to infected tissues after several days. On the other hand, circulating TEM cells 
can be recruited directly to the inflamed tissue within hours or days, providing a faster response. 
Taking this into consideration, circulating memory T cells may not offer the most effective local 
protective immunity in peripheral sites 82,83,104,105. Moreover, there is emerging evidence that TRM 
cells can be multifunctional and that they have qualitative functional differences. For example, 
human BM TRM cells are polyfunctional in terms of cytokine production 86,105, and a great number 
of human lung TRM 106 and intestinal TRM cells produce multiple pro-inflammatory cytokines. 
Recent studies have shown that TRM cells can function in recall responses through effector 
mechanisms other than killing. For example, they can respond to antigens in situ by producing 
different cytokines such as IFNγ, which enhance the recruitment of circulating T cells from the 
blood 107,108.  
In humans, antigen-specific memory T cells are generated and dynamically maintained as a 
heterogeneous T cell population in the context of thousands of different pathogens that are 
introduced at various stages of life. Several studies have shown that there is a higher generation 
and maintenance of virus-specific effector/memory T cells in tissues compared with circulation. 
For instance, cutaneous challenge with varicella zoster virus resulted in memory T cells 
accumulation in the skin 109. In addition, lung tissue contained an increased frequency of 
influenza virus-specific memory CD8+ T cells compared with blood 110,111 and human BM was 
found to be also enriched with measles, mumps and rubella antigen-specific CD4+ memory          
T cells compared with blood 59. These findings suggest that there is a compartmentalization of 
pathogen-specific memory T cells in different tissues. 
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1.4 BM memory T cells 
The BM is a primary lymphoid tissue, were major part of hematopoiesis occurs. It is formed by 
islets of hematopoietic-active regions and fatty areas, which mainly contain adipose tissue112, all 
contained inside central cavities of long bones. In addition to its hematopoietic function, the BM 
plays a role in several physiological and pathological processes, including B and T cell memory, 
long-term antibody production, inflammatory response, bone metabolism and tissue            
repair 42,59,113–117.  
In both humans and mice, mature T cells represent 3-8% of total nucleated cells in the BM 118,119.  
BM CD4+ and CD8+ T cell populations contain a high proportion of cells with a memory 
phenotype, expressing low levels of CD45RA in humans 59, and high levels of CD44 in mice118. 
Several studies have pointed out that, long time after priming, memory T cells can be found all 
over the body120, with a preferential enrichment either in the BM59 or at the site of pathogen 
entry109–111, even in the absence of residual antigen. BM resident memory T cells are then 
thought to contribute to systemic memory, whereas TRM cells in peripheral tissues participate in 
local protection. 
 
1.4.1  Regulation of T cell migration and retention into the BM 
In the BM, there is no lymphatic drainage present, so BM exchanges with the rest of the body 
only occurs via blood circulation. Indeed, the BM is the only lymphoid organ which is not 
integrated in the lymphatic system. T lymphocytes can enter the BM only by crossing flat 
endothelium-lined vessels. T cells attach to the endothelium through selectin- and integrin-
mediated interactions, which allow T cell migration across the vascular endothelium 121. After 
that, firm adhesion is mostly mediated by interaction of the lymphocyte integrin α4β1 (VLA-4), 
expressed at high levels by activated T cells 122, and the endothelial adhesion molecule     
VCAM-1, which is constitutively expressed by BM microvasculature and stromal cells123. 
CXCL12 (stromal cell-derived factor-1 SDF-1) has been shown to be important in cell attraction 
to the BM, in addition to hyaluronic acid124. This chemokine is expressed at high levels by 
sinusoidal endothelium in the BM and it is recognized by the chemokine receptor CXCR4, which 
is expressed by T cells.  
Molecular regulation of T cell egress from the BM involves Sphingosine-1-phosphate (S1P) 
interaction with its receptor S1P1125. Bankovich and colleagues demonstrated the biochemical 
interaction between CD69 and S1PR1 by western blot 126, and then, it was suggested that 
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binding of CD69 to S1PR1 initiates its internalization and degradation127. In concordance with 
these findings, it was observed that CD4+ memory T cells accumulated less in CD69 ko mice 
compared with the WT counterparts, so it was proposed that CD69 could mediate retention of 
memory CD4+ T cells in the BM 128. Relocation of antigen-specific memory CD4+ T cells to the 
BM has been suggested to be in a CD69 and Integrin-α2 dependent manner, as cells lacking the 
expression of one of those molecules failed to immigrate into BM128,129.  
 
1.4.2  Functional long-term memory provided by BM memory T cells 
Several studies have shown that the contribution of BM memory T cells to systemic immunity is 
greater than previously thought 59,123,130. For example, it has been long known, that T-B cell 
cooperation in the BM can lead to antibody formation113.  Moreover, BM memory CD4+ T cells 
were shown to be polyfunctional, expressing multiple effector cytokines, a property that has 
been correlated with enhanced immunological protection 59.  
The human BM T cell population is significantly enriched for specificities against systemic 
pathogens, which represent persistent, recurrent and childhood immunological challenges. 
Pathogen-specific memory T cells specific for acute viral infections, such as measles, mumps 
and rubella (MMR) 59, and also persistent viruses, such as cytomegalovirus (CMV), Epstein-Barr 
Virus (EBV), and Human Hepatitis C virus (HCV) 131–133could be detected in the BM. However, 
when looking at typical skin or mucosa pathogens such as vaccinia virus or Candida albicans-
MP-65, CD4+ T cells specific for these antigens are not enriched in the BM, suggesting that they 
may be mostly maintained locally as TRM in skin and mucosal sites59. Of note, MMR-specific 
memory CD4+ T cells were shown to be maintained in the BM of elderly individuals, even when 
they are non-detectable in blood circulation59, indicating that BM is the site for long-term 
maintenance of memory T cells specific for systemic antigens. In some cases, antigens were 
expressed in the BM, for example in the EVB infected subjects 132. However, the presence of 
antigen in the BM was not reasonable in other cases, for example long time after vaccination 
against tetanus or other childhood antigens59,134. Therefore, it appears that long-lived antigen-
specific memory T cells go to the BM during immune responses to a high variety of antigens, 
and are maintained there without the presence of the antigen. 
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1.4.3 Long-term survival of BM memory T cells 
It was shown that memory T cells in the BM are resting in terms of activation, proliferation and 
transcription 59,135. The memory T cell pool acts as a repository of heterogeneous long-lived       
T cells that had been previously in contact with the antigen. To date, no unique mediator has 
been described as an inducer of memory T cell survival. It is possible that multiple signals with 
redundant or partially overlapping functions are involved to ensure the optimal survival of 
memory T cells. The anatomical location of the niches where T cells localize in the BM, and the 
cellular components of these niches are still under investigation. One major problem when 
investigating the “BM stromal niches” is the high degree of stromal cell heterogeneity. For 
example, it was shown that BM stromal cells expressing high levels of CXCL12 were different 
from those providing IL-7 136. Each type of stromal cells was associated with B lymphocytes at 
different developmental stages, and it could be seen as a mechanism to maintain immunological 
memory of different cell types with different requirements preventing competition between them. 
 
1.4.3.1 Relationship of BM memory T cells with the local microenvironment 
Hormones, antigen receptors, regulatory cells and, in particular, cytokines are the principal 
signals for maintaining lymphocyte homeostasis137. In the BM, reticular-like BM stromal cells 
have been shown to produce high levels of IL-7, IL-6 and VCAM-1 138–141, which are involved in 
the maintenance of B lymphocytes, long-lived plasma cells and T cells. 
Histological analysis of memory CD4+ T cells in the murine BM revealed direct contact of these 
cells with VCAM+ IL-7 producing stroma77. Also, murine CD8+ memory T cells were found to 
reside in close proximity with IL-7+ stromal cells135, and clusters of memory T cells and IL-15 
producing cells were observed in human BM sections 78. Dendritic cells, monocytes, CD34+ 
hematopoietic cells and BM stromal cells have been described to produce IL-15 142,143. 
Several studies have highlighted the role of cytokines that signal through the common -chain 
receptor (IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21) in the survival and homeostatic proliferation of 
lymphocyte populations 137,144. Especially, several groups have demonstrated the involvement of 
IL-7 and IL-15 in the survival of memory CD8+ T cells 145–147, whereas their involvement in the 
persistence of CD4+ T cells remains more controversial 144,148. The receptor for IL-15, assessed 
by the expression of the -chain (CD122), is expressed at significantly higher levels on memory 
CD8+ T cells compared to memory CD4+ T cells 149. This could explain why IL-15 has been 
shown to have an important role on the homeostasis of memory CD8+ T cells but not so much in 
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memory CD4+ T cells 144,149–151. In contrast, the receptor of IL-7, measured as CD127 expression 
is expressed at comparable high levels on both populations of memory T cells 152.  
Apart from the soluble factors present in the BM survival niches, cell-cell contacts generated 
between T cells and stromal cells are also thought to be important for the maintenance of 
memory T cells. BM resident memory T cells express both, VLA-2 and VLA-4, the alpha2- and 
alpha4-beta1-integrin heterodimers, which bind mainly to collagens I, II and XI 153,154, and 
VCAM-1155,156 respectively. The importance of adhesion signals presumably mediating contact to 
stromal cells has been demonstrated for several immune cell types. For example, the disruption 
of cell-cell contact between hematopoietic cells and stroma via VLA-4 and VCAM-1 interaction 
resulted in an increase of apoptosis of CD34+ hematopoietic cells 157, and antibodies that block 
VLA-4 in plasma cells have been shown to eliminate these cells from the BM 158. Regarding 
VLA-2, the homing of adoptively transferred T cells to BM can be blocked by antibodies against 
this integrin 77. Moreover, collagen XI, one of the putative ligands for VLA-2 is exclusively 
expressed in the BM 129, although its implication in memory T cell maintenance remains to be 
determined. 
Other factors that could influence the potential survival of BM memory T cells compared with the 
PB circulating ones are the levels of oxygen. Oxygen supply and diffusion into tissues are 
necessary for survival. The oxygen partial pressure (pO2) results from the balance between 
oxygen delivery and its consumption. In mammals, oxygen is transported by red blood cells 
circulating in a well-organized vasculature. In a physiologycal condition, each organ and tissue 
are characterized by their own unique “tissue normoxia”. In some human studies, it has been 
estimated that arterial blood has a pO2 = 13.2, whereas this is reduced in venous blood          
(pO2 = 5.3) and in BM (pO2 = 6.4±0.6) 159. Taking that into account, BM resident memory T cells 
may present an adapted metabolism to the local environment, which favors their survival in 
reduced oxygen conditions. 
Long-term memory T cell maintenance may not be simply influenced by single factors, but rather 
via the combination of different conditions present in the BM survival niches, which at the end 
will ensure the long-term survival of resting memory T cells.  
 
1.4.3.2 Molecular mechanisms involved in the maintenance of memory T cells 
The JAK/STAT, PI3K/AKT and MAPK/ERK signaling molecules are major cell survival pathways. 
Signals transduced through cytokines or other molecules and their specific receptors can 
activate these pathways that promote survival and inhibit cell death. Cytokine signaling through 
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tyrosine kinases can lead to the transcription of anti-apoptotic factors, but the exact molecular 
mechanisms implicated in memory T cell survival are still under investigation.  
The members of the B-cell lymphoma 2 (BCL-2) family can be assigned to three groups. The 
pro-survival members are BCL-2, BCL-XL (also known as BCL-2L1), BCL-W (also known as 
BCL-2L2), MCL1 (myeloid cell leukemia sequence 1), A1 and BOO (also known as (BCL-2L10). 
Pro-survival factors prevent the effectors BCL-2-associated X protein (BAX) and BCL-2 
antagonist/killer (BAK), which are considered the second group, from inducing mitochondrial 
outer membrane permeabilization, thereby preventing the activation of caspases 160,161. The third 
group includes the BCL-2-homology domain 3-only proteins, BIM, BAD (BCL-2-antagonist of cell 
death), BIK (BCL-2-interacting killer), BID (BH3-interacting-domain death agonist), harakiri 
(HKR), NOXA (NADPH oxidase activator 1), PUMA (p53-upregulated modulator of apoptosis; 
also known as BBC3) and BMF (BCL-2-modifying factor). Group three members sense the 
stress signals and release the inhibition imposed on BAX / BAK by the pro-survival proteins 162. 
When BH3-only proteins are induced or activated, they interact with BCL-2 family proteins to 
promote apoptosis. Various studies indicate that some BH3-only proteins, such as BIM and 
PUMA, bind to all anti-apoptotic BCL-2 family members, whereas others, like BAD and NOXA 
bind only certain anti-apoptotic BCL-2 family members, which are BCL-2, BCL-XL and BCL-W 
for BID and MCL-1 and A1 for NOXA 163–165. Interaction between the pro- and anti-apoptotic 
proteins prevents the inhibition of BAX and BAK by the pro-survival molecules and promotes 
caspase activation by its interaction with mitochondria, which will lead to apoptosis. 
Regulation of the expression levels of anti-apoptotic BCL-2 family proteins controls apoptosis. 
For example, BCL-2 and BCL-XL can be transcriptionally induced by growth factors through the 
Janus-kinase-signal transducer and activator of transcription (JAK/STAT) pathway to promote 
cell survival 166. Moreover, MCL-1 is rapidly degraded by the ubiquitin-proteasome pathway in 
response to cytokine deprivation or other death stimuli, and can be up-regulated post-
transcriptionally to prevent apoptosis by inhibiting the rate of degradation 167. NOXA is 
expressed at low levels in different tissues 168 and its expression is induced as a response for 
DNA damage 168, cytokine signaling 169 and hypoxic conditions 170. On the other hand, regulation 
of expression of the pro-apoptotic proteins BAX and BAK is less apparent and they appear to be 
constitutively expressed at constant levels, so these proteins are mainly post-translational 
regulated by other members of the BCL-2 family.  
BIM has shown to be important for memory T cell maintenance. In Bim-/- mice, resting memory 
CD8+ T cells accumulated in the periphery 171, suggesting its implication in memory T cell 
survival. BCL-2 and MCL-1 have both a shared role, the inhibition of BIM. Both are required for 
INTRODUCTION 
 
 
22
the survival of developing thymocytes and mature T cells 172,173. Studies from mice, primary cells 
and cell lines have implicated the BCL-2 family, especially the BIM/BCL-2 axis downstream        
-chain cytokine signaling 137, but the role of MCL-1 in cytokine-induced survival is less well 
described. In addition, studies performed in mice showed that IL-7 and IL-15 promote survival by 
up-regulating both MCL-1 and BCL-2. Each of the pro-survival molecules follow different 
pathways in promoting cell survival, so the balance between the functions of BCL-2 and MCL-1 
may be important in regulating memory T cell survival 174. 
NOXA selectively binds and targets MCL-1 for proteasomal degradation, event that has been 
considered to be a prerequisite for cell death in response to UV irradiation 175 and cytokine 
deprivation173. It has been shown the involvement of NOXA in the maintenance of memory 
Th1/Th2 homeostasis, but not in proliferating T cells 176. 
The receptors for the two cytokines known to be important for T cell homeostasis, IL-7 and IL-15, 
share the common cytokine-receptor -chain, which is associated with Janus Kinase 3 (JAK3), a 
kinase that is likely to be involved in lymphocyte homeostasis 137. Studies using mouse naïve      
T cells indicated that IL-7 stimulation is connected to the JAK1-3/STAT5 and the PI3K/AKT cell 
signaling pathways 177–179, which are major cell survival pathways. However, in vitro studies 
performed in effector/memory CD4+ T cells, using IL-7 stimulation and specific inhibitors for 
these pathways suggested that the IL-7 pro-survival function is mediated through the JAK/STAT 
pathway, independently of PI3K/AKT 180. Interestingly, the PI3K/AKT pathway was shown to be 
also important in maintaining basal cell viability 180, maybe by modulating other pro- or anti-
apoptotic molecules of the BCL-2 family. 
Taking together, a balanced relation between anti-apoptotic molecules and BH3-only pro-
apoptotic molecules may play an essential role in preventing apoptosis and maintaining cell 
survival. Until now, it is not completely known which pathways are more important in the 
maintenance of memory T cells, but it is possible that different survival factors provided by the 
niches function through different signaling molecules, and the combination of all of them is the 
responsible for long-term memory T cell maintenance. 
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Figure 1-5: The BCL-2 family control of cell apoptosis. Pro-apoptotic BCL-2 family protein activation, such as BIM 
and NOXA, is triggered by extra- and intra-cellular signaling. De-repressor BH3-only proteins (NOXA) prevent or 
disrupt inhibition by MCL-1. Direct activator BH3-only proteins (BIM) bind BAK and BAX to induce their homo-
oligomerization and cell death by apoptosis. Anti-apoptotic proteins (MCL-1, BCL-2 and BCL-XL) can interact with 
BIM to inhibit its interaction with BAX and BAK and suppress cell death by apoptosis. 
 
1.5 Aim of the thesis and study objectives 
With the discovery of TRM cells, the previous concept that memory T cells are continuously 
circulating through the body has been challenged. TRM cells can be found in a great variety of 
tissues, including the BM. Although TRM cells are thought to confer us with higher local protection 
at the site of infection, the exact division of tasks and the differences on the lifestyle of resident 
versus circulating memory T cells remains poorly understood. 
Previous work of our group showed that BM memory T cells are quiescently maintained for long 
times in specific survival niches, without signs of activation or circulation59. However, the survival 
signals as well as the survival mechanisms involved in this long-term maintenance of BM 
memory T cells remain poorly understood. In addition, memory CD4+ T cells specific to systemic 
childhood antigens like measles, mumps or rubella (MMR) were enriched in the BM oh elderly 
donors, even when they were no longer detectable in blood circulation59. Whether both, the 
CD69+ and the CD69- BM memory T cells maintain these long-term memory, and whether and 
how resident memory T cells specific for systemic antigens can be mobilized and reactivated to 
confer as with immune protections remains still unclear. 
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Therefore, in this thesis I hypothesized:  
That BM memory T cells remain quiescent for long-periods of time in specific BM niches, where 
they receive diverse survival signals from their microenvironment. Due to the differences in the 
environment of resident and circulating memory T cells, both cell populations may require 
different factors and be maintained by different survival mechanisms. 
That BM resident memory T cells form a pool of cells separated from the circulating memory      
T cells, which could be reflected by differences in their functional capacities and TCR 
repertoires. 
That antigen-specific memory CD4+ T cells to systemic antigens have the capability to be 
mobilized from their resting sites and mount a secondary immune reaction to confer us with 
faster and greater immune protection after systemic re-challenge. 
I compared the survival mechanisms of resident BM CD69+/CD69- with PB circulating CD69- 
memory CD4+/CD8+ T cells. I also investigated some of the essential factors for memory T cell 
maintenance as well as the molecular mechanisms triggered by them and involved in memory    
T cell survival. Furthermore, in order to determine the relationship between resident BM and 
circulating memory T cells, I compared the CDR3 TCRβ repertoires of BM CD69+/CD69- and 
blood circulating CD69- memory CD4+/CD8+ T cells, as well as the capacity of both, the BM 
CD69+/CD69- respond to antigen stimulation. Finally, in order to find out whether and how TRM 
cells are able to react to systemic re-immunization and be mobilized into the blood to mount a 
secondary immune reaction, we I followed the dynamics of antigen specific memory CD4+          
T cells in response to a secondary MMR vaccination. Altogether, these results provide a better 
understanding of human T cell memory maintenance and functionality, helping us in the 
development of vaccines and immunotherapies. 
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2 Materials and methods 
2.1 Materials 
2.1.1 Reagents and kits  
Reagent Manufacturer  Remarks 
10X BD FACS Lysing Solution  BD Biosciences  
10X BD FACS Perm Solution 2 BD Biosciences   
Anti-human CD4 Microbeads Miltenyi Biotec  
Anti-human CD8 Microbeads Miltenyi Biotec  
Brefeldin A  Biolegend 10 μg/mL 
CD28 functional grade pur Miltenyi Biotec 100 μg/mL 
CD40 functional grade pur Miltenyi Biotec 100 μg/mL 
Cell Proliferation Dye eFluor 670 eBioscience 2,5 μg/mL 
CFSE Live Technologies GmbH 2,5 μg/mL 
EDTA Live Technologies GmbH  
EL Buffer Qiagen  
FcR blocking reagent Miltenyi Biotec 50μg/ml 
Ficoll-Paque Plus GE Healthcare  
Fetal Bovine Serum  Biowest  
Human FcR blocking Reagent  Miltenyi Biotec  
Human IL-6, premium grade Miltenyi Biotec 1 μg/mL 
Human IL-7, premium grade Miltenyi Biotec 1 μg/mL 
Human IL-15, premium grade Miltenyi Biotec 1 μg/mL 
Human IL-33, premium grade Miltenyi Biotec 1 μg/mL 
Human TGFβ, premium grade Miltenyi Biotec 1 μg/mL 
Human TNFα, premium grade Miltenyi Biotec 1 μg/mL 
Human male Ab serum Sigma-Aldrich Heat-inactivated 
Inside Fix Solution Miltenyi Biotec  
5X Lyse/Fix Solution BD Biosciences  
MMR vaccine (Priorix) GSK For vaccination 
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Permeabilization Buffer A Miltenyi Biotec  
Proleukin (IL2 clinical use) Novartis 200 IU/mL 
Propidium Iodide solution (PI) Sigma-Aldrich 1 μg/mL  
Pure Orange In house 1 μg/mL 
Q5 High-Fidelity DNA Polymerase New England Biolabs  
Qiazol Reagent Live Technologies GmbH  
RNAse inhibitor Live Technologies GmbH  
RPMI Medium 1640 - GlutaMax Gibco, Life Technologies  
Smartscribe Reverse Transcriptase Clontech  
Trypsin-EDTA (1X)  Live Technologies GmbH  
Uracil-DNA glycosilase (UDG) New England Biolabs  
X-VIVO 15 Chemically defined medium Lonza  
Kit Manufacturer  
CD69 Microbead kit II, human Miltenyi Biotec 
IOTest Beta Mark TCRβ Repertoire Kit Beckman Coulter 
miRNAeasy Micro Kit Qiagen 
MinElute PCR Purification Kit Qiagen 
QIAquick PCR purification kit Qiagen 
PCR-clean-up Gel extraction  MACHEREI-NAGEL 
TruSeq DNA PCR-Free Library Prep Clontech 
Masenvirus IgG ELISA IBL International 
Masenvirus μ-capture IgM ELISA IBL International 
Mumpsvirus IgG ELISA IBL International 
Mumpsvirus IgM ELISA IBL International 
Rubella-Virus IgG ELISA IBL International 
Rubella-Virus μ-capture IgM ELISA IBL International 
Tetanus IgG ELISA IBL International 
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2.1.2 Buffers and media 
Buffer/Medium Preparation 
1X BD FACS Lysing solution 10X BD FACS Lysing solution 1:10 in H2O 
1X BD FACS Perm solution 2 10X BD FACS Perm solution 2 1:10 in H2O 
1X Lyse/Fix Solution 5X Lyse/Fix solution 1:5 in H2o 
1X Annexin V Binding Buffer 20X Annexin V Binding Buffer 1:20 in H2O 
Cell culture medium - RPMI Complete RPMI Medium 1640 - GlutaMAX  
100 U/ml penicillin, 100 μg/ml streptomycin 
0.5 M HEPES 
5% human AB serum  
Cell culture medium stromal cell line - 
RPMI Complete 
RPMI Medium 1640 - GlutaMAX  
100 U/ml penicillin, 100 μg/ml streptomycin 
10% FCS  
HEPES 1M 238,3 g HEPES 
100 mL H2O 
PBS 0.2g KCl; 0.2g KH2PO4; 
8g NaCl; 
1.15g Na2HPO4 x 2 H2O; 
+ H2O (final V = 1L) 
PBS/BSA/EDTA PBS + 0.2g/L BSA; 
2mM EDTA 
Expansion medium – X-VIVO Complete X-VIVO 15 Chemically defined medium  
100 U/ml penicillin, 100 μg/ml streptomycin 
0.5 M HEPES 
5% human AB serum  
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2.1.3 Antigens  
Antigen Type of antigen Manufacturer Concentration 
CMV-pp65  Recombinant protein Miltenyi Biotec 38µg/ml 
Measles Virus Lysate Microbix Biosystems, Inc. 5µg/ml 
Mumps Virus Lysate Microbix Biosystems, Inc. 10µg/ml 
Rubella Virus protein Microbix Biosystems, Inc. 5µg/ml 
SEB Staphylococcus 
enterotoxin B 
Sigma-Aldrich 1µg/ml 
Tetanus Toxoid Toxoid National Institute for Biological 
Standards and Control 
1 LF/mL 
 
2.1.4 Antibodies 
Antigen Fluorophore Clone Manufacturer 
Annexin V FITC  Miltenyi Biotec 
Bcl2 PE 100 Biolegend 
Bim Pure/A647 conj. Y36 Abcam/House conj. 
CD3 APC-H7 SK7 BD Biosciences 
CD3 PerCP SK7 Miltenyi Biotec 
CD3  Cy5 UCHT-1 House conjugate 
CD3  FITC OKT3 House conjugate 
CD4 PECy5.5 SK3 eBioscience 
CD4 BV650 OKT4 Biolegend 
CD4 PE TT1 House conjugate 
CD8 BV875 RPA-T8 Biolegend 
CD8 APC-Cy7 HIT8a Biolegend 
CD8 PE-Cy7 GN11/B4D7 House conjugate 
CD8 FITC GN11/B4D7 House conjugate 
CD8 Cy5 GN11/B4D7 House conjugate 
CD14 V500 HCD14 BD Bioscience 
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CD14 Cy5 TM1 House conjugate 
CD19 PO BV12 House conjugate 
CD19 VioBlue LT19 Miltenyi Biotec 
CD25 APC 4E3 Miltenyi Biotec 
CD27 BV605 LI28 BD Bioscience 
CD45 FITC HI30 Biolegend 
CD45RA PE-Cy7 HI100 Biolegend 
CD45RA BV570 HI100 Biolegend 
CD45RA BV605 HI100 Biolegend 
CD45RO PE-Cy7 UCHL1 Biolegend 
CD56 PE HCD56 Biolegend 
CD69 BV421 FN50 Biolegend 
CD69 APC-Cy7 FN50 Biolegend 
CD69 PE-CF594 FN50 BD Biosciences 
CD127 PE REA614 Miltenyi Biotec 
CD137 FITC 484 eBioscience 
CD154 BV421 24-31 Biolegend 
CD185 (CXCR5) APC REA103 Miltenyi Biotec 
CCR7 A488 G043H7 Biolegend 
CLA A647 HECA-452 Biolegend 
IFNγ PE-Cy7 4S.B3 Biolegend 
IL-2 FITC MQ1-17H12 Biolegend 
IL-2 APC-H7 MQ1-17H12 Biolegend 
Ki-67 PE 20Raj1 eBioscience 
Mcl1 A488 Y37 abcam 
NOXA Pure/A405 conj. 114C307 Abcam/House conj. 
PD1 BV786 EH12:2H7 Biolegend 
TNFα APC MAb11 BD Pharminogen 
TNFα PE 2-17-9-E11 House conjugated 
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2.1.5 Consumables 
Product Manufacturer  
BD Safety-Lok™ blood collection set 21G  BD Biosciences 
BD Vacutainer® 170 U/mL Li-Hep 10 mL  BD Biosciences  
Conical 50 mL tubes  Sarstedt  
Conical 15 mL tubes Sarstedt 
Culture flasks (25 cm2, 75 cm2) Cellstar 
Eppendorf tubes 0.5, 1.5, 2.0 mL Safe-Lock™  Eppendorf 
FACS tubes round-bottom PS 5 mL  BD Biosciences  
Greiner CELLSTAR 24 well cell culture plates Sigma-Aldrich 
Greiner CELLSTAR 48 well  cell culture plates Sigma-Aldrich 
Greiner CELLSTAR 96 well cell culture plates Sigma-Aldrich 
Greiner CELLSTAR 96 well cell culture plates (round bottom) Sigma-Aldrich 
LS magnetic separation columns Miltenyi Biotec 
Pipettes (2μl, 10 μl, 200 μl, 1000 μl) Eppendorf  
Pre-separation filters, 30 μm Miltenyi Biotec 
Serum tubes BD Biosciences 
0,2 mL PCR tubes Eppendorf 
 
2.1.6 Primers for TCR sequencing 
Primer  name Oligo Sequence Manufacturer  
UMI AAGCAGUGGTAUCAACGCAGAGU NNNN U NNNN U NNNNN UCTT gggg Metabion 
Na-SB2-M1_V2 CGA GCG TGA CGA CGA CAG TAG TCG TGG TAT CAA CGC AGA GT Metabion 
Na-SB4-M1_V2 CGA GCG TGA CGA CGA CAG TCA TCG TGG TAT CAA CGC AGA GT Metabion 
Na-SB5-M1_V2 CGA GCG TGA CGA CGA CAG GAT TCG TGG TAT CAA CGC AGA GT Metabion 
Na-SB6-M1_V2 CGA GCG TGA CGA CGA CAG GTC TTG TGG TAT CAA CGC AGA GT Metabion 
Na-SB7-M1_V2 CGA GCG TGA CGA CGA CAG AGT CTG TGG TAT CAA CGC AGA GT Metabion 
Na-SB8-M1_V2 CGA GCG TGA CGA CGA CAG ACT TCA GTG GTA TCA ACG CAG AGT Metabion 
Na-SB9-M1_V2 CGA GCG TGA CGA CGA CAG ATC CTA GTG GTA TCA ACG CAG AGT Metabion 
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Na-SB10-M1_V2 CGA GCG TGA CGA CGA CAG CAA CTT GTG GTA TCA ACG CAG AGT Metabion 
Na-SB11-M1_V2 CGA GCG TGA CGA CGA CAG CCT AAT GTG GTA TCA ACG CAG AGT Metabion 
Na-SB12-M1_V2 CGA GCG TGA CGA CGA CAG CGG TCT GTG GTA TCA ACG CAG AGT Metabion 
Na-SB13-M1_V2 CGA GCG TGA CGA CGA CAG CTC GGT GTG GTA TCA ACG CAG AGT Metabion 
Na-SB14-M1_V2 CGA GCG TGA CGA CGA CAG GCT CTG GTG GTA TCA ACG CAG AGT Metabion 
Na-SB16-M1_V2 CGA GCG TGA CGA CGA CAG TAA TCC GTG GTA TCA ACG CAG AGT Metabion 
Na-SB17-M1_V2 CGA GCG TGA CGA CGA CAG TCT GGC GTG GTA TCA ACG CAG AGT Metabion 
Na-SB18-M1_V2 CGA GCG TGA CGA CGA CAG TGG CTC GTG GTA TCA ACG CAG AGT Metabion 
Na-SB19-M1_V2 CGA GCG TGA CGA CGA CAG TTC AAC GTG GTA TCA ACG CAG AGT Metabion 
Na-SB20-M1_V2 CGA GCG TGA CGA CGA CAG GTC TCG GTG GTA TCA ACG CAG AGT Metabion 
N2Na  NNC GAG CGT GAC GAC GAC AG Metabion 
N3Na NNN CGA GCG TGA CGA CGA CAG Metabion 
N4Na NNN NCG AGC GTG ACG ACG ACA G Metabion 
bc1R  CAG TAT CTG GAG TCA TTG A Metabion 
bc2R  TGC TTC TGA TGG CTC AAA CAC Metabion 
bc3R-SB2r TAG TCA CAC STT KTT CAG GTC CTC Metabion 
bc3R-SB4r TCA TCA CAC STT KTT CAG GTC CTC Metabion 
bc3R-SB5r GAT TCA CAC STT KTT CAG GTC CTC Metabion 
bc3R-SB6r GTC TTA CAC STT KTT CAG GTC CTC Metabion 
bc3R-SB7r AGT CTA CAC STT KTT CAG GTC CTC Metabion 
bc3R-SB8r ACT TCA ACA CST TKT TCA GGT CCT C Metabion 
bc3R-SB9r ATC CTA ACA CST TKT TCA GGT CCT C Metabion 
bc3R-SB10r CAA CTT ACA CST TKT TCA GGT CCT C Metabion 
bc3R-SB11r CCT AAT ACA CST TKT TCA GGT CCT C Metabion 
bc3R-SB12 CGG TCT ACA CST TKT TCA GGT CCT C Metabion 
bc3R-SB13 CTC GGT ACA CST TKT TCA GGT CCT C Metabion 
bc3R-SB14 GCT CTG ACA CST TKT TCA GGT CCT C Metabion 
bc3R-SB16 TAA TCC ACA CST TKT TCA GGT CCT C Metabion 
bc3R-SB17 TCT GGC ACA CST TKT TCA GGT CCT C Metabion 
bc3R-SB18 TGG CTC ACA CST TKT TCA GGT CCT C Metabion 
bc3R-SB19 TTC AAC ACA CST TKT TCA GGT CCT C Metabion 
bc3R-SB20 GTC TCG ACA CST TKT TCA GGT CCT C Metabion 
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2.1.7 Equipment 
Product Manufacturer 
BD Aria II cell sorter BD Biosciences 
BD  LSR II flow cytometer BD Biosciences 
Centrifuge 5810R Eppendorf 
SPECTRAmax PLUS 384 Molecular Devices 
Heraeus Biofuge Fresco 17 Thermo Scientific 
Heraeus Biofuge Fresco 21 Thermo Scientific 
Heraeus Multifuge 3SR Thermo Scientific 
HERAsafe biosafety cabinet Thermo Scientific 
Hypoxia biosafety cabinet BioSpherix 
MACSQuant analyzer Miltenyi Biotec 
Miseq 500 Illumina 
NanoDrop Peqlab 
Standard CO2 incubator Binder 
Vacuum pump BVC  21 Vacuubrand 
Vortex Mixer VWR International 
Water bath Memmert 
 
2.1.8 Software 
Software Provider 
BD FACSDiva 6 BD Biosciences 
MACSQuantify software Miltenyi Biotec 
Flowjo 9.9.4 / 10.2 Tree Star 
GraphPad Prism 5.x GraphPad Software 
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2.2 Methods 
2.2.1 Stromal cells culture 
The human stromal cell line HS5 was kindly provided by Dr. Torok-Storb (FHCRC, Seattle, 
WA, USA). Cells were thawed following the habitual protocol and maintained through all 
the experimental time in 75 cm2 culture flasks filled with 10 mL of RPIM + 10% FCS + 1% 
PenStrep. Cells were passaged when reaching 80% of confluence by tripsinization. After 
10-15 passages, cultured stromal cells were discarded and new aliquots thawed in order 
to assure their support on survival.  
The day before the co-culture experiment, stromal cells were tripsinized, and 5 x 103 cells 
were plated in 96 well plates. For transwell experiments, 2 x 104 stromal cells were plated 
in 24-well plates.  
 
2.2.2 Sample collection and cell preparation 
Paired BM and PB samples were collected from anonymous systemically healthy adult 
donors undergoing hip replacement operations. All samples were obtained with local 
ethical committee (Ethikkommission der Charité-Univerisitätsmedizin Berlin) approvals and 
informed consent in accordance with the Declaration of Helsinki. Freshly obtained samples 
were subjected to immediate preparation. PB and BM mononuclear cells were isolated by 
density gradient sedimentation using Ficoll-Paque Plus. PB was diluted 1:1 with PBS 
(room temperature). BM samples were thoroughly washed with room temperature PBS 
and filtered through using a 70µm filter. Afterwards each cell suspension was carefully 
layered on Ficoll in proportion 35ml cell suspension to 15ml Ficoll and centrifuged at 
2000rpm for 20 minutes at room temperature (acceleration = 7; deceleration = 0). The 
upper plasma layer was removed and the intermediate lymphocyte layer transferred into a 
clean 50ml falcon tube. PBMCs/BMMCs were washed with cold PBE and centrifuged for 
10 minutes at 300xg and 4°C. The supernatant was discarded and the cell pellet 
resuspended in 50ml cold PBS/BSA/EDTA. To dispose of residual granulocytes the cells 
were ultimately centrifuged for 15 minutes at 180xg and 4°C, the supernatant was 
discarded. 
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2.2.3 FACS sorting of memory T cells subsets 
Isolated cells were surface stained with the following antibody mix [anti-CD4 (OKT4), anti-
CD8 (HIT8a), anti-CD45RA (HI100), anti-CD45RO (UCHL1), anti-CD69 (FN50), anti-CD25 
(4A3), anti-CD19 (BV12), anti-CD14 (HCD14)] for 10 minutes at 4°C. After that, cells were 
washed with PBE and centrifuged 5 minutes at 1200 rpm. Supernatant was discarded and 
cells were re-suspended in PBE according with the cell numbers for sorting. Memory T cell 
subsets were sorted in a FACS Aria II using the following gating strategy:  
 
 
 
Figure 2-1: Gating strategy for the sorting of PB and BM memory T cell populations. Memory T cell 
subsets were sorted in a FACS Aria II using the following gating strategy: (1) PI-CD14-CD19-CD4+CD25-
CD45RA-CD45RO+CD69+, (2) PI-CD14-CD19-CD4+CD25-CD45RA-CD45RO+CD69-, (3) PI-CD14-CD19-
CD8+CD25-CD45RA-CD45RO+CD69+, (4) PI-CD14-CD19-CD8+CD25-CD45RA-CD45RO+CD69-.  
 
2.2.4 Cell culture conditions 
After FACS sorting, cells were centrifuged 5 minutes at 1200 rpm and re-suspended in 
complete RPMI, in a final concentration of 5x104cell/mL. 100 uL of cells were plated in 96 
well plates previously prepared with 100 uL of the tested conditions in each experiment 
(IL7, IL15, IL6, IL33, TNFα, TGFβ and HS5). Cells were cultured in 96 well plates at 37°C, 
5%CO2 and 21% (NOX) or 4% (HOX) O2, depending on the experiment. For transwell 
experiments, the same amount of cells were plated into an insert and placed in 24 well 
plates previously seeded with stromal cells.  
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2.2.5 Cell survival assessment / intracellular staining of pro/anti-apoptotic 
proteins 
Cell survival and/or expression of pro/anti-apoptotic markers were measured at days 0, 1, 
3 and 5 of culture. Cell survival was measured by ANNV/PI staining following 
manufacturer´s instructions. Briefly, cells were harvested from wells and transferred to 96-
well plated with U bottom, after that, plates were centrifuged 5 min at 1200 rpm and cells 
were resuspended in the following mix, prepared in ANNV binding Buffer [ANNV, anti-
CD127 (REA614), anti-CD3 (UCHT-1)] and incubated for 15 min at room temperature. 
After that, plates were centrifuged 5 min at 1200 rpm and resuspended in 150 uL of ANNV 
Binding Buffer. PI was added just before measuring to all samples and they were analyzed 
by MACS Quant. 
  
Figure 2-2: Gating strategy followed during survival experiments and representative dot plot of all 
conditions analyzed. First, lymphocytes were gated regarding their FCS-SSC properties and duplets were 
excluded. Afterwards, I gated in CD3+ T cells and analyzed the percentages and numbers of surviving cells by 
gating on Annexin V- PI- cells. The expression of CD127 was examined in living cells, determining the mean 
fluorescence intensity (MFI) of the receptor in each cell subset during the different culture conditions and times.  
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For the intracellular staining of pro/anti-apoptotic proteins, cells were fixed with 2% PF for 
10 minutes at room temperature. Fixed cells were washed with PBE and centrifuged 5 
minutes at 500 xg. After that, cells were incubated with Permeabilization Buffer A 30 
minutes on ice and stained with the following antibody mix [anti-CD3 (SK7), anti-Bcl2 
(100), anti-Bim (Y36), anti-Mcl1 (Y37), anti-NOXA (114C307)] for 30 minutes at room 
temperature. After that, cells were washed with PBE, centrifuged 5 minutes at 500xg and 
resuspended in 70 uL PBE. Samples were analysed by MACS Quant.  
 
 
Figure 2-3: Intracellular analysis of pro-and anti-apoptotic markers at day 3 of culture in all conditions 
analyzed. First, lymphocytes were gated regarding their FCS-SSC properties and duplets were excluded. 
Afterwards, I gated in CD3+ T cells and analyzed the expression of BCL-2, BIM, MCL-1 and NOXA in all cell 
subsets regarding the different cell culture conditions tested. 
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2.2.6 Isolation of CD69+/- cells and CFSE/efluo670 labelling 
Mononuclear cells from PB and BM paired samples were isolated as explained in 2.2.1.2. 
After isolation, BM cells were sorted for CD69 expression using CD69 Microbeads Kit II 
(Miltenyi), following manufacturer´s instructions. Briefly, mononuclear cells were 
resuspended in PBS/BSA/EDTA with the final concentration of 107 cells per 40µl buffer, 
2µl of FcR Blocking Reagent and 10µl of CD69-Biotin were added and the cell suspension 
was incubated for 15 minutes at 4°C. Afterwards, 30 µL of PBS/BSA/EDTA and 20 µL of 
anti-Biotin Microbeads were added to the cell suspension and samples were incubated for 
an additional 15 minutes at 4°C. Finally, cells were washed with 20-fold volume of 
PBS/BSA/EDTA and centrifuged for 10 minutes at 300xg and 4°C. The supernatant was 
discarded and the cell pellet was resuspended in 500µl PBS/BSA/EDTA (if cell number 
exceeded 108 cells, 2ml of buffer and two MACS LS separation columns were used).      
LS separation columns and 30µm filter were rinsed with 3ml PBS/BSA/EDTA and the cells 
were loaded onto the column. After the cell suspension has passed the column, the 
column was washed with 3x3ml PBE and magnetically labeled cell fraction was flushed out 
of the column with 5ml buffer. The flow-through and positive fraction were collected and 
purity was assessed by CD69 staining and measurement at MACSQuant.  
After Magnetic Activated Cell Surface Sorting (MACS sorting) of the CD69+ and CD69- 
fractions, mononuclear cells were washed with PBS and spun down at 300xg and 4°C for 
10 minutes. Subsequently, the cells were resuspended in PBS at final concentration 107 
cells/ml. Stock solutions of CFSE and efluo670 were diluted in PBS to the double working 
concentration and drop by drop added to the cell suspension while vortexing (final 
concentration 2.5µM). Afterwards cells were incubated for 15 minutes at 37°C and the 
staining was quenched by adding serum-containing RPMI medium and incubation for 
further 10 minutes at 37°C. Ultimately, cells were spun down and washed twice with RPMI 
plus 5% human AB-Serum. Staining of different fractions was assessed in MACSQuant, 
and both fractions were mixed for antigen specific T cell stimulation. 
 
2.2.7 Antigen specific T cell stimulation 
To access antigen-specific memory T cells 107 PB and/or BM mononuclear cells were 
stimulated in 1ml complete RPMI medium with antigens described in section 2.1.3. Cells 
were stimulated for 12 hours with protein- or peptide-antigens. To block cytokine secretion, 
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brefeldin A (5 µg/mL) was added after first 2 hours of stimulation. As a high control a 
fraction of cells was stimulated the superantigen SEB (1 μg/mL) for 12 hours. 
Subsequently, stimulated cells were harvested, stained for surface antigens followed by 
fixation, permeabilisation and intracellular cytokine staining. 
 
2.2.8 Cell surface and intracellular cytokine staining 
Phenotype of PB and BM resident T cells was analyzed using cell surface marker staining. 
Mononuclear cells were washed and resuspended in 100µl of cold PBS/BSA/EDTA with 
the cell density of up to 5x106 cells in 100µl buffer. Subsequently, staining antibodies in 
combination with Fc Blocking reagent to prevent unspecific Fc Receptor binding were 
added. Mononuclear cells were stained for 10 minutes in the dark at 4°C, and in case of 
chemokine receptor staining for 15 minutes in the dark at 37°C. After this the cells were 
washed with cold PBS/BSA/EDTA and acquired using LSR Fortessa. Data analysis was 
performed using FlowJo (Treestar) software. 
To access the cytokine production by in vitro activated T lymphocytes, intracellular 
cytokine staining was performed. Pre-stimulated cells were harvested, washed with cold 
PBS/BSA/EDTA and spun down at 300xg and 4°C for 10 minutes. The supernatant was 
discarded and the cells were fixed for 10 minutes with 100µl 1X Lysing solution (BD 
Biosciences) at room temperature. Subsequently fixed cells were washed with 2ml cold 
PBS and centrifuged down at 490xg and 4°C for 10 minutes. To permeabilize the cells 
FACS Permeabilizing Solution 2 (BD Biosciences) was used. 100µl of 1x Permeabilizing 
Solution 2 Buffer were added to fixed cells and incubated for 10 minutes at room 
temperature in the dark. After washing the cells with PBS (490xg, 4°C, 10 minutes) 
antibody staining was performed. Final staining volume was adjusted to 100µl per max. 
5x106cells. Cells were stained for 30 minutes at room temperature in the dark, washed 
with cold PBS (490xg, 4°C, and 10 minutes) and analysed using LSR Fortessa and FlowJo 
(Treestar). At least 1×106 lymphocytes were acquired. 
 
2.2.9 Quantitative TCRVβ chain repertoire analysis 
Quantitative analysis of TCRVβ chain repertoire was performed using IOTest Beta Mark 
TCRVβ Repertoire Kit according to manufacturer’s instructions. Additionally, to 
differentiate distinct T cell subsets anti-CD3 (SK7), anti-CD4 (OKT4), anti-CD8 (HIT8a), 
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anti-CD45RA (HI100) and anti-CD69 (FN50) surface stainings were performed. Samples 
were acquired using LSRFortessa and analyzed using FlowJo (Treestar). Following TCRβ 
chain variants composing up to 70% of TCRβ chain repertoire were covered181: Vβ1, Vβ2, 
Vβ3, Vβ4, Vβ5.1, Vβ5.2, Vβ5.3, Vβ7.1, Vβ7.2, Vβ8, Vβ9, Vβ11, Vβ12, Vβ13.1, Vβ13.2, 
Vβ13.6, Vβ14, Vβ16, Vβ17, Vβ18, Vβ20, Vβ21.3, Vβ22, Vβ23.  
 
2.2.10 Cell isolation and FACS sorting for TCRβ NGS 
Paired PB and BM samples were directly sorted in the different memory T cell subsets or 
stimulated with different antigens for the sorting of antigen specific memory T cells.  
For the sorting of directly ex vivo cell subsets, isolated cells were surface stained with the 
following antibody mix [anti-CD4 (OKT4), anti-CD8 (HIT8a), anti-CD45RA (HI100), anti-
CD45RO (UCHL1), anti-CD69 (FN50), anti-CD25 (4A3), anti-CD19 (BV12), anti-CD14 
(HCD14)] for 10 minutes at 4°C. After that, cells were washed with PBE and centrifuged 5 
minutes at 1200 rpm. Supernatant was discarded and cells were re-suspended in PBE 
according with the cell numbers for sorting. 25.000 memory T cell subsets were sorted in a 
FACS Aria II using the following gating strategy:  
(1) PI-CD14-CD19-CD4+CD25-CD45RA-CD45RO+CD69+,  
(2) PI-CD14-CD19-CD4+CD25-CD45RA-CD45RO+CD69-,  
(3) PI-CD14-CD19-CD8+CD25-CD45RA-CD45RO+CD69+,  
(4) PI-CD14-CD19-CD8+CD25-CD45RA-CD45RO+CD69-.  
When sorting antigen specific memory CD4+ T cells, at least 5 x 107 mononuclear cells 
(both from PB and BM) were stimulated for 12 h with tetanus toxoid (TT) in the presence of 
1 μg/ml CD40 functional grade pure Ab (Miltenyi Biotec). After stimulation, cells were 
stained 15 min at room temperature with the following mixture of antibodies [anti-CD3 
(UCHT1), anti-CD4 (TT1), anti-CD8 (GN11/134D7), anti-CD19 (BU12), anti-CD14 (TM1), 
anti-CD45RA (HI100), anti-CD69 (FN50) and anti-CD154 (24-31)]. 2500 antigen-specific T 
cells were sorted by using an Aria II FACS sorter according the following gate strategy  
- PI-CD19-CD14-CD3+CD8-CD4+CD45RA-CD154+CD69+.  
Sorted cells were resuspended in 700 µL of Qiazol Reagent and kept at -80°C until RNA 
extraction. 
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2.2.11 Preparation of TCRβ-seq library and sequencing 
RNA extraction. For total RNA extraction, I used Qiazol reagent in combination with 
miRNAeasy Micro Kit (Qiagen), following manufacturer´s protocol. RNA concentration and 
quality were determined by Bioanalyzer picogram analysis. 
cDNA synthesis.  RNA solution was combined with 2µM 5’-template switch adapter 
SmartNNNa and 2µM β-chain reverse primer (section 2.1.6). After that, a premix 
containing SMARTScribe buffer, 20 mM DTT, 10 mM each dNTP and 20 U/µL and 
SMARTScribe reverse transcriptase (100U/µL). The solutions were incubated for 90 min at 
42°C for cDNA priming, synthesis and template switch. The reaction was stopped by 
incubating further 15 min at 70°C and the deoxyuridine-containing template switch adapter 
was removed by treating the cDNA with uracil-DNA glycosylase (New England BioLabs, 
5U/µL) for 40 min at 37°C. cDNA products were purified using MinElute PCR purification 
Kit (Qiagen), following manufacturer´s instructions. 
PCR amplification. For the first PCR amplification, all obtained cDNA was processed. I 
prepared a mix containing 5X buffer for Q5 DNA polymerase (New England Biolabs), 0.2 
mM of each dNTP, 0.5 µM forward barcoded  primers annealing the SmartNNNa adapter 
and 0.5 µM reverse primer for β-chain amplification (section 2.1.6) , Q5 DNA polymerase 
(New England Biolabs) and sterile water to a final volume of 50 µL. PCR reaction was 
performed using the following optimized cycling conditions: 94°C for 2 min, then 94°C for 
10s, 55°C for 10s and 72°C for 50s (21 cycles), with a final elongation at 72°C for 2 min. 
PCR products were purified using QIAquick PCR purification kit (Qiagen). 
Each 1st PCR reaction was divided into several reactions for the second step PCR. 
Reaction mix included 5X buffer for Q5 DNA polymerase (New England Biolabs), 0.2 mM 
of each dNTP, 0.5 µM forward primers annealing the adapter and 0.5 µM barcoded 
reverse primers for β-chain constant gene segment (section 2.1.6), Q5 DNA polymerase 
(New England Biolabs) and sterile water to a final volume of 50 µL. PCR reaction was 
performed using the following optimized cycling conditions: 94°C for 2 min, then 94°C for 
10s, 55°C for 10s and 72°C for 50s (18 cycles), with a final elongation at 72°C for 2 min. 
PCR products were purified using QIAquick PCR purification kit (Qiagen). 
Final products were purified using PCR-clean-up Gel extraction (MACHEREI-NAGEL) and 
stored at -20°C until adaptor ligation and sequencing. 
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PCR product concentration in each library was determined using a Qubit fluorometer 
(Invitrogen). PCR products were mixed together in an equal ratio, and Illumina adapters 
were ligated according to the manufacturer´s protocol. After adaptor ligation, pooled 
libraries were further purified using PCR-clean-up Gel extraction (MACHEREI-NAGEL). 
 
2.2.12 Illumina sequencing and data processing 
2x150bp paired-end sequencing of TCRβ amplicons was performed on the Illumina 
NextSeq 500 platform. Inline barcodes were demultiplexed and Illumnia Adapters removed 
by Illuminas bcl2fastq 1.8.4 software. De-multiplexing of sample barcodes as well as the 
extraction of the CDR3-sequences were performed by migec 1.2.4 using the unique 
molecular identifier guided assembling and error correction with default setting, minimal 
number of 5 reads per UMI and blast. Downstream analyses were performed based on 
functional CDR3 nucleotide sequences, i.e. not containing a stop codon or frame shift, 
using own scripts. Technical replicates were merged if specified. Diversity of the TCRβ 
repertoires was compared using the Efron and Thisted index and hill numbers. Similarity of 
TCRß repertories for CD4, CD8, CD69+ and CD69- samples from BM and peripheral blood 
were evaluated using circle plots with merged technical replicates and clusterisation by 
cosine distance and WARD as linkage criteria.  
 
Figure 2-4: Schematic strategy for preparation of TCRβ libraries. Process is explained in section 2.2.11. 
MATERIALS AND METHODS 
 
 
42 
2.2.13 MMR Vaccination and study cohort 
Approval for this study was obtained from the ethics committee of the Faculty of Medicine-
Charité, Berlin, Germany (EA1/303/12 and EA1/342/14). After informed consent and prior 
vaccination, 24 volunteers were screened for the presence of neutralizing antibodies 
against measles-mumps and rubella in their serum (Labor Berlin) but non-detectable or 
low numbers of antigen-specific T cells in blood circulation by flow cytometry analysis. 
Finally, 11 healthy adults (age ± SEM= 34.8±6.2; 4male/7 female; table S6.3) were 
vaccinated with a measles-mumps-rubella (MMR) live attenuated vaccine (Priorix®, GSK, 
Germany). 50 mL of blood were drawn immediately before vaccination (day 0), and at 6 
further time points (16 hours and days 1, 2, 3,7 and 14) or 2 further time points (days 1 
and 14) after vaccination in EDTA tubes (BD Biosciences, Plymouth, U.K.). Collected 
blood was processed and analysed directly. Serum from all donors was collected at days 
0, 1, 3 and 14 after vaccination in serum gel tubes (BD Biosciences, Plymouth, U.K.) and 
stored at -20°C until use. 
 
2.2.14 Measles, mumps, rubella and tetanus toxoid (TT) serology  
Specific IgM and IgG responses against measles, mumps and rubella, and IgG responses 
against TT were analyzed in days 0, 1, 3 and 14 of all vaccinees. Serum was analyzed 
with the measles, mumps, rubella and TT IgM and IgG-ELISAS (IBL International Gmbh, 
Hamburg, Germany) following manufacturer´s instructions. 
 
2.2.15 Isolation of PB mononuclear cellsBMC) 
Peripheral blood mononuclear cells were isolated by density gradient sedimentation using 
Ficoll-Paque Plus. PB was diluted 1:1 with PBS (room temperature). Each cell suspension 
was carefully layered on Ficoll in proportion 35ml cell suspension to 15ml Ficoll and 
centrifuged at 2000rpm for 20 minutes at room temperature (acceleration=7; 
deceleration=0). The upper plasma layer was removed and the intermediate lymphocyte 
layer transferred into a clean 50ml falcon tube. PBMCs/BMMCs were washed with cold 
PBS/BSA/EDTA and centrifuged for 10 minutes at 300xg and 4°C. The supernatant was 
discarded and the cell pellet resuspended in 50ml cold PBS/BSA/EDTA. To dispose of 
residual granulocytes the cells were ultimately centrifuged for 15 minutes at 180xg and 
4°C, the supernatant was discarded. 
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2.2.16 Analysis of absolute numbers of leukocyte populations 
To determine absolute counts of the analysed leukocyte populations, 50 µL of freshly 
drawn whole blood with 50 µL of antibody mixture [anti-CD45 (HI30), anti-CD56 (HCD56) 
and anti-CD3 (SK7), anti-CD19 (LT19), anti-CD4 (SK3) anti-CD8 (GN11/134D7) and anti-
CD14 (TM1)]. The staining was performed in the presence of FcR-blocking reagent 
(Miltenyi Biotec). After staining, erythrocytes were lysed by adding 500 µL of Buffer EL 
(Qiagen) and incubating 30 min at 4°C. Samples were directly analysed on a MACSQuant 
(Miltenyi Biotec), and counts of leukocyte populations measured were used for calculations 
of total cell populations determined in further FACS panels.  
 
 
 
 
 
 
2.2.17 Identification of MMR-reactive memory CD4+ T cells. 
For the identification of antigen-reactive CD4+ T cells, isolated PBMCs were cultured in 
RPMI 1640 supplemented with 1% GlutaMAX, 100 U/mL penicillin, 100 µg/mL 
streptomycin (Invitrogen Life Technologies), and 5% (vol/vol) human AB serum (Sigma-
Aldrich). Cells were stimulated with measles (5µg/mL) and mumps (5µg/mL) grade 2 
antigens, rubella K2S (10 µg/mL) antigen and tetanus toxoid (TT) (1,000 Lethal factor/mL) 
in the presence of CD28 functional grade (1 µg/mL). The specific reaction was controlled 
by including cells stimulated only with CD28 and CD28 plus SEB (1 µg/mL). For each 
condition, at least 5-10 x 106 cells were stimulated for 7 h at 37° and 5% CO2, in the 
presence of brefeldin A (1 µg/mL) for the last 2 h. After stimulation, cells were transferred 
to flow cytometry tubes and surface staining was performed for 10 min at 4°C with the 
Figure 2-5: Gating strategy for the whole blood cell counting panel measured in MACSQuant.  After 
exclusion of aggregates, cells from lysed whole blood were gated on CD45+ cells. Monocytes (CD14+) and B 
cells (CD19+) were identified. Cells being neither a monocyte nor a B cell were further distinguished into T cells 
(CD3+) and NK cells (CD56+): T cells were sub-divided into CD4+ and CD8+ T cells. Calculations of whole 
blood cell count on other panels were based on measured events of populations determined in this panel. 
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following Ab mixture [anti-CD3 (BW264/56), anti-CD4 (SK3), anti-CD8 (RPA-T8), anti-
CD45RA (HI100), anti-CD19 (BU12), anti-CD14 (TM1) and LD-PO]. Cells were fixed by 
incubating with 100 µL of 1X BD FACS Lysing solution and permeabilized by additional 10 
min incubation with 100 µL of 1X BD Perm2 solution. PBMCs were then washed with 
PBS/BSA and stained for 30 min at room temperature with the following antibody mix [anti-
CD154 (24-31), anti-IFNγ (45B3), anti-IL2 (MQ1-17H12), anti-TNFα (Mab11) and anti-KI67 
(20Raj1)]. Stained cells were measured using an LSR II flow cytometer (BD Biosciences). 
The antigen-reactive memory CD4+ T cells were identified as Live/Dead-CD19-CD14-CD3+ 
CD4+CD45RA-CD154+cytokine+ and the antigen-reactive proliferating cells were measured 
as Live/Dead-CD19-CD14-CD3+CD4+CD45RA-CD154+ Ki-67+. At least 1 x 106 lymphocytes 
were acquired. An exemplary gating is shown in figure 2.6: 
 
 
 
Figure 2-6: Gating strategy for the antigen-reactive memory T cells panel. Activated and cytokine 
expressing CD4+ T cells were assessed after antigen-specific stimulation of PBMCs at different time points. 
First, we gated on lymphocytes based on FSC-SSC properties and excluded aggregates. Then we gated on 
DUMP – (including dead, CD19+ and CD14+ cells) CD3+ T cells. After distinguishing from CD8+ and CD4+, we 
analyzed activation marker (CD154); cytokine (IFNγ; IL-2 and TNFα) and proliferation marker (KI-67) 
expression in CD4+ CD45RA- T cells. Co-expression of CD154 and cytokines or KI-67 is reported in the 
results. For assessment of the qualitative CD4+ T cell response, CD154+ CD4+ T cells were further used in 
Boolean gating approach generating results for all possible cytokine combinations. For each subpopulation, 
the background (as detected in the anti-CD28 stimulated control samples) was subtracted. 
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2.2.18 Multiparametric Flow cytometric analysis 
Eight- to twelve- colour flow cytometry analysis was performed in directly “ex vivo” isolated 
cells and antigen-stimulated samples for the analysis of phenotype and activation status. 
The following anti-human antibodies were used for this purpose [anti-CD3 (BW264/56), 
anti-CD4 (SK3), anti-CD8 (RPA-T8), anti-CD45RA (HI100), anti-CD69 (FN50), anti-CD127 
(REA614), anti-CXCR5 (REA215), anti-Ki-67 (20Raj1), anti-CD137 (484), anti-PD1 
(EH12:2H7), anti-CCR7 (G043H7), anti-CD154 (24-31), anti-CD19 (BU12), anti-CD14 
(TM1) and fixable Live/Dead PO. Stained cells were acquired in an LSR II flow cytometer 
(BD Biosciences). An example of the gating strategy used to define the expression of 
activation and phenotypic markers is depicted in figure 2.7: 
 
 
 
Figure 2-7: Gating strategy for cellular profiling of antigen-reactive CD4+ T cells. Antigen-reactive CD4+ 
T cells were further phenotypically characterized after antigen-specific stimulation of PBMCs at different time 
points. First, I gated on lymphocytes based on FSC-SSC properties and excluded aggregates. Then I gated on 
DUMP – (including dead, CD19+ and CD14+ cells) CD3+ T cells. After distinguishing from CD8+ and CD4+, I 
gated on the activation marker (CD154) and assessed the expression of various cell subset defining (CD127; 
CD137, CCR7, PD-1 and CXCR5) markers.  
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2.2.19 FACS enrichment of antigen-reactive CD4+ T cells 
For enrichment of antigen-specific memory CD4+ T cells, at least 5 x 107 PBMCs were 
stimulated for 7 h with measles grade 2 antigens (5µg/mL) in the presence of 1 μg/ml 
CD40 functional grade pure Ab (Miltenyi Biotec). After stimulation, cells were stained 15 
min at room temperature with the following mixture of antibodies [anti-CD3 (UCHT1), anti-
CD4 (TT1), anti-CD8 (GN11/134D7), anti-CD19 (BU12), anti-CD14 (TM1), anti-CD45RA 
(HI100), anti-CD69 (FN50) and anti-CD154 (24-31)]. Stained cells were purified by using 
an Aria II FACS sorter according the following gate strategy: 
- PI-CD19-CD14-CD3+ CD4+CD45RA-CD154+CD69+. 
Measles-specific memory CD4+ T cells sorted at days 0, 1 and 14 after vaccination were 
further processed for TCR sequencing, and measles-specific  memory CD4+ T cells sorted 
at day 1 after vaccination were used for the generation of antigen-specific T cell lines. 
 
2.2.20 Expansion and re-stimulation of Ag-specific T cell lines 
Stimulation of PBMCs and isolation of antigen-reactive memory CD4+ T cells were 
performed as described above. Isolated CD69+CD154+ CD4+ T cells were cultured with 
CD3 depleted and irradiated (40 Gy for 35 min) autologous feeder cells in a ratio of 1:100 
in 48-well plates in X-VIVO15 (Lonza), supplemented with 100 U/mL penicillin, 100 µg/mL 
streptomycin (Invitrogen Life Technologies), 5% (vol/vol) human AB serum and 200 IU/mL 
IL-2 (Proleukin®). Cells were expanded for 14 days, changing culture media with 
containing new IL-2 every 3 days during the first 10 days.  
For re-stimulation, freshly isolated autologous PBMCs were labelled with CFSE (1 μM) 
following manufacturer´s protocol. 2,5 x 105 expanded T cells were combined with labeled 
PBMCs in a ratio of 1:2 and stimulated with different antigens (measles, mumps, rubella, 
TT and CMV) in the presence of CD28 functional grade pure (1 µg/mL; Miltenyi Biotec) for 
6 h, adding brefeldin A (1 µg/mL; Sigma-Aldrich) after the first 2 hours. Cells were stained 
with surface and intracellular markers as described above for the analysis of CD154 and 
cytokine expression, using the following antibodies [anti-CD3 (BW264/56; Miltenyi Biotec), 
anti-CD4 (SK3; eBioscience), anti-CD8 (RPA-T8; Biolegend), anti-CD45RA (HI100; 
Biolegend), anti-CD19 (BU12, DRFZ), anti-CD14 (TM1, DRFZ), anti-CD154 (24-31), anti-
IFNγ (45B3), anti-IL2 (MQ1-17H12; all from Biolegend), anti-TNFα (Mab11; 
BDPharminogen) and anti-KI67 (20Raj1; eBioscience)]. 
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2.2.21 TCRV libraries preparation and data analysis 
2500 Measles-specific memory CD4+ T cells were sorted at days 0, 1 and 14 as described 
above for CDR3 TCRβ library preparation and sequencing. Total RNA extraction and 
library preparation were performed as explained in section 2.2.11. 
2x150bp paired-end sequencing of TCRβ amplicons was performed on the Illumina 
NextSeq 500 platform. Inline barcodes were demultiplexed and Illumnia Adapters removed 
by Illuminas bcl2fastq 1.8.4 software. De-multiplexing of sample barcodes as well as the 
extraction of the CDR3-sequences were performed by migec 1.2.4 using the unique 
molecular identifier guided assembling and error correction with default setting, minimal 
number of 5 reads per UMI and blast. Downstream analyses were performed based on 
functional CDR3 nucleotide sequences, i.e. not containing a stop codon or frame shift, 
using own scripts. Technical replicates were merged if specified. Diversity of the TCRβ 
repertoires was compared using the Efron and Thisted index and hill numbers. The TCRβ 
repertoire for measles-specific clonotypes were evaluated by comparing clonotypes solely 
appearing on a particular day post vaccination, that is constantly present in both replicates 
at that day and not appearing in any sample from different day.  
 
2.2.22 Data acquisition, analysis and statistics 
FACS data was acquired on LSR II by FACSDiva 6 and on MACSQuant by MACSQuantify 
Software. All FACS data were properly compensated using matching single-stain and 
FMO controls182. Data was exported into fcs-data files and analyzed with Flowjo 9.7.4 / 
Flowjo 10 (MacOS Version). Finalized, gated data was exported into data tables. For 
statistical analysis of any observed data GraphPad Prism 7 was used. To analyze two 
groups of paired samples, two-tailed Wilkoxon signed-rank test was used. For analyzing 
more than two groups, ANOVA analysis was applied. For the statistical analysis of The 
MMR vaccination study, 2-WAY repeated measurement ANOVA with time as a factor was 
used. P-value of<0.05 was considered significant. 
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3 Results 
3.1 Survival mechanisms of PB circulating versus BM resident 
memory T cells 
3.1.1 Differential survival patterns of PB and BM memory T cell subsets 
PB circulating and BM resident memory T cells are subjected to different environmental 
conditions, and therefore, might present different lifestyles. BM memory T cells are thought 
to be maintained in specialized stromal niches, which provide them with constant survival 
signals in order to maintain them alive and in a resting state. On the other hand, memory   
T cells from blood are in constant circulation, mostly receiving these survival signals during 
blood circulation or when going through secondary lymphoid organs or tissues. Oxygen 
levels present in blood differ from the BM microenvironment (from 13% in blood to 6.4% in 
BM 159), being a possible factor which could influence memory T cell survival. In order to 
determine the intrinsic survival capacity as such of memory T cells isolated from PB and 
BM, I analyzed the survival of CD4+ and CD8+ memory T cell populations when cultured in 
vitro. In addition, we assessed the influence of oxygen levels in memory T cell survival by 
culturing the cells in RPMI supplemented with %5 AB serum, in the presence of 21% or 
4% O2 (Figure 3.1). 
When culturing cells under 21% O2, both CD4+ and CD8+ CD69+ BM memory T cells 
showed reduced survival at days 3 and 5 of culture compared to BM CD69- and PB CD69- 
memory T cells. On average, 60% and 52% of CD69- memory CD4+ T cells of PB and BM 
were still alive at day 3 of culture, whereas only 45% of CD69+ BM memory CD4+ T cells 
survived in medium alone. Similarly, the average survival of memory CD8+ T at day 3 were 
47%, 48% and 36% for CD69- PB, CD69- BM, and CD69+ BM memory T cells, 
respectively. When cultured in 4% O2, survival of memory T cells was different. On 
average, at day three of culture, only 45% of PB memory CD4+ T cells were alive, whereas 
52% of CD69- BM and 56% of CD69+ BM memory T cells survived. All cell subsets of 
CD8+ memory T cells analyzed showed a similar survival at day 3 of culture at ~55%.  
In order to define the half-lives in hours for memory T cells, I determined time where 50% 
of the population was still alive compared to the starting cell numbers at day 0 of culture. In 
concordance with the results obtained from the survival curves, under 21% O2, PB 
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memory CD4+ T cells showed a significantly increased half-life compared to the BM 
counterparts (p=0.0033 and p=0.0458 compared to BM CD69+ and BM CD69- 
respectively). CD69+ BM memory T cells displayed the shortest half-life (Figure 3.1). 
Similar tendency was observed in the memory CD8+ memory T cell populations, where 
CD69- and CD69+ BM memory CD8+ T cells showed a reduced half-life compared to the 
PB counterparts. In particular, CD69+ BM memory CD8+ T cells had a significantly 
decreased half-life compared to the PB counterparts (p=0.0027). When culturing cells with 
4% O2, no significant differences in half-lives were detected between any of the memory   
T cell subsets and half-life of BM memory T cells were increased compared to the ones 
obtained with 21% O2. 
 
 
 
    
Figure 3-1: Different ex vivo PB and BM cell survival. Ex vivo CD69+ and CD69- memory CD4+ and CD8+   
T cells were isolated from paired blood and BM samples (n=6). Cells were cultured in RPMI supplemented with 
5% human AB serum. (A) Cell viability was assessed by flow cytometry at the indicated time points by annexin 
V (ANV) and propidium iodide (PI) staining and frequencies of surviving cells were normalized to the numbers 
of viable cells counted at day 0. (B) Half-life was calculated for each individual donor and plotted for the 
different cell subsets.  
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3.1.2 Determination of IL-7/IL-15 concentration to maintain resting, non-
proliferating memory T cells 
Several studies have already demonstrated the involvement of IL-7 and IL-15 in the 
survival of memory CD8+ T cells 144,145 and memory CD4+ T cells, although with 
controversial data for the latter 144,147. Previous studies from our group showed that BM 
memory T cells are residing in specific survival niches, where they rest in terms of 
proliferation, transcription and migration 59,135. In order to determine the appropriate 
working concentration to maintain memory T cell survival without inducing proliferation, I 
tested an array of concentrations of both IL-7 and IL-15 (0.1/1/10 ng/mL) and measured 
the survival rates at indicated time points following the protocol as described before.  
High concentrations of either cytokines (10 ng/mL) induced proliferation of PB and BM 
memory CD4+ and CD8+ memory T cells, identified by the appearance of blasting cells and 
the increase of cell numbers at day 5 of culture. Cell numbers at day 5 of culture increased 
by 1.5- to 3-fold compared to the number of cells plated at day 0 (Figure 3.2A). On the 
other hand, when using 0.1-1 ng/mL of either cytokines, none of the effects mentioned 
above was detected, suggesting that cytokine concentrations below 1 ng/mL maintain 
memory T cells in a resting state. Survival of memory CD4+ T cells was enhanced when 
cultured with 1 ng/mL compared to 0.1 ng/mL, with some variations in CD8+ memory         
T cells. Interestingly, we detected no significant improvement in memory CD4+ T cell 
survival when adding both IL-7 and IL-15 to the cell cultures compared to the effect of 
each cytokine alone (Figure 3.2B).  
Finally, to control whether proliferation was induced in the presence of 1ng/ml of cytokines, 
I measured the expression of Ki-67 in BM memory T cells at day 3 of culture with or 
without IL-7 and IL-15 at 1 ng/mL. In all analyzed conditions (-, IL-7 at 1 ng/mL or IL-15 at 
1 ng/mL), the frequency of Ki-67+ cells remained below 1%, and no increased proliferation 
was detected in the conditions where cytokines were added at a concentration of 1 ng/mL 
(Figure 3.2C). Taking all this information into account, I chose 1 ng/mL as the 
concentration to be used for further survival experiments, as it was able to maintain 
survival of all memory T cell subsets to a greater extent than 0.1 ng/mL, keeping cells in a 
resting state, with no signs of proliferation. 
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Figure 3-2: Determination of concentrations of IL-7 and IL-15 that support memory T cell survival 
without induction of proliferation. CD69+ and CD69- memory CD4+ and CD8+ T cells were isolated from BM 
samples. Cells were cultured under 21% O2 in RPMI supplemented with 5% human AB serum (-) or in medium 
supplemented with IL-7 and IL-15 at 0.1-1-10 ng/mL. Cell viability was assessed by flow cytometry at the 
indicated time points by annexin V (ANV) and propidium iodide (PI) staining and frequencies of surviving cells 
were normalized to the numbers of viable cells counted at day 0. (A) Test of IL-7 and IL-15 at 10 ng/mL. (B) 
Test of IL-7 and IL-15 at 0.1-10 ng/mL. (C) Ki-67 expression was measured in memory T cells at day 3 of 
culture by intracellular staining. 
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3.1.3 IL-7 and IL-15 but no other cytokines tested support memory T cell 
survival 
IL-7 and IL-15 showed to have a clear effect in sustaining memory T cell survival. In 
addition to that, data supporting the role of other cytokines, such as IL-33, TGFβ and TNF, 
which have been implicated in the generation of tissue resident memory T cells, on the 
maintenance of memory T cells is sparse 92. In order to identify possible additional soluble 
factors involved in the maintenance of BM memory T cells, I cultured sorted memory CD4+ 
and CD8+ T cells with or without different cytokines (IL-7 andIL-15 at 1 ng/ mL; and IL-6, 
IL-33, TGFβ and TNFα at 10 ng/mL) and assessed their survival. Of all the tested 
cytokines, only IL-7 and IL-15 improved cell survival compared with medium-only controls 
in both, CD4+ and CD8+ memory T cells (Figure 3.3). Less than 20% of memory T cells 
cultured in medium-only conditions (-) were alive after 5 days of culture. The addition IL-7 
and IL-15 to the cultures maintained ~40% of CD4+CD45RA-CD69+ and ~55% of 
CD4+CD45RA-CD69- at day 5 of culture, with IL-7 having a slightly better effect than IL-15 
in both cell populations (Figure 3.3A). When looking at CD8+ memory T cells, both 
cytokines also kept ~50% of CD8+CD45RA-CD69+ and ~40% of CD4+CD45RA-CD69- alive 
at day 5 of culture, with IL-15 being more effective in maintaining cell survival in this case 
(Figure 3.3B). 
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Figure 3-3: IL-7 and IL-15 but no other cytokines tested support memory T cell survival. CD69+ and 
CD69- memory CD4+ and CD8+ T cells were isolated from BM samples. Cells were cultured under 21% O2 in 
RPMI supplemented with 5% human AB serum (-) or in medium supplemented with indicated cytokines and 
concentrations. Cell viability was assessed by flow cytometry at the indicated time points by annexin V (ANV) 
and propidium iodide (PI) staining and frequencies of surviving cells were normalized to the numbers of viable 
cells counted at day 0. (A) Survival curves for BM memory CD4+ T cells. (B) Survival curves for BM memory 
CD8+ T cells. 
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3.1.4 IL-7 and IL-15 partially but significantly increase the survival of PB/BM 
memory T cells 
After testing different cytokines and selecting the right working concentrations of IL-7 and 
IL-15, I performed a more extensive analysis of the effect of the cytokines in cell survival 
using cells from 6 donors (2 males and 4 females, age 70  10). I cultured memory T cells 
from both PB and BM from the same donor under 21% O2 with or without the indicated 
cytokines at a concentration of 1 ng/mL. As shown above (Figure 3.1), under these oxygen 
conditions both PB memory CD4+ and CD8+ T cells survived better than the BM 
counterparts in the absence of any additional stimulus (Figure 3.4).In CD4+ memory          
T cells, IL-7 had a significant effect on cell survival, significantly increasing cell survival of 
all cells at day 5 of culture; from ~20% of cells alive in medium-only conditions to > 50% 
alive when the cytokine was present (p=0.0019 in BM CD4+CD69+, p=0.0052 in BM 
CD4+CD69- and p< 0.0001 in PB CD4+CD69-). IL-15 also improved cell survival, but to a 
lesser extent, maintaining from 40 to 48% of cells alive at day 5 and reaching only 
significance at day 5 in BM CD4+CD69+ (p=0.017) and PB CD4+CD69- (p=0.002) cells 
(Figure 3.4A). I found much more variances between donors when analyzing the survival 
of CD8+ memory T cells. However, both cytokines also increased CD8+ memory T cell 
survival in a similar way. In particular, survival of BM CD8+CD69+ T cells was significantly 
increased at day 5 of culture (p=0.0182). Moreover, IL-7 and IL-15 significantly supported 
the survival of PB CD8+CD69- cells at day 5 of culture (p=0.002 for IL-7 and p=0.001 for   
IL-15) (Figure 3.4B). Altogether, these results suggest that IL-7 and IL-15 are able to 
maintain the survival of memory T cells, significantly increasing the numbers of live cells at 
days 3 or 5 of culture. However, I could not maintain more than 65% of the cells alive in 
any of the assays performed; suggesting that they may be additional factors involved in 
the long-term maintenance of memory T cells. 
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Figure 3-4: IL-7 and IL-15 significantly increase survival of memory T cells. Ex vivo CD69+ and CD69- 
memory CD4+ and CD8+ T cells were isolated from BM samples. Cells were cultured under 21% O2 in RPMI 
supplemented with 5% human AB serum (-) or in medium supplemented with IL-7 or IL-15 at 1 ng/mL. Cell 
viability was assessed by flow cytometry at the indicated time points by annexin V (ANV) and propidium iodide 
(PI) staining and frequencies of surviving cells were normalized to the numbers of viable cells counted at day 
0. (A) Survival curves for BM memory CD4+ T cells. (B) Survival curves for BM memory CD8+ T cells. 
Statistical differences were calculated by 2-WAY ANOVA with Turkey correction (p<0.0332 (*), p<0.0021 (**), 
p<0.0002 (***), p<0.00001 (****)). 
 
3.1.5 Stromal cells maintain memory T cell survival similar to cytokines 
Apart from the soluble factors, cell-cell contacts between T cells and stromal cells are also 
thought to be important for the maintenance of memory T cells. Molecules expressed by 
stromal cells, such as VCAM-1 and collagens I, II and XI were shown to interact with 
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specific receptors expressed in memory T cells and could contribute to the maintenance of 
memory T cells. To test the role of stromal cells in memory T cell survival, I used a human 
bone marrow stromal cell line (HS5) and compared its effect on memory T cell survival 
with the one exerted by the cytokines. Publicly available transcriptomes from this cell line 
(http://www.ncbi.nlm.niih.gov/geo) show that the HS5 cells do not express IL-7 and 
express only little amounts of IL-15, whereas they express high amounts of VCAM-1 and 
collagens in their surface. Moreover, analysis of supernatants of stromal cell co-cultured 
with and without memory T cells by Luminex beads revealed no detectable levels of IL-7 
and IL-15 (data generated by Jessica Dysarz during her Bachelor´s Thesis). As the human 
BM oxygen levels are approximately 6% 159, I performed the following experiments using 
4% O2, in order to mimic as closely as possible the BM environment. 
I analyzed cells of 6 donors (3 males and 3 females, age 66  8) and determined the 
survival of PB and BM memory T cells without any stimulus (-), in the presence of IL-7 and 
IL-15, or when co-cultured with HS5 stromal cells. As showed before (Figure 3.1), when 
culturing memory T cells under reduced levels of oxygen (4% O2), BM memory T cells 
survive better than their PB counterparts when no additional stimulus is present (Figure 
3.5). For memory CD4+ T cells, IL-7 and IL-15 had similar effects than the ones described 
in section 3.1.4. When memory T cells were cultured without any additional stimulus (-), 
~20% of the cells were alive at day 5 of culture, whereas IL-7 and IL-15 were able to 
maintain ~50% of cells alive at day 5. Co-culture of CD4+ memory T cells with HS5 
resulted in a significant improvement of survival, keeping from 50 to 62% of memory         
T cells alive at day 5 of culture. Cell survival was significantly improved in BM CD4+CD69+ 
(p=0.009 (day 3) and p<0.0001 (day 5), BM CD4+CD69- (p=0.0137 (day 3) and p<0.0001 
(day 5) as well as PB CD4+CD69- (p=0.0006 (day 1), p<0.0001 (day 3) and p<0.0001 (day 
5) (Figure 3.5A). When analyzing memory CD8+ T cells, I could also detect a similar effect 
of the cytokines as described in section 3.1.4, with IL-15 showing a greater role in the 
maintenance of memory CD8+ T cells compared with IL-7. Co-culture of memory CD8+      
T cells with HS5 cells increased the survival of memory T cells from ~20% to 50-60% at 
day 5 of culture. The numbers of viable cells were increased in BM CD8+CD69+ (p=0.001 
(day 3) and p<0.0001 (day 5), BM CD8+CD69- (p<0.0001 (day 5) as well as PB 
CD8+CD69- (p=0.0059 (day 1), p<0.0001 (day 3) and p<0.0001 (day 5) (Figure 3.5B). 
Altogether, the co-culture of memory T cells with a bone marrow stromal cell line maintains 
the survival of the cells, to the same or better extent than IL-7 and IL-15. However, neither 
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cytokines nor stromal cells are sufficient by themselves to maintain memory T cells long-
term, as they cannot keep all cells alive after 5 days of culture (Figure 3.5). 
 
 
 
 
Figure 3-5: IL-7 / IL-15 and stromal cells are involved in the maintenance of memory T cells survival. Ex 
vivo CD69+ and CD69- memory CD4+ and CD8+ T cells were isolated from BM samples. Cells were cultured 
under 4% O2 in RPMI supplemented with 5% human AB serum (-), in medium supplemented with IL-7 or IL-15 
at 1 ng/mL or co-cultured with HS5. Cell viability was assessed by flow cytometry at the indicated time points 
by annexin V (ANV) and propidium iodide (PI) staining and frequencies of surviving cells were normalized to 
the numbers of viable cells counted at day 0. (A) Survival curves for BM memory CD4+ T cells. (B) Survival 
curves for BM memory CD8+ T cells. Statistical differences were calculated by 2-WAY ANOVA with Turkey 
correction (p<0.0332 (*), p<0.0021 (**), p<0.0002 (***), p<0.00001 (****)). 
Next, I analyzed the expression of the IL-7R (CD127) as marker of IL-7 signaling. It has 
been shown, that exposure to IL-7 decreases cell-surface expression of CD127 in CD4+ 183 
and memory CD8+ T cells within 24-48 h of culture 184. Therefore, I aimed to know whether 
the culture of our memory T cells, either with cytokines or the stromal cells, induced a 
down-regulation of CD127.  
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I could detect a rapid down-regulation of CD127 expression in all memory T cell 
populations when cultured with IL-7, compared to the non-stimulated (-) samples. This 
down-regulation was already visible 24h after the start of the cultures and was maintained 
during all the analyzed time-points, suggesting the continuous action of IL-7. Moreover,  
IL-15 also induced a down-regulation of CD127 in BM CD69- and PB CD69-, for both CD4+ 
and CD8+ memory T cells (Figure 3.6), albeit to a lower degree. This data further 
reinforces the hypothesis that stromal cells support memory T cell survival via different 
mechanisms than cytokine secretion (IL-7 and IL-15), as the co-culture of memory T cells 
with HS5 cells did not induce down-regulation of CD127 surface expression. 
 
 
 
 
 
Figure 3-6: IL-7 and IL-15, but not co-culture with stromal cells down-regulate CD127 expression on 
memory T cell surface. Ex vivo CD69+ and CD69- memory CD4+ and CD8+ T cells were isolated from BM 
samples. Cells were cultured under 4% O2 in RPMI supplemented with 5% human AB serum (-), in medium 
supplemented with IL-7 or IL-15 at 1 ng/mL or co-cultured with the human BM stromal cell line HS5. CD127 
surface expression was analyzed on live cells at different timepoints. 
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3.1.6 Stromal cells mediate memory T cell survival via contact-dependent 
mechanisms 
The HS5 human bone marrow stromal cell line does not express IL-7 at an mRNA level 
and does not produce high levels of either, IL-7 and IL-15 proteins, as they were not 
detected in the supernatants by Luminex analysis (performed by Jessica Dysarz). Other 
soluble factors produced by stromal cells as well as cell-cell interactions could be 
responsible for the maintenance of memory T cells. To determine whether the effect on 
cell survival performed by HS5 cells was cell-contact dependent or not, I designed a 
transwell (TW) assay (performed by Jessica Dysarz) in which memory T cells were plated 
on the top of a membrane which was placed onto a well seeded with stromal cells. This 
assay allows the memory T cells to be in contact with the soluble factors secreted by the 
stromal cell line without having direct contact with it. The analysis of viable cell numbers at 
day 3 of culture, comparing memory T cells without any stimulus (-), in direct contact with 
HS5 cells or in transwells (TW) revealed that the survival effect produced by stromal cells 
is contact-dependent (Figure 3.7A). In all donors analyzed (n=3), we could reproducibility 
detect an increased frequency of viable memory T cells (40-60%) when cultured in direct 
contact with HS5 , whereas the survival of BM memory T cells cultured in the transwells 
remained similar to the non-stimulated ones (10-20%). 
In addition, we tested the capacity of HS5 supernatants to support the survival of BM 
memory T cells (study performed by Kathrin Stilz during her Master´s Thesis). For that, we 
took the supernatant of 1 day cultured stromal cells and added it to the memory T cell 
cultures. As shown before, BM memory CD4+ and CD8+ T cell directly co-cultured with 
HS5 cells had significantly increased survival (Figure 3.7B). The addition of stromal cell 
supernatant (SBNT) to memory T cell cultures resulted only in a minor increase of 
surviving cells, reinforcing the idea that BM stromal cells exert their role on the 
maintenance of memory T cells mainly via cell-cell interactions. 
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Figure 3-7: Cell-contact dependency of memory T cells with BM stromal cells. Ex vivo isolated CD69+ 
and CD69- memory CD4+ and CD8+ T cells of BM were were cultured under 4% O2 in RPMI supplemented with 
5% human AB serum (-) or in co-culture with stromal cells in different conditions. (A) Memory T cells were 
cultured directly with HS5 stromal cells or in transwell (TW). (B) Memory T cells were cultured in direct contact 
with HS5 cells or with HS5 supernatants (SBNT). Cell viability was assessed by flow cytometry at the indicated 
time-points by annexin V (ANV) and propidium iodide (PI) staining and frequencies of surviving cells were 
normalized to the numbers of viable cells counted at day 0. 
 
3.1.7 Combination of cytokines and HS5 cells induce memory T cell 
proliferation 
Histological analysis of memory CD4+ T cells in the murine BM have revealed direct 
contact of these cells with VCAM+ IL-7 producing stromal cells 77, suggesting both factors, 
cell-cell contact and cytokine signaling, are involved in the maintenance of memory T cells. 
Moreover, when culturing memory T cells either with cytokines or stromal cells, I could 
only achieve a partial effect in the survival of memory T cells. Therefore, I decided to 
combine both factors in order to investigate whether they could have synergistic roles in 
the long-term maintenance of memory T cells. I cultured BM memory T cells in the 
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presence of HS5 cells and cytokines, and measured survival (Figure 3.8). In all BM 
memory T cell populations, I detected an increase of cell numbers from day 3 to day 5 
when cells were cultured with HS5 cells and cytokines, suggesting that the levels of 
cytokines used together with HS5 were inducing T cell proliferation (Figure 3.8A).Thus, I 
titrated the cytokines from 1 ng/mL to 0.001 ng/mL in order to see whether with lower 
cytokine concentrations memory T cells stayed in a quiescent state. The addition of IL-7 
and IL-15 at concentrations of 1-0.1 ng/mL with the stromal cell line induced an increase 
on the cell numbers of memory T cells at day 5 compared with day 3, indicating 
proliferation. Concentrations of 0.01 ng/mL did not induce proliferation, but also did not 
show a significant improvement in cell survival when comparing with memory T cells co-
cultured with HS5 alone (Figure 3.8B). Taking this information into account, until now, our 
in vitro system does not allow us to fully mimic the conditions found in the BM 
environment, where memory T cells are maintained in a resting state 59.  
 
 
Figure 3-8: No synergistic effects of cytokines and stromal cells in the maintenance of memory T cells 
survival. CD69+ and CD69- memory CD4+ and CD8+ T cells were isolated from BM samples. Cells were 
cultured under 4% O2 in RPMI supplemented with 5% human AB serum (-), or in co-culture with HS5 stromal 
cells with and without cytokines. Cell viability was assessed by flow cytometry at the indicated time-points by 
annexin V (ANV) and propidium iodide (PI) staining and frequencies of surviving cells were normalized to the 
numbers of viable cells counted at day 0. (A) Memory T cells were cultured with HS5 plus IL-7 or IL-15 at 1 
ng/mL. (B) Memory T cells were cultured with HS5 stromal cells and different concentrations of IL-7plus IL-15 
(0.01-0.1 and 1 ng/mL).  
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3.1.8 Cytokines and HS5cells support memory T cell survival via different 
molecular mechanisms 
So far, results obtained in our studies suggested that either cytokines or stromal cell 
contact contribute to the survival of non-proliferating memory T cells via different 
pathways. The co-culture of memory T cells with HS5 cells did not induce a down-
regulation of CD127 (Figure 3.6) and the analysis of survival when using the transwell and 
the stromal cell supernatant indicated the contact dependency between stromal cells and 
memory T cells (Figure 3.7).  
It is known, that the receptors for the common -chain cytokines (including IL-7 and IL-15) 
are involved in the regulation of circulating naïve and memory T cell homeostasis 145, 
inducing the expression of anti-apoptotic factors (BCL-2 and BCL-XL). Moreover, BIM is a 
probable candidate for cell death inducer after IL-7 or IL-15 withdrawal from memory         
T cells 171. However, the survival pathways involved in memory T cell maintenance and the 
role of these factors in activating or inhibiting the different pro- and anti-apoptotic 
molecules remains still unknown. In order to better understand which molecular factors are 
important for memory T cell survival and how are they modulated by IL-7, IL-15 or cell 
contact with stromal cells, we measured the expression of two pro-apoptotic (BIM and 
NOXA) and two anti-apoptotic (BCL-2 and MCL-1) factors in memory T cells under 
different conditions at day 3 of in vitro culture.  
I detected a significant increase in the anti-apoptotic molecule BCL-2 expression in the 
presence of both IL-7 and IL-15, but not when cells were co-cultured with the stromal cell 
line HS5. On average, the increase on the mean fluorescence intensity of BCL-2 was 0.5-
fold (p<0.0001) with IL-7 and 0.3-fold (p=0.0005) with IL-15 in the BM CD4 CD69+ memory 
T cells, 0.46-fold (p<0.0001) with IL-7 and 0.26-fold (p=0.00073) with IL-15 in the BM CD4 
CD69- memory T cells and 0.48-fold (p<0.0001) with IL-7 and 0.17-fold (p=0.022) with     
IL-15 in the PB CD4 CD69- memory T cells. In all cases IL-7 increased BCL-2 to a greater 
extent than IL-15, correlating with the increased survival of memory CD4+ T cells when 
cultured with IL-7 compared to IL-15 (Figures 3.4 and 3.5). I did not observe any significant 
differences in the mean fluorescence intensity of the pro-apoptotic molecule BIM in any of 
the conditions analyzed. In consequence, the ratio of BCL-2 to BIM, an important 
parameter determining death or survival of the cells, was significantly increased in the 
memory T cells in the presence of both cytokines but not upon contact with HS5 (Figure 
3.9A).  
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On the other hand, the mean fluorescence intensity of the pro-apoptotic protein NOXA was 
significantly decreased when CD4+ memory T cells were co-cultured with stromal cells but 
not in the presence of both cytokines. On average, the decrease in the mean fluorescence 
intensity of NOXA was 0.23-fold (p=0.001) in the BM CD4 CD69+ T cells, 0.22-fold 
(p=0.0018) in the BM CD4 CD69- memory T cells and 0.15-fold (p=0.0082) in the PB CD4 
CD69- memory T cells. Moreover, I did not detect any significant changes in the 
expression of the pro-survival molecule MCL-1. As a result, I could see a significant 
increase of the MCL-1/NOXA ratio in memory cells co-cultured with stromal cells, but not 
when cultured with either IL-7 or IL-15 (Figure 3.9B). 
Within memory CD8+ T cells, the increase on the mean fluorescence intensity of BCL-2 
was 0.42 fold (p=0.0013) with IL-7 and 0.7-fold (p<0.0001) with IL-15 in the BM CD8 
CD69+ memory T cells, 0.62-fold (p<0.0001) with IL-7 and 0.62-fold (p=0.00073) with IL-15 
in the BM CD8 CD69- memory T cells and 0.54-fold (p<0.0001) with IL-7 and 0.2-fold (n.s.) 
with IL-15 in the PB CD8 CD69- memory T cells. As before, I did not detect any significant 
differences in BIM expression, thus leading to a significant increase of the BCL-2/BIM ratio 
in all memory T cell populations analyzed when cultured with IL-7 or IL-15. The BCL-2/BIM 
ratio was unaffected by contact with stromal cells (Figure 3.9C). 
Expression of NOXA was decreased 0.37 fold (p=0.00018) in the BM CD8 CD69+ memory         
T cells, 0.26-fold (p=0.0016) in the BM CD8 CD69- memory T cells and 0.23-fold (p=0.002) 
in the PB CD8 CD69- memory T cells. MCL-1 expression was unaffected resulting in a 
significantly increased MCL-1/NOXA ratio in cells co-cultured with the HS5 stromal cell 
line. 
These results suggest that whereas IL-7 and IL-15 exert their survival function through            
up-regulation of pro-survival factors, such as BCL-2, and therefore increasing a BCL-2/BIM 
ratio, memory T cell contact with stromal cells down-regulates the expression of the pro-
apoptotic protein NOXA, thus increasing the MCL-1/NOXA ratio. Thus, I can conclude that 
cytokines and contact with stromal cells are supporting memory T cell maintenance via 
different pathways, having each the potential to only partially maintain the survival of 
memory T cells (Figure 3.5). 
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Figure 3-9: Regulation of pro- and anti-apoptotic factors in memory T cells. CD69+ and CD69- memory 
CD4+ and CD8+ T cells were isolated from paired blood and bone marrow samples and. cultured under 4% O2 
in RPMI supplemented with 5% human AB serum (-) or in medium supplemented with IL-7, IL-15 or the human 
stromal cell line HS5. The expression of pro-/anti-apoptotic markers was determined at day 3 of culture by 
intracellular staining. Mean fluorescence intensity of each marker at the different tested conditions was 
normalized to the values detected in control samples without any stimulus (-). BCL-2/BIM and MCL-1/NOXA 
ratios were calculated by dividing the normalized value of one marker with the other. (A) Survival molecules 
expression on memory CD4+ T cells (n=8). (B) Survival molecules expression on memory CD4+ T cells (n=8). 
Statistical differences were calculated by 2-WAY ANOVA with Turkey correction (p<0.0332 (*), p<0.0021 (**), 
p<0.0002 (***), p<0.00001 (****)). 
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3.2 Compartmentalization of PB and BM memory T cells  
3.2.1 Antigen specificities of the BM are maintained by CD69+/- CD4+ memory 
T cells  
Previous studies performed in our group showed that the human BM is enriched for 
antigen-specific memory CD4+ T cells against long-term systemic antigens, such as 
measles, mumps or rubella; even when they are no longer detectable in blood circulation 
59. In order to investigate whether the enrichment of antigen-specific memory CD4+ T cells 
in BM in due to their specific accumulation in the CD69+ memory T cell population, or both 
CD69+ and CD69- memory CD4+ T cells maintain these long-term specificities, I analyzed 
the compartmentalization of measles and TT-specific CD4+ memory T cells, using SEB as 
a positive control for the capacity of each of the populations to respond to stimulation. For 
that, I separated CD69+ and CD69- memory T cells by magnetic cell separation, stained 
them with CFSE or efluor670 as described in material and methods, mixed and stimulated 
them with the corresponding antigens. In some cases, I included paired blood samples 
(also labeled with CFSE) when analyzing measles-specific memory CD4+ T cells. The 
magnitude of antigen-specific response was assessed by intracellular CD154, TNFα, IFNγ 
and IL2 staining and flow cytometric analysis. Memory CD4+ T cells expressing CD154 
and at least one of the above-mentioned cytokines were considered specific for the tested 
antigens. Stimulation with aCD28 alone was performed as negative control, and 
background generated with this stimulation was subtracted from frequencies of cells 
reactive to aCD28 plus antigen before all calculations. 
I did not detect any significant differences on the frequencies of measles-reactive CD69- 
and CD69+ memory T cells. On average, I could detect 0.23 ± 0.18% and 0.19 ± 0.11% of 
measles-specific T cells and 0.056 ± 0.032% and 0.057 ± 0.029% among CD69- and 
CD69+ BM memory CD4+ T cells, respectively (Figure 3.10A). Average frequencies of    
TT-specific cells differed from 0.13 ± 0.11% in the CD69- to 0.021 ± 0.02% in the CD69+ 
cell subsets, showing an enrichment of TT-specific cells in the CD69- compartment, albeit 
not statistically significant. Unspecific stimulation of BM cells with SEB resulted in similar 
responses in both cell subsets, with an average of 6.38 ± 4.18% in the CD69- and 7.47 ± 
3.59% in the CD69+ fractions (Figure 3.10B). The analysis of measles-specific memory 
CD4+ T cells from paired PB and BM samples corroborated previous results showing the 
enrichment of measles-specific memory CD4+ T cells in BM compared with PB59. 2 of the 5 
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donors analyzed showed frequencies of measles-reactive cells among memory CD4+        
T cells below the established limit of detection. In average, I detected significant 
differences in the percentages of measles-specific memory T cells between PB and BM, 
with a p=0.0122 and p= 0.0388 when compared to the CD69+ and the CD69- populations 
respectively. As mentioned above, no differences in percentages of measles-specific 
memory T cells were found between CD69+ and CD69- cells (Figure 3.10C). 
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Figure 3-10: Distribution of measles and TT-specific cells in CD69+ and CD69- BM memory CD4+ T cells. 
The antigen-specific T cell response was quantified by the expression of CD154, TNFα, IFNγ and IL2. aCD28 
background was subtracted from all samples. Cells positive for CD154 and expressing at least one of the 
analyzed cytokines were considered as antigen-specific and polyfunctional cells were calculated using Boolean 
gates from FlowJo software. (A) Percentages of antigen-specific T cells among memory CD4+ T cells and (B) 
percentages of polyfunctional antigen-specific T cells.  Data shown represent n=8, n=5 and n=5 for measles, 
TT and SEB respectively. (C) Analysis of measles-specific T cells in paired PB / BM samples. Each donor is 
represented by a symbol for the three different cell subsets (n=5). The reliable detection limit was set at 0.01% 
among memory CD4+ T cells. To analyze two groups of paired samples, two-tailed Wilkoxon signed-rank test 
was used. For analyzing more than two groups, ANOVA analysis with Turkey correction was applied 
(p<0.0332 (*), p<0.0021 (**), p<0.0002 (***), p<0.00001 (****)). 
 
3.2.2 Flow cytometric analysis reveals different TCR Vβ repertoire of PB and 
BM memory T cells 
To determine the clonal heterogeneity of memory T cells isolated from PB versus BM, the 
distribution of T cell Vβ families was compared between both populations. Using a flow 
cytometry approach, I assessed the expression of 24 TCR Vβ chains (~70% of the Vβ 
TCR181) among CD4+ and CD8+ memory T cells from PB and BM. Our results showed a 
highly diversified TCR repertoire in memory T cells from PB and BM. All Vβ families tested 
were found to be present in all of the CD4+ and CD8+ memory T cell subsets. Moreover, 
frequencies of the individual TCR Vβ families in the different analyzed donors were very 
heterogeneous. TCR Vβ family distribution of each cell population was characterized by 
mean, standard deviation (SD), minimal and maximal values (Appendix tables 6.1A and 
6.1B). The composition of TCR Vβ families was similar among CD69- and CD69+ BM 
memory CD4+ T cells, where no significant differences were found in any of the variants 
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analyzed. In contrast, I could detect a significant enrichment of Vβ5.1 in PB compared to 
both CD69-/+ BM memory CD4+ T cells (p= 0.001) and of Vβ21.3 compared to the CD69- 
BM population (p=0.038) (Figure 3.11). No significant differences were found among the 
CD8+ memory T cell populations, where the variation between donors was much higher 
(Figure 3.11).  
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Figure 3-11: Comparison of the TCRβ repertoire in CD4+ (A) and CD8+ (B) memory T cell subsets 
from PB and BM. Mononuclear cells were isolated from paired blood and BM samples. Cells were directly 
stained with 24 TCRβ-specific monoclonal antibodies. Individual TCRβ expression was analyzed on gated 
CD69+ and CD69- memory CD4+ T cells by flow cytometry. Average frequencies for each of the TCRβ 
families are shown in the box plots with Min to Max Whiskers (n=8). Statistical differences were calculated 
by 2-WAY ANOVA with Turkey correction (p<0.0332 (*), p<0.0021 (**), p<0.0002 (***), p<0.00001 (****)). 
 
3.2.3 CDR3 TCRβ sequencing reveals different compartmentalization of 
memory T cells 
Flow cytometric analysis of the TCR repertoire using antibodies specific for 24 Vβ families 
identified in humans provided us with an overall view of TCR usage. However, this did not 
account for the plethora of individual clones within each family. CDR3 TCRβ Next 
Generation Sequencing (NGS) allowed me to identify and quantify the distribution and 
expansion of individual T cell clones in PB and BM of an individual. The hypervariable 
complementary determining region 3 (CDR3) of the TCRβ chain is largely responsible for 
determining T cell specificity. The nucleotide sequence of CDR3 is unique for each T cell 
clone and thus can be used to track it and quantify its abundance in human PB and BM. I 
sorted CD4+ and CD8+ memory T cells (both CD69+ and CD69-) from paired PB and BM 
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samples and determined the different CDR3 sequences of the TCRV-chains in 4 donors. 
I chose RNA as starting material in order to analyze only functional molecules. Moreover, I 
introduced Unique Molecular Identifiers (UMIs) to all samples. UMI barcoding controls the 
numbers of molecules that have successfully entered cDNA synthesis and passed through 
amplification, which Ire then analyzed in the sequencing output. Such quantification is 
important to be able to perform normalized comparison of repertoires, as it excludes errors 
due to biased amplification during the PCR amplification steps185. To control for 
experimental variation in the library preparation and sequencing, samples from 1 donor 
were split following RNA extraction. Library preparation, NGS and analysis were 
performed in parallel to control for the robustness of the method. For the final analysis the 
data for this sample were pooled again. 
First of all, I analyzed the clonal distribution of all replicates to determine the robustness of 
the method and the diversity of all studied samples. Technical replicates showed similar 
numbers of found sequences and clonotypes (Appendix table 6.2). I 
I found 31-34% overlap between memory CD4+ replicates, whereas the overlaps between 
memory CD8+ technical replicates was higher than 83% in all cases (Figure 3.12). Even 
though the overlap between memory CD4+ T cell replicates is low, the high overlap 
observed between the memory CD8+ T cell samples indicates high reproducibility of the 
technical method used. When looking at the TCRβ diversity of analyzed samples, CD4+ 
memory T cells showed a more diverse repertoire compared to the CD8+ memory T cells 
(Appendix table 6.2). On average, the 10 most abundant clones found in all CD4+ memory 
T cell subsets occupied less than 10% of the clonal space, whereas in CD8+ memory        
T cells the clonal space occupied by the 10 most abundant clones was higher than 80%. 
These observations were also supported by the Shannon eveness index (SEI) of each 
sample, which is defined as a diversity index and quantifies how equal a population is 
numerically186. Memory CD4+ T cells presented a SEI ranging from 0.96 to 0.98, meaning 
that all clonotypes found in the samples are almost equally distributed. On the other hand, 
the SEI for memory CD8+ T cells was between 0.24 and 0.46, suggesting an unequal 
distribution of clonotypes found and less clonal diversity (Appendix table 6.2). Results 
obtained from the analysis of diversity in different cell subsets suggest that the low overlap 
found between memory CD4+ T cells replicates may be due to technical limitations when 
working with highly diverse samples, as I do not see this effect among memory CD8+ T cell 
replicates.  
RESULTS 
 
 
72 
After that, I pooled the sequences from both technical replicates and analyzed the clonal 
space overlap between PB and BM memory T cell subsets.CD4+ memory T cells showed 
low overlap between all 3 cell subsets. In all cases, more than 75% of the clonal space of 
each sample was exclusive for each cell subset. In the depicted representative donor, 20-
25% of the clonal space was shared between CD69+ and CD69- BM memory CD4+ T cells; 
whereas the overlap between BM and PB CD4+ memory T cells was lower than 10-15% in 
both cases (Figure 3.13A). Additional donors analyzed showed similar observations 
(Appendix figure 6.2). These results indicate that CD69+ and CD69- BM CD4+ memory      
T cells are more similar between them than compared to their PB counterparts, supporting 
the data obtained from the flow cytometric analysis. CD8+ memory T cells showed a higher 
overlap between all memory T cell subsets (PB CD69-, BM CD69- and BM CD69+). I found 
50 to 75% of overlap between all BM and PB memory CD8+ T cell subsets with similar 
overlaps between all 3 memory T cell subsets (Figure 3.13). Additional donors analyzed 
showed similar observations (Appendix figure S6.2). Altogether, these data suggest that, 
at least in the CD4+ population, PB and BM memory T cells form separated cell 
populations containing a different TCRβ repertoire, and that CD69+ and CD69- cells from 
BM contain a more similar TCRβ repertoire between them, being closer between them 
compared to their PB counterparts.  
Results obtained from the analysis of the total memory compartment indicate that different 
memory T cell populations are maintained separately in their respective compartments. 
However, the memory T cell pool is very extensive and diverse, so I performed a more 
accurate study by analyzing antigen-specific memory CD4+ T cells from both 
compartments. To determine whether antigen specific memory CD4+ T cells recognizing 
different epitopes are also preferentially maintained in different PB or BM, I analyzed the 
TCRβ repertoire of TT-specific CD4+ memory T cells from both sites. Mononuclear cells Ire 
stimulated with TT (7 hours) and TT-reactive CD4+ memory T cells Ire sorted according to 
CD154 and CD69 co-expression. Sorted TT-specific memory CD4+ T cells were then 
sequenced by NGS and analyzed as performed before. In the depicted representative 
donor, I found 15% of overlap between PB and BM CDR3 sequences from TT-specific 
memory CD4+ T cells (Figure 3.13). Similar results Ire observed in additional 2 donors 
analyzed (Appendix figure S6.2). These results suggest that there is little to no exchange 
between TT-reactive memory CD4+ T cells from PB and BM compartments. 
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Figure 3-13. Clonal space shared between memory T cell subsets from PB and BM samples. TCR CDR3 
sequencing was performed as described before. CDR3 sequences obtained from replicates were pooled and 
down-sampled. Frequencies of the clonal space shared between different memory T cell subsets are 
represented as circular graphs. (A) Frequencies of overlap between memory CD4+ T cell subsets from PB and 
BM sorted according to CD69 expression. (B) Frequencies of overlap between memory CD8+ T cell subsets 
from PB and BM sorted according to CD69 expression. (C) Frequencies of overlap between TT-specific 
memory CD4+ T cells from PB and BM. 
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Figure 3-12: Analysis of TCR CDR3 clonotypes of ex vivo isolated memory CD4+ and CD8+ T cells.
Memory T cell subsets from different samples were sorted according to the phenotype indicated and library 
preparation and data analysis was performed as detailed in material and methods. Overlaps between replicates 
and cell subsets were determined. Frequencies of overlaps between TCRβ CDR3 clonotypes from technical 
replicates and different memory T cells. 
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3.3 Mobilization of human antigen-specific TRM cells into blood 
after systemic immune re-challenge 
In humans, it is still unclear whether and how TRM cells can be mobilized to blood 
circulation after antigen re-challenge to mount a secondary immune response. To 
investigate which is the contribution of TRM cells to systemic recall immune responses, I 
performed a longitudinal study of the memory CD4+ T cell response to the live attenuated 
measles-mumps-rubella (MMR) viral vaccine in PB of healthy adult donors. Measles, 
mumps and rubella viruses, are a highly infectious RNA virus that infects humans through 
the respiratory tract, resulting in a systemic immune response in the host and long-life 
antiviral immunity187,188. 24 volunteers were screened for the presence of IgG-specific 
antibodies for measles, mumps and rubella and undetectable or low pre-existing numbers 
of antigen-specific memory CD4+ T cells in blood circulation prior to vaccination. 
Volunteers selected had had an initial exposure to at least one of the vaccine antigens (via 
infection or vaccination) (Appendix table 6.3) over 30 years ago, reason why they 
maintained positive levels of IgG antibodies whereas the numbers of blood circulating 
MMR-specific memory CD4+ T cells were very low38,59 . 
The experimental design used to probe the early memory response to MMR vaccination 
and characterize the response is depicted in Figure 3.14. 
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Figure 3-14: Experimental design for the study of the dynamics, functionality and specificities of the memory 
CD4+ T cell response after MMR vaccination. 24 healthy volunteers were screened to fulfill the donor inclusion 
criteria and suitable donors were re-vaccinated with and combined MMR vaccine. (I) Isolated PBMCs were 
directly analyzed or following in vitro stimulation with the vaccine-antigens. Afterwards, surface and intracellular 
flow cytometric analysis was performed. In all analyses, subtraction of anti-CD28 background was performed. 
(II) PBMCs isolated at day 1 after vaccination were stimulated for 7 hours in the presence of measles or TT 
antigens, and antigen-specific memory CD4+ T cells were isolated and expanded for 2 weeks. Expanded cells 
were re-stimulated for 6 hours with an array of antigens and FACS analysis was performed to identify reactive 
cells. (III) Serum samples were collected at the indicated time-points and antigen-specific IgM and IgG 
neutralizing antibodies were measured by ELISA. (IV) Measles-specific memory CD4+ T cells were isolated as 
described in II before and at days 1 and 14 after MMR vaccination to perform Next Generation Sequencing 
(NGS) of the TCR Vβ-chain. 
 
3.3.1 Kinetics and magnitude of antigen-reactive memory CD4+ T cells after 
MMR vaccination 
To probe the early memory response to MMR vaccination, I analyzed the kinetics and 
magnitude of MMR-reactive memory CD4+ T cells before, 16 hours, and days 1, 2, 3, 7 
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and 14 after MMR vaccination. MMR-reactive memory CD4+ T cells were identified 
according the expression of CD154, and the fraction of cytokine-producing cells was 
determined by the co-expression of CD154 and one or more of the anti-viral effector 
cytokines IL-2, TNF-α and IFNγ (Gating strategy in Figure 2.5 materials and methods). By 
applying Boolean gating, single-, double-, and triple-cytokine producing cells were 
addressed.  
With our protocol, I was able to detect in a reliable and reproducible way, as low as 0.01% 
of CD154+ Cytokine+ cells among memory CD4+ T cells; and the threshold for differences 
was 0.005% between measurements (Appendix figure 6.3). In combination with the blood 
CD4+ T cell counts (Appendix figure 6.4), the protocol allowed us to reliable quantify as low 
as 50 CD154+ Cytokine+ cells per 106 CD4+ T cells. 
The dynamics of the MMR-specific memory CD4+ responses over 14 days following MMR 
vaccination are shown for 5 representative donors (Figure 3.15A-C). Each vaccine-
specificity is plotted separately. Prior to MMR vaccination, the numbers of pre-existing total 
measles-reactive CD154+ memory cells were 100-200 per 106 CD4+ T cells. For mumps 
and rubella, similar numbers were found in 4 out of 5 donors. Despite of the differential 
levels of pre-existing CD4+ T cell memory in blood circulation, MMR vaccination induced 
similar but independent CD4+ T cell responses to all antigens (Figure 3.15-3.16). For all 
specificities, a rapid increase in the numbers of antigen-reactive memory CD4+ T cells was 
detected in blood as early as 16 hours, peaking at day 1 (from a MEAN ± SE of             
164 ± 31.58 at day 0, to 349.1 ± 46 at 16 h and 624 ± 88 at day 1 after vaccination). At 
days 2-3, the numbers of antigen-reactive memory CD4+ T cells declined to 225 ± 56 and 
262 ± 49 respectively, further increasing to 696 ± 115 and 991 ± 137 at days 7 and 14 after 
MMR vaccination (Figure 3.15A).  
To quantify the effector response, I analyzed the numbers of total CD154+cytokine+ 
memory cells per million CD4+ T cells. The average numbers of CD154+cytokine+ memory 
CD4+ T cells followed similar kinetics to the ones observed before, with a 2-fold increase at 
16 hours, 3 fold increase at day 1 and 3- 5 fold increase at days 7 and 14, respectively, 
compared to the numbers of antigen-reactive memory T cells present before vaccination 
(Figure 3.15B). 
Finally, to further quantify the effectiveness of the CD4+ T cell response, I analyzed the 
dynamics of polyfunctional cells (expressing 2 or 3 cytokines) after MMR vaccination. The 
kinetics and magnitude of CD154+ polyfunctional cytokine+ memory CD4+ T cells were 
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similar to the ones observed for total antigen-reactive CD154+ memory CD4+ T cells 
(Figure 3.15C). 
Among all donors and specificities, I found a maximum of ~8 fold increase on antigen-
reactive total-cytokine+, and ~20 fold increase polyfunctional memory CD4+ T cells at early 
time-points after vaccination (16 h and day 1). Altogether, these results show a rapid and 
transient increase of antigen-reactive memory CD4+ T cells in blood circulation after 
systemic re-immunization.  
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Figure 3-15: Cellular kinetics of antigen-reactive / memory CD4+ T cells after MMR immunization. After 
in vitro antigen stimulation and ICS of PBMCs isolated at different time-points, we analyzed the expression of 
CD154, IFNγ, TNFα and IL-2 and followed the dynamics of the numbers of CD154+ (B), CD154+ Cyt+ (C) and 
CD154+ Poly-Cyt+ (D) per million CD4+ T cells. 5 representative donors are shown for each of the specificities. 
Statistical differences were calculated by 2-WAY ANOVA with Turkey´s multiple comparisons test (p<0.0332 
(*), p<0.0021 (**), p<0.0002 (***), p<0.00001 (****)). 
 
Early appearing antigen-reactive CD4+ T cells were mostly polyfunctional, producing two or 
three cytokines at the same time. For all specificities, on average 68% of the total 
CD154+cytokine+ memory CD4+ T cells expressed more than one cytokine. 
Polyfunctionality has been associated with an increase in the cytokine content per cell, 
which is related with a higher protective capacity 189–191. I compared the geometric mean 
(GEOM MEAN) of IFNγ on antigen-reactive CD154+cytokine+ memory CD4+ T cells that 
produced three, two, versus one cytokines, named 3, 2, versus 1 effector functions. 
Despite the presence of polyfunctional cells at all time-points analyzed, the most 
significant differences in cytokine content were detected only at 16 hours and day 1 after 
MMR vaccination. At 16 hours and day 1 after vaccination, double and triple producers 
contained in average 2 times and 3 times more IFNγ, respectively, compared to the single-
producing cells. Contents of IL-2 and TNFα in double and triple producers were also 
increased in a similar way as described for IFNγ (data not shown). Both, the major 
proportion of polyfunctional antigen-reactive CD4+ T cells and the higher cytokine 
production from double and triple-cytokine producers suggest that early mobilized cells 
provide an immune response of enhanced quality. 
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Figure 3-16: Cellular kinetics and functional capacities of antigen-reactive memory CD4+ T cells after 
MMR immunization. Using in vitro antigen-stimulation with the indicated antigens and ICS I followed the 
frequencies of CD154+Cyt+ memory CD4+ T cells present in blood at indicated time-points. (A) Representative 
dot-plots with magnitude and number of functions of antigen-reactive memory CD4+ T cells appearing after 
MMR immunization. (B) Dynamics of the secondary response to measles, mumps and rubella, showing the 
number of single, double and triple cytokine producers in a representative donor. (C) Geometric mean 
fluorescence intensity (GMFI) of IFNγ in double and triple producers normalized to the GMFI detected in single 
cytokine producers. Statistical differences were calculated by 1-WAY ANOVA with Turkey correction. 
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A part from analyzing the immune responses in antigen-experienced volunteers, I had the 
opportunity to analyze the primary response to MMR vaccination in a naïve donor. The 
analysis of the immune response of a measles-naïve donor (with non-detectable levels of 
both measles-specific IgM and IgG antibodies as well as non-existing measles-reactive 
memory CD4+ T cells in blood circulation) showed a response different from the one 
observed in antigen-experienced donors, with the appearance of CD154+Cytokine+ (1500 
cells per million CD4+ T cells) and CD154+Ki-67+ (2100 cells per million CD4+ T cells) 
measles-specific CD4+ T cells at day 14 after MMR vaccination, together with an increase 
of both IgG and IgM specific antibodies (Figure 3.17A). These results are in line with the 
results obtained from the kinetics of primary T cell response observed in yellow fever 
vaccine studies192,193. Interestingly, the response measured for the other two antigens 
present in the vaccine showed the above-mentioned dynamics of a secondary immune 
response, and I detected only and increase on the levels of IgG specific antibodies at day 
14 after vaccination, reflecting a secondary immune response (data not shown).  
 
 
           
 
Figure 3-17: Kinetics of a naïve response to MMR vaccination. Cellular and humoral kinetiks were 
determined as described before. (A) Total and polyfunctional CD154+Cyt+CD45RA-as well as CD154+Ki-
67+CD45RA-CD4+  T cells dynamics in response to MMR vaccination. (B) Levels of both IgG and IgM measles 
neutralizing antibodies were measured at the indicated timepoints by ELISA. 
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3.3.2 MMR vaccine-induced early antigen-reactive memory CD4+ T cells 
contain mobilized TRM cells 
Compared with pre-existing circulating T cell memory, the increase on antigen-reactive 
memory T cells detected at 16 hours/day 1 after MMR vaccination suggest an influx of 
memory T cells either from proliferated pre-existing memory T cells or from a hidden 
distinct population of TRM cells that are mobilized into the blood circulation. In order to test 
these two scenarios, I measured expression of the proliferation marker Ki-67194 in MMR-
reactive CD154+ memory CD4+ T cells before and after MMR vaccination. Cells in G0 of 
their cell cycle do not express Ki-67, whereas cycling or recently divided T cells up-
regulate Ki-67 expression 194,195.  
In our study, Ki-67 was not expressed by any of the measles-, mumps- and rubella- 
reactive memory CD4+ T cells before (0) and at the early time-points (16 hours, and days 
1, 2 and 3) after vaccination. Antigen-reactive memory CD4+ T cells were only detectable 
from 7 days (236 ± 48) and 14 days (153 ± 33) after MMR vaccination (Figure 3.18A-B). 
These results demonstrate that the rapid increase of circulating antigen-reactive memory 
CD4+ T cells after MMR vaccination is a result of the mobilization into blood circulation of 
memory T cells resident in other compartments, such as the BM, instead of expansion of 
pre-existing circulating cells. 
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Figure 3-18: Kinetics of appearance of antigen-reactive proliferating cells (CD154+ Ki-67+) after MMR 
vaccination. Using ex vivo stimulation with the indicated antigens and ICS I followed the numbers of 
CD154+Ki-67+ memory CD4+ T cells present in blood at indicated time-points. (A) Representative dot-plots with 
frequencies of proliferating antigen-reactive memory CD4+ T cells appearing after MMR immunization.(B) 
Numbers of antigen-reactive CD45RA-CD154+Ki-67+ T cells per million CD4+ T cells of 4 representative donors 
for each of the antigen specificities. 
  
3.3.3 Early mobilized MMR-reactive memory CD4+ T cells show mainly a 
TRM/TEM, memory precursor-like phenotype 
To further characterize the memory CD4+ response, I determined whether MMR mobilized 
MMR-reactive memory CD4+ T cells phenotypically resembled functional TRM cells. For 
that, I analyzed the expression of CCR7 on antigen-reactive memory CD4+ T cells before, 
and at different time-points after immunization (Figure 3.19A). It is know that, TRM 
resemble TEM cells, being able to provide with immediate enhanced effector functions and 
do not express the chemokine receptor CCR7 196. TCM have the capacity to circulate 
through secondary lymphoid organs, whereas TEM and TRM preferentially localize in 
peripheral tissues61,197. The frequencies of CCR7- cells among measles-reactive memory 
CD4+ T cells increased from 45 ± 2.25% before vaccination to 56.5 ± 3.22% and 58.3 ± 
6.9% at 16 hours and day 1 after immunization, respectively. The levels dropped to levels 
seen before vaccination at days 2 and 3, rising again to 56 ± 6.5% and 61.5 ± 4.5% at 
days 7 and 14 after vaccination, respectively (Figure 3.20B). These results indicate that 
early mobilized antigen-reactive memory CD4+ T cells mostly resemble TRM/TEM cells, with 
no expression of CCR7 and high expression of effector cytokines, such as IFNγ and TNFα 
(Figure 3.16B).  
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High expression of the IL-7Rα and the anti-apoptotic molecule BCL-2 are correlated with 
high survival  potential, and tend to decrease in recently generated effector CD4+ T cells 
198. Our results showed that 80-90% of the measles-reactive memory CD4+ T cells 
expressed this marker on the surface at the early time-points after vaccination, with only a 
slight decrease in expression one week after vaccination (56-85% CD127+ among 
measles-reactive T cells) which was more prominent 14 days after vaccination (35-85% 
CD127+ among measles-reactive T cells) (Figure 3.19B). These results suggest that early 
mobilized antigen-reactive memory CD4+ T cells maintain a high survival potential, 
whereas the later increase of antigen-reactive memory CD4+ T cells may contain a pool of 
newly generated effector cells with low CD127 expression. 
Finally, to gain a better understanding of the functions of the mobilized CD4+ T cells, I 
determined the expression of various cell surface molecules on the antigen-reactive CD4+ 
T cells. Phenotypic analysis performed by surface staining with CD137, PD-1 and CXCR5 
revealed that there was no mobilization of antigen-specific T regulatory or T follicular 
helper cells into the blood as a consequence of MMR vaccination (Appendix figure 6.5). 
Moreover, the analysis of expression of CLA, (a typical marker for skin homing) showed a 
constant frequency of ~20% among measles-reactive memory CD4+ T cells at all time-
points analyzed (except at day 14, where the frequencies of CLA+ cells increased to 32%) 
(Figure 3.19C). Although these results should be confirmed in further experiments, it 
indicates that early mobilized antigen-specific memory CD4+ T cells were not derived from 
a skin resident memory T cell pool. 
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Figure 3-19: Phenotypic analysis of antigen-reactive CD4+CD45RA-CD154+ T cells. Using ex vivo 
stimulation with the indicated antigens I performed a phenotypic analysis of CD154+ memory CD4+ T cells 
present in blood. Frequencies of CCR7- (A), CD127+ (B) and CLA+ (C) cells among antigen-reactive CD154+ 
memory CD4+ T cells. 
 
3.3.4 MMR vaccination induces bystander mobilization of TT-specific 
memory T cells with similar dynamics to the vaccine-specific response 
Di Genova and colleagues have previously shown that TT boost vaccination of healthy 
volunteers results in an expansion of both, TT-specific T cells but also of T cells with other 
specificities 199. To understand whether MMR vaccine also trigger bystander memory T cell 
responses to unrelated antigens, I analysed the time course of TT-reactive memory T cell 
responses after MMR vaccination. Similar to measles, mumps, and rubella, at 16 hours 
and day 1 after vaccination, numbers of total TT-reactive CD154+, CD154+cytokine+, and 
CD154+ polyfunctional cytokine+ memory CD4+ T cells were all readily and transiently 
increased by 2.5-19-flod, dropping to baseline by day 2/3 and increasing again by day 7/14 
in three out of four donors (Fig. 3.20A).  Bystander mobilized memory CD4+ T cells were 
also polyfunctional, mainly secreting IL-2 and TNFα, but low levels of IFNγ (Figure 3.20B). 
These results suggest that, after MMR vaccination, bystander mobilization of unrelated 
antigen-specificities occur in parallel with the MMR-specific memory CD4+ T cell response 
(Figure 3.20A).  
Previous studies have shown that vaccine-reactive and bystander mobilized memory CD4+ 
T cells differ in their proliferative status, as well as their expression of markers such as 
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CCR7 and CD127 1-2 weeks after boost vaccination 200. In order to better characterize the 
bystander mobilized memory CD4+ T cells, and distinguish them functionally and 
phenotypically from MMR-specific memory CD4+ T cells, I analyzed the expression of     
Ki-67, CCR7 and CD127 in TT-reactive memory CD4+ T cells. Our results showed low 
expression of the proliferation marker Ki-67 TT-reactive memory CD4+ T cells at any 
time-point of the study, i.e. below 2% Ki-67+ among CD4+CD54RA-CD154+ TT-reactive 
T cells (Figure 3.20C). Frequencies of CCR7- cells were maintained (~50%) among 
CD4+CD54RA-CD154+ TT-reactive memory CD4+ T cells (Figure 3.20D). Finally,     
TT-reactive memory CD4+ T cells showed high expression (80-90%) of the IL-7Rα 
(CD127) at all time-point analyzed (Figure 3.20E). 
Altogether, these results show that early bystander mobilized TT-reactive memory CD4+    
T cells show a similar phenotype compared to vaccine-specific memory CD4+ T cells, with 
no expression of Ki-67 and high expression of CD127, but with a more central memory-like 
phenotype. However, 1-2 weeks after vaccination, bystander mobilized cells show 
differences in their phenotype compared to the MMR-reactive memory CD4+ T cells, with 
no signs of increased proliferation and no down-regulation of CD127 expression. 
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Figure 3-20: Dynamics and phenotypical characteristics of bystander mobilized TT-specific memory 
CD4+ T cells. (A) After in vitro TT stimulation and ICS of PBMCs isolated at different time-points, I analyzed 
the expression of CD154, IFNγ, TNFα and IL-2 and followed the dynamics of the numbers of CD154+, CD154+ 
Cyt+ and CD154+ Poly-Cyt+ per million CD4+ T cells. 4 representative donors are shown. (B) Representative 
dynamics of the specific secondary response to TT, analyzing the number of single, double and triple cytokine 
producers in a representative donor. (C) Frequencies of Ki-67+ cells among TT-specific memory CD4+ T cells 
(D) Frequencies of CCR7- cells among TT-specific memory CD4+ T cells (E) Frequencies of CD127+ cells 
among TT-specific memory CD4+ T cells before and at indicated time-points after MMR vaccination. 
 
3.3.5 The early MMR-reactive memory CD4+ T cells and the antibody 
response are highly specific for the vaccine antigens  
To verify the specificity of MMR vaccine responses and exclude the possibility that the 
observed mobilization and response against unrelated antigen (TT) were due to cross-
reactivity, I evaluated the memory T cell responses as well as antibody responses to 
vaccine antigens or unrelated antigens. I isolated measles- and TT-reactive CD154+CD69+ 
memory CD4+ T cells from day 1 after MMR vaccination. Day 1 antigen-reactive memory 
CD4+ T cells were expanded for 14 days201, and re-stimulated with autologous APCs and 
the indicated antigens. As shown in Figure 3.21A-B, measles-reactive, expanded CD4+ T 
cells specifically reacted to the inducing antigen, whereas reactivity against other antigens, 
present in the vaccine (mumps and rubella) or not (TT and CMV) was at background level 
(Figure 3.21A). Cytokine-producing T cells were mostly polyfunctional, expressing TNFα 
and IFNγ, or TNFα, IFNγ and IL-2 (Figure 3.21A-B). After background subtraction, 8-20% 
of the expanded T cells expressed CD154 and at least one of the three analyzed 
cytokines. When re-stimulating with other antigens present in the MMR vaccine (mumps 
and rubella), only 0,5-1,5% of the expanded T cells reacted. No reactivity was observed 
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when the expanded T cells were re-stimulated with TT or CMV (Figure 3.21C). On the 
other hand, 6% of expanded TT-reactive CD4+ memory T cells were reactive to TT           
re-stimulation, showing cross-reactivity to measles in one of the analyzed donors and to 
CMV in the other two ones (Figure 3.21C). These data indicate little to no cross-reactivity 
and high specificity of the early mobilized vaccine-reactive memory CD4+ T cells, whereas 
the bystander mobilized TT-reactive memory CD4+ T cells seem to include multiple 
specificities. 
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Figure 3-21: Specificities of early appearing antigen-reactive memory T cells. Measles-reactive memory 
CD4+ T  cells isolated at d1 after vaccination were expanded with proleukin (IL-2) for 14 days and then re-
stimulated with indicated antigens and aCD28 for 7 h and stained ICS with CD154, IL2, IFNγ and TNFα . (A) 
Representative dotplots of cytokine expression after stimulation with different antigens. (B) Percentages of 
CD154+Cyt+ among memory CD4+ T cells  after stimulation of measles-reactive CD4+ T cells (n=3). (C) 
Percentages of CD154+Cyt+ among memory CD4+ T cells  after stimulation of d1 TT-reactive CD4+ T cells 
expanded for 14 days (n=3). 
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To correlate the MMR-induced memory T cell responses with the corresponding antibody 
responses, as we as assess the specificity of the antibody response, I analyzed the 
magnitude of measles, mumps, rubella and TT-specific antibodies before, and at days 1, 3 
and 14 after MMR vaccination. In all pre-immunized subjects, who were serum-positive for 
measles-, mumps- and rubella-specific IgG antibodies before vaccination, I detected a 2- 
to 4-fold increase of IgG-titers at day 14 after re-immunization. IgM levels were below level 
of detection at all time-points (Figures 3.22A-B). In contrast to MMR, no increase in TT-
specific IgG antibodies was observed in any of the analyzed donors, which remained 
remarkably stable (Figure 3.22B). These results demonstrate that MMR vaccination 
induces a highly specific antibody response. 
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Figure 3-22: Kinetics of neutralizing antibody response to MMR vaccination. Serum from immunized 
donors was obtained at indicated time-points and the levels of IgG and IgM antibodies specific for measles, 
mumps, rubella and tetanus toxoid (TT) were analyzed by ELISA.  (A) IgG levels detected at different time-
points for measles, mumps, rubella and TT. (B) Levels of IgM antibodies specific for measles, mumps and 
rubella specificities. 
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3.3.6 The early mobilized MMR-reactive memory CD4+ T cells suppose an 
influx of new TCR Vβ diversity, which contributes to the immune 
response 
Previous studies performed in humans demonstrated there is a preferential enrichment of 
antigen-reactive memory CD4+ T cells for childhood antigens in the BM 59. Moreover, the 
TCRβ sequencing shown in section 3.2.3 indicate that PB and BM memory CD4+ T cells 
represent different populations according to TCRβ-chain repertoires (section 3.2.3). 
In order to get an insight about the origin of the mobilized antigen-reactive memory CD4+   
T cells, as well as their contribution to the secondary immune response, I analyzed the 
CDR3 TCRβ repertoire of measles-reactive memory CD4+ T cells. The CDR3 sequences 
of 2500 sorted CD154+CD69+ measles-reactive memory CD4+ T cells were determined in 
two healthy individuals immunized with the MMR vaccine before, and at days 1 and 14 
after vaccination. Both donors showed low numbers of measles-specific memory CD4+     
T cells before vaccination, which were increased at both days 1 and day 14 after re-
immunization (similar to previous results when analyzing further donors). I found an 
increase in CDR3 TCRβ diversity at day 1 after immunization compared to day 0 in both 
studied volunteers (139 ± 25 / 322 ± 9 to 346 ± 37 / 613 ± 21 of clonotypes found at day 0 
and 1 respectively), which was then maintained in MMR10 and decreased to basal levels 
in MMR11 at day 14 (Figure 3.24A). To estimate the total number of unique TCR Vβ CDR3 
sequences present in the sampled blood, rarefaction curves were calculated by Pawel 
Durek, and a computational approach developed by Fischer et al. 203 and subsequentially 
extended by Efron and Thisted 204 was used. This method has already been used to 
estimate the total CDR3 TCRβ diversity of human blood samples 205,206, and has been 
demonstrated to provide a reasonable estimate of the total diversity of CDR3 TCRβ 
sequences in the repertoire 205. Based in the assumption that T cells circulate freely in the 
blood, this method predicts the number of unseen sequences that would be detected if the 
experiment was repeated an infinite number of times. Efron and Thisted indexes of 
diversity varied in both donors from 329 ± 64 / 971 ± 5 to 924 ± 109 / 1795 ± 17 and 1223 
± 127 / 926 ± 32 at days 0, 1 and 14 respectively (Appendix table 6.4). Moreover, 
compared with day 0, day 1 measles-reactive memory CD4+ T exhibited higher sampled 
diversity at orders from 1 to 10, as indicated by Hill numbers, which quantify the diversity in 
units of equivalent numbers of equally abundant species (Figure 3.24B). These results 
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suggest that early mobilization of antigen-reactive memory CD4+ T cells induced by MMR 
vaccination results from an influx of new CDR3 clonotypes. 
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Figure 3-23. Influx of new CDR3 TCR clonotypes from MMR-mobilized measles-specific CD4+ TRM cells 
persist and continue by day 14 post-vaccination. 2500 measles-specific memory CD4+ T cells were 
isolated after in vitro stimulation before, and at days 1 and 14 after MMR vaccination. TCR Vβ CDR3 
nucleotide sequences obtained by NGS from 2 technical replicates were analyzed. (A) Rarefaction curves 
were calculated. Individual points indicate the number of clonotypes found in each sequenced sample, and 
dashed lines predicts the number of unseen sequences that would be detected if the experiment was repeated 
an infinite number of times. (B) Diversity of clonotypes at different time-points is plotted at different orders. At 
order 0, the Hill numbers are the number of clonotypes found. At higher orders (>1) the Hill numbers are more 
influenced by the most abundant clones 
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I further assessed the appearance of new CDR3 clonotypes at day 1, which could still be 
found at day 14 post-vaccination. For that, I identified abundant clones that were 
undetectable before vaccination, but that were constantly present in both replicates of 
days 1 and 14 after MMR vaccination. I found 6 and 5 clonotypes in donnor MMR10 and 
MMR11 respectively, which appeared on day 1 and were still present at day 14. In 
MMR10, the clonal space occupied by newly appearing clonotypes increased from ~2% at 
day 1 to ~7 % at day 14 after vaccination. 2 out of 6 clonotypes were expanded 4 fold at 
day 14 compared to day 1, whereas the others were maintained at similar frequencies. 
MMR11 showed similar frequencies of all clonotypes at both time-points, occupying ~2% 
of the total clonal space (Figure 3.25). In order to determine the contribution of pre-existing 
clones to the generation of the secondary immune response, I also analyzed the numbers 
and frequencies of the clonotypes present before, and at days 1 and 14 after MMR 
vaccination. In this case, I did not observe any expansion of the abundant clonotypes 
already present at day 0 in any of the analyzed donors (Figure 3.25).These results show 
that, systemic re-challenge with the MMR vaccine induces an influx of new CDR3 TCRβ 
clonotypes, which are maintained and presumably play a role in the generation of the 
secondary immune response. Newly appearing clonotypes may appear in blood circulation 
as a result of the mobilization of tissue resident memory T cells from other tissues, such us 
the BM. 
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Figure 3-24. Analysis of the contribution of newly generated clones to the secondary immune 
response. Abundant clones present in both of the replicates were analyzed. (A) Identification and frequences 
of clonotypes not present before vaccination and constantly present at days 1 and 14 after vaccination. Data of  
two independent donors is shown. (B) Identification and frequences of clonotypes constantly present before 
and at days 1 and 14 after vaccination. Data of  two independent donors is shown. 
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4 Discussion 
Immunological memory provides us with efficient and directed protection against 
secondary infections, having the capacity to clear re-occurring pathogens. Memory T cells 
play an essential role in sustaining long-term immunological memory. These cells have 
been identified in PB circulation but also resident in different tissues such as the skin, gut 
and the bone marrow 59,72–76,90. Previous work of our group showed that the human BM is 
home to high numbers of professional memory T cells, and that it is especially enriched for 
memory CD4+ T cells specific for systemic childhood antigens like measles, mumps and 
rubella59. However how memory T cells are maintained for such long times in the BM, what 
is the relationship the relationship between circulating and resident memory T cells, and 
whether and how tissue resident memory T cells are they capable to confer us with 
systemic immune protection after immune re-challenges remained not fully understood. 
The experimental work presented here aimed to better understand the different lifestyle 
and compartmentalization of PB circulating versus BM resident memory T cells, as well as 
the contribution of TRM cells (such as the ones resident in the BM) to secondary systemic 
immune reactions in humans. 
I found differences in the survival mechanisms of PB versus BM memory T cells, as well 
as some of the key factors involved in the maintenance of these cells. Moreover, the 
analysis of the TCR repertoire of PB and BM memory T cells by flow cytometric analysis 
and NGS demonstrated their different compartmentalization in the respective tissue. 
Finally, the analysis of the dynamics of MMR-specific memory CD4+ T cells into blood after 
systemic immune re-challenge in the long-term (i.e. 30 years) showed a rapid mobilization 
into blood circulation of antigen-reactive memory CD4+ T cells from other tissues (such as 
the BM), which then contribute to the secondary immune response. 
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4.1 PB and BM memory T cells present different survival 
patterns, and are maintained via cytokines (IL-7 and IL-15) 
and direct contact with stromal cells 
4.1.1 Different lifestyles of circulating versus BM memory T cells 
PB circulating and BM resident memory T cells are subjected to different environments. 
PB memory T cells circulate through the blood and secondary lymphoid organs or tissues. 
Some studies suggested that most mature lymphocytes recirculate continuously from 
blood to tissue and again blood almost 1-2 times per day 207. On the other hand, our group 
has provided evidence that BM resident memory T cells are maintained in a quiescent 
state in specific survival niches59, where stromal and other accessory cells provide them 
with signals to survive 90,208,209. Several studies have suggested that CD69 regulates local 
T cell retention in the BM by a variety of mechanisms 125,128,210. Considering PB and BM 
memory T cells as different cell populations submitted to very distinct environments, they 
may present different survival capabilities without or in response to diverse survival 
factors.  
The survival kinetics of ex vivo PB CD69-, BM CD69-/+ memory CD4+ and CD8+ T cells 
showed that BM memory T cells (both CD4+ and CD8+) survived to a lesser extent and had 
reduced half-life compared to their PB counterparts, being the CD69+ BM cell subset the 
one with shortest half-life. PB memory T cells must have higher capacities to survive in the 
absence of any survival stimulus while they are circulating through the bloodstream, where 
the concentrations of cytokines such as IL-7 or IL-15 are low211; whereas BM memory       
T cells may be continuously receiving these signals from their environment, being 
therefore more dependent on them. The fact that CD69- BM memory T cells are in the 
middle of PB and CD69+ BM memory T cells regarding survival capacity could suggest 
they may have the capability to enter the circulation in some cases, instead of being 
always in the BM survival niches. 
In addition, I tested the effect of the oxygen concentrations in the survival of PB and BM 
memory T cells. It has been estimated that in humans, arterial blood has a pO2 = 13.2, 
whereas this is reduced in venous blood (pO2 = 5.3) and in BM (pO2 = 6.4±0.6) 159. 
Therefore, the “normal” oxygen levels in which experiments are typically performed 
(pO2=21) may not be adequate for any of the populations analyzed, especially for BM 
memory T cells. I compared the survival kinetics and half-lives of PB CD69- and BM   
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CD69-/+ when cells were cultured in 21% and 4% O2. Our results showed that both CD69- 
and CD69+ BM memory T cells had an increased half-life when cultured at lower oxygen 
levels, whereas PB CD69- memory T cells maintained similar survival capacities in either 
O2 level. 
Effector memory CD4+ T cells recirculate between normoxic blood and hypoxic tissues to 
screen for cognate antigens. Circulating memory T cells, thus, face and must adapt to 
different environmental conditions while circulating through the blood, or passing through 
secondary lymphoid organs and tissues (where the levels of oxygen are reduced159). This 
fact could explain that there was no obvious differences in survival when culturing the cells 
under 21% or 4% O2. BM memory T cells are maintained in a quiescent state in specific 
survival niches 90, where they adapt to the low levels of oxygen present into the tissue. 
This fact explains why BM memory T cells had increased survival rates when submitted to 
low oxygen concentrations (4%) compared to 21% oxygen. Differential survival of PB and 
BM memory T cells at different oxygen concentrations indicate that indeed, they are 
different populations maintained in their respective compartment, where they adapt to the 
local environment to survive.  
A recent publication investigating the survival and metabolism of skin TRM CD8+ memory    
T cells demonstrated increased mitochondrial oxidative metabolism of these cells in the 
presence of exogenous fatty acids (FA), compared to TCM memory T cells. Moreover, the 
persistence of CD8+ TRM cells in the skin was strongly diminished by inhibition of 
mitochondrial FA-oxidation. When comparing transcriptomes of TRM and TCM cells, an up-
regulation of the genes encoding lipid chaperone proteins that bind to hydrophobic ligands 
coordinating lipid uptake and intracellular trafficking212 (FABP4 and FABP5) was detected. 
The lack of FABP4 and FABP5 in TRM cells resulted in lower lipid uptake and survival of 
tissue resident memory T cells213. Similarly, when looking at transcriptomes of human 
CD4+ memory T cells from paired PB and BM samples59, I could detect an increase on 
FABP5 expression in BM CD69+ memory T cells compared to the PB counterparts           
( 3-fold increase), suggesting their metabolism resembles to the one found in TRM cells, 
and is different from their PB counterparts. A more detailed understanding of the metabolic 
programs intrinsic to BM resident and circulating memory T cells should be investigated in 
order to see how these programs could be manipulated to increase or decrease T cell 
memory longevity and function. 
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4.1.2 Maintenance of resting BM memory T cells by IL-7 and IL-15 
Some reports showed an increased proliferation of BM memory CD8+ T cells by 
bromodeoxiuridine (BrdU) labelling in murine BM214,215, and interpreted these data as 
evidence for maintenance of memory CD8+ T cells by homeostatic proliferation. However, 
studies from our group support the idea that long-lived BM memory T cells are maintained 
in a quiescent state, with no signs of activation, migration or proliferation59,90. Moreover, 
studies performed in mice eliminating proliferating cells by cyclophosphamide treatment 
have further demonstrated that BM memory CD8+ T cells are resting in terms of 
proliferation216.Furthermore, our group has recently demonstrated that BrdU feeding itself 
induces proliferation of memory CD8+ T cells 135. From these studies, we could conclude 
that BM memory T cells are maintained in a quiescent state, with no signs of proliferation. 
-chain cytokines, such as IL-7 and IL-15 have been shown to be involved in the 
maintenance of circulating memory CD8+ T cells 145,146 and memory CD4+ T cells, with 
some discrepancies in the latest144,147,148. However, it is still not completely clear what role 
these two cytokines play in the maintenance of TRM cells. For instance, TRM isolated from 
the brain are incapable of surviving outside their tissue niche 81 and do not appear to use 
IL-7 or IL-15 for survival 96,. On the other hand, recent studies using skin TRM cells 
demonstrated that hair-follicle-derived IL-7 and IL-15 are required for CD4+ and CD8+ TRM 
cells to persist in the epidermis 217. It remains unknown whether there are common survival 
factors that maintain TRM in all tissues, or whether each tissue provides its own unique 
signal. In the context of this thesis, I aimed to confirm whether IL-7 and IL-15 play an 
important role in the maintenance of BM memory T cells. The addition of each cytokine to 
BM T cell cultures resulted in an improvement in their survival, demonstrating their 
involvement in the long-term maintenance of BM memory T cells. 
Regarding the question of how memory T cell is maintained in the BM, some studies have 
shown that IL-7 and IL-15 can induce CD8+ T cell proliferation 149,214,215. However, the 
amounts of cytokines used in these studies are usually high (above 10 ng/mL), and 
probably not reflecting the physiological conditions found in the BM. In our experiments, I 
could confirm that high concentrations of IL-7 and IL-15 (10 ng/mL) induced proliferation of 
memory T cells in vitro. However, concentrations until 1 ng/mL of IL-7 and IL-15 were able 
to maintain memory T cell survival without signs of proliferation (no blasts, increase in cell 
numbers and Ki-67 expression). It would be important to determine the local 
concentrations of both cytokines in the BM stromal survival niches in order to better 
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understand the conditions to which memory T cells are subjected locally and how these 
influence their maintenance. 
Apart from IL-7 and IL-15; there is less information about the existence of other factors that 
could be involved in the long-term maintenance of BM memory T cells. For this reason, I 
aimed to better characterize the factors involved in the maintenance of BM memory          
T cells. IL-6 is also present in high amounts in the BM and it is an important survival factor 
for memory plasma cells, another long-lived memory cell type resident in the BM218,219. 
Other cytokines like IL-33, TNFα, TGF and type I interferons have also been implicated in 
the generation and persistence of TRM cells 92 and seem to have a role in the maintenance 
of skin and gut resident memory T cells 87,220. However, in our in vitro experiments, only   
IL-7 and IL-15 showed an effect in the maintenance of BM memory T cells.  
The fact that IL-6 does not play a role in the survival of memory T cells like it does for 
plasma cells suggests that different memory cell types are maintained in specialized 
stromal survival niches. This could be reflected in the heterogeneity of stromal cells in the 
BM. Long-lived memory plasma cells translocate into the BM and dock onto stromal cells 
that express CXCL-chemokine ligand-12 (CXCL12 or SDF1) and vascular cell-adhesion 
molecule 1 (VCAM1 or CD106) 136,208, memory CD4+ and CD8+ T cells were shown to be in 
direct contact with VCAM+ IL-7 producing stromal cells 90,135. Moreover, in humans, CD8+ 
memory T cells were also found  in clusters with IL-15 producing cells 78. These findings 
indicate that different memory T cell types are maintained in different specialized niches, 
which will provide the essential signals for each cell type to be kept alive. 
On the other hand, IL-33 and TGF were shown to be important during the generation and 
persistence of the TRM phenotype221, but did not have any effect on the survival of BM 
memory T cells. These data suggest that the role of IL-33 and TGF is limited to the first 
phase of establishment of the TRM cells, and does not extend to the long-term maintenance 
of those cells. However, we cannot exclude their importance on maintaining TRM cells from 
other tissues, as I only tested them in BM memory T cells. Further experiments using TRM 
from other tissues may be needed to better understand whether cells from different tissues 
are maintained by similar or different factors. 
In conclusion, our results showed that both IL-7 and IL-15, but none of the other cytokines 
tested supported the survival of both CD4+ and CD8+ BM memory T cells. A more detailed 
histological analysis of human BM sections would help to determine the heterogeneity of 
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the BM stromal niches and to identify additional factors involved in the long-term 
maintenance of memory T cells. 
 
4.1.3 In addition to IL-7and IL-15, stromal cell contact also play an important 
role in maintaining quiescent memory T cells 
I further tested the effect of IL-7 and IL-15 in PB and BM patients in both, CD4+ and CD8+ 
memory T cells in order to investigate whether both cytokines would have the same or 
different effects in all memory T cell subsets. In all BM T cells, both cytokines were able to 
significantly improve the survival of memory T cells. The survival of PB memory T cells 
was also increased with both cytokines to a similar extent than to BM memory T cells, 
suggesting that IL-7 and IL-15 are also important in the maintenance of circulating memory 
T cells. Interestingly, the analysis of 27 multiplexed serum cytokine concentrations in 
healthy subjects showed the existence of low concentrations of IL-7 ( 50 pg/mL) and non-
detectable levels of IL-15 211 in human serum samples, suggesting that circulating memory 
T cells may be receiving a boost of survival factors while going through secondary 
lymphoid organs or tissues in order to be kept alive. 
IL-7 showed a major role in sustaining cell survival in CD4+ compared to CD8+ memory     
T cells; whereas IL-15 showed to be more important for the maintenance of memory CD8+ 
T cells. IL-7 receptor (CD127) expression has been reported to be high and similar in both 
CD4+ and CD8+ memory T cells152. On the other hand, the receptor for IL-15 (CD122) is 
highly expressed on memory CD8+ T cells compared to memory CD4+ T cells 137, which 
could be related with the major influence of this cytokine on memory CD8+ T cell but not so 
much in memory CD4+ T cell survival 144,150,151. Until now, it is not known whether CD4+ 
and CD8+ memory T cells are maintained in the same or different survival niches. 
However, from our data it seems that both cell populations have slightly different 
requirements for their maintenance, so the fact that they are maintained in different and 
separated BM survival niches could be possible. Again, further histological analysis of 
human BM tissue would be important to decipher the heterogeneity of BM survival niches 
and the contribution of each of them to the maintenance of different cell types.  
Of note, both cytokines could not maintain 100% of memory T cell survival, suggesting that 
other factors provided within the stromal cell niche may have an additional role in 
supporting memory T cell long-term maintenance. Apart from soluble factors, cell-cell 
DISCUSSION 
 
 
99 
interactions could also be important for the maintenance of memory T cells. BM resident 
memory T cells express both, VLA-2 and VLA-4, which bind to collagens I, II and XI 153,154 
and VCAM-1155,156 respectively. Interaction with VCAM-1 is important for the maintenance 
of hematopoietic stem cells 157 and plasma cells 158 in the BM. Moreover, memory CD4+    
T cells have been found in direct contact with VCAM+ IL-7 producing stromal cells 90 by 
histological analyses of mouse BM sections. In order to test the role of T cell-stromal cell 
contact in memory T cell survival, I performed in vitro co-cultures of PB and BM memory T 
cells with the human stromal cell line HS5. Publicly available transcriptomes of the HS5 
human stromal cell line (http://www.ncbi.nlm.niih.gov/geo) showed no expression of IL-7 
and low expression of IL-15, but high expression of VCAM-1 and collagens. Luminex 
assays performed with the supernatants of the stromal cell line confirmed the absence of 
both cytokines, and flow cytometric analysis of VCAM-1 corroborated its high expression 
on the cell surface of HS5 cells. Co-culture of human memory T cells with HS5 supported 
to a similar extent their survival compared to the addition of IL-7 or IL-15. Interestingly, PB 
memory T cell survival was also improved when cultured with the stromal cell line, 
suggesting PB memory T cells are also capable to integrate pro-survival signals from    
cell-cell interactions when circulating through the secondary lymphoid organs or tissues. 
In order to assure that stromal cells were not sustaining cell viability by the secretion of IL-
7 or IL-15, I measured the expression of CD127 in all memory T cell subsets cultured in 
different conditions. After contact with IL-7, CD127 (the -chain of the IL-7 receptor) is 
internalized and down-regulated as feedback control. It had been previously shown, that 
the incubation of human PBMCs with IL-7 decreased cell-surface expression of CD127 on 
CD4+ 183 and memory CD8+ T cells within 24-48 hours of culture 184. Our results showed a 
total down-regulation of CD127 when memory T cells were cultured with IL-7 with also a 
slight down-regulation in the presence of IL-15. No decrease in the expression of CD127 
was detected in memory T cells co-cultured with the stromal cell line, strongly suggesting 
that the BM HS5 stromal cell line is not supporting memory T cell survival via the 
expression of IL-7 or IL-15. In addition, transwell experiments performed by Jessica 
Dysarz (Bachelor student at the DRFZ) and cultures of memory T cells with BM stromal 
supernatants performed by Kathrin Stilz (Master student at the DRFZ) demonstrated that 
direct cell-cell interaction between memory T cells and HS5 cells was essential to maintain 
cell survival. Further experiments will be needed to elucidate which surface molecules of 
stromal cells are important for maintaining the survival of memory T cells. Blocking 
experiments with antibodies as well as genetic manipulation of the stromal cells to inhibit 
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the expression of candidate molecules should be performed in order to assure their 
implication in BM memory T cell survival.  
Both cytokines and direct contact with stromal cells could not maintain 100% of memory   
T cell survival. In BM survival niches, all pro-survival signals may be integrated in order to 
maintain a constant population of memory T cells in a resting state. To test if cytokine and 
stromal signals could be integrated to maintain  100% of cells alive, I performed an 
experiment where BM memory T cells were co-cultured with HS5 cells and the cytokines. 
Our results showed that under these conditions, BM memory T cells were induced to 
proliferate (observed by cell blasting and increase on cell numbers at day 5), taking out the 
memory T cells from their resting state. The human HS5 BM stromal cell line shows high 
expression of the IL-7 receptor in its surface, so it is possible that the interaction of the 
cytokines with the stromal cells could cause changes on them, therefore inducing memory 
T cell proliferation. Until now, our in vitro system does not allow us to fully mimic the 
physiological conditions found in the BM niches, where memory T cells can be maintained 
for long-time periods in a resting state59. In order to obtain a more accurate system to 
mimic the in vivo BM environment, further experiments should be performed using 
autologous primary stromal cells. Since now, I was able to expand BM stromal cells in vitro 
for months and use them for some preliminary survival experiments, but there is a time-
delay until the stromal cells are expanded and ready to be used in experimental 
procedures, challenging the performance of such experiments using autologous stromal 
and memory T cells.  
In conclusion, our results show that IL-7, IL-15 and direct contact with stromal cells play a 
role on maintaining the survival of both, PB and BM memory T cells. The integration of 
both pro-survival mechanisms as well as additional ones triggered by factors yet unknown 
must be needed for the fully maintenance of resting long-term memory. The investigation 
of the closest neighbors in situ of the different populations of memory T cells in the specific 
BM stromal niches is needed to fully understand all the players involved in the 
maintenance of BM memory T cells. 
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4.1.4 Molecular mechanisms involved in the survival of memory T cells 
So far, evidence suggests that multiple molecular signals derived from different cellular 
sources are needed to maintain memory T cell survival in the BM niche. However, it is not 
known how these signals are integrated to ensure memory T cell survival. IL-7 and IL-15 
activate the JAK-STAT pathway which induces expression of anti-apoptotic BCL-2 family 
members, including BCL-2 and MCL-1180,222.  
Direct contact with stromal cells through a combination of adhesion molecules have also 
shown to be important for the persistence of some memory cell types in the BM. For 
instance, direct cell-cell interaction via VLA-4/VCAM-1 has been shown to be required for 
the survival of plasma cells in BM niches 223. Signaling through VLA-4 results in the 
activation of the PI3K/Akt pathway, which could also be implicated on the maintenance of 
memory T cells.  
To better understand which molecular signals are implicated in the maintenance of 
memory T cells, I analyzed the expression of anti-apoptotic (BCL-2 and MCL-1) and pro-
apoptotic (BIM and NOXA) molecules in in vitro cultured BM and PB memory T cells. Our 
results show a significant increase on BCL-2 expression in all memory T cell subsets 
cultured with IL-7 and IL-15, resulting in a pro-survival balance on the BCL-2/BIM ratios. 
Moreover, the fact IL-7 induced BCL-2 expression to a greater extent in CD4+ than in CD8+ 
memory T cells, whereas IL-15 induced BCL-2 more strongly in CD8+ memory T cells 
compared to their CD4+ counterpart. These results are in concordance with the results 
obtained in the survival assays, and suggest that IL-7 has a major role in CD4+ memory    
T cells survival whereas IL-15 is more important for the maintenance of CD8+ memory      
T cells. Both cytokines acted similarly in all BM and PB T cell subsets, indicating that both 
BM resident and circulating memory T cells can equally respond to these signals with up-
regulation of anti-apoptotic molecules. IL-7 and IL-15 induced only a non-significant 
increase in MCL-1 expression and had no influence on BIM and NOXA expression, 
indicating that they act primarily through the up-regulation of BCL-2. 
Direct contact with stromal cells significantly increased the MCL-1/NOXA ratios by down-
regulating NOXA expression in all PB and BM memory T cell subsets. NOXA has been 
related to the control of memory CD4+ T cell homeostasis 176, and its expression is directly 
regulated by the p53 tumor suppressor protein. p53 is negatively regulated by Akt, which 
enhances degradation of p53 in a MDM2-dependent manner, thereby inhibiting cell 
apoptosis224,225. Therefore, cell-cell contact of memory T cells with stromal cells via 
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integrins may lead to Akt activation and p53 suppression, resulting in the final NOXA 
down-regulation and survival. The fact that both BM and PB memory T cells down-regulate 
NOXA upon stromal cell contact suggests that both PB circulating and BM resident 
memory T cells have the capacity to interact with stromal cells and respond with enhanced 
survival. BM memory T cells could be constantly receiving these pro-survival signals, as 
they are in direct contact with VCAM-1+IL7+ stromal cells77.  
In conclusion, our results demonstrate that cytokines and direct cell-cell interaction with 
stromal cells promote cell survival via different but complementing mechanisms. Activation 
of γ-chain cytokine receptors signals through the JAK/STAT pathway, resulting in BCL-2 
up-regulation, and thereby increasing the BCL-2/BIM ratio. On the other hand, direct 
contact with stromal cells could activate the PI3K/AKT pathway, leading to NOXA down-
regulation, and a positive MCL-1/NOXA balance. The integration of both pro-survival 
signals thus results in the proper equilibrium of pro- and anti-apoptotic molecules, 
promoting memory T cell survival. Further experiments investigating the signaling 
pathways upstream of these molecules are needed to fully understand the molecular 
mechanisms required for the survival of memory T cells. Ablation of the different pro-
survival pathways with chemical inhibitors would provide with information about which are 
the most important survival pathways in memory T cells. Moreover, the identification of 
additional pro-survival molecules as well as the molecular pathways activated by these 
ones is of great importance to fully decipher the survival mechanisms of BM memory        
T cells. The integrated information of signals required as well as molecular mechanisms 
implicated in the survival of memory T cells will be very useful in order to see how these 
survival programs could be manipulated to increase or decrease T cell memory longevity 
and function. 
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4.2 Compartmentalization of PB circulating versus BM resident 
memory T cells 
4.2.1 BM CD69+ and BM CD69- CD4+ memory T cells maintain antigen 
specificities against long-term antigens 
Previous studies of our group analyzing antigen-specific memory T cells in human PB and 
BM paired samples demonstrated an enrichment of memory CD4+ T cells in BM compared 
to PB specific for systemic childhood antigens like measles, mumps or rubella, but also for 
other antigens like TT (recurring antigen) or CMV-pp65 (chronic antigen)59. In this study, I 
aimed to know whether these antigen specificities were maintained or not by both CD69+ 
and CD69- memory CD4+ T cells in the BM. Several studies have shown that TRM cells are 
heterogeneous regarding their CD69 expression 59,71,226. Studies focused on tissue 
resident CD8+ T cells using parabiotic mice demonstrated that CD8+ CD69- T cells were 
constantly recirculating, whereas tissue resident CD8+ CD69+ cells were non-
recirculating69,79. In contrast, Steinert and colleagues have provided evidence that both 
CD69+ and CD69- memory T cells are tissue resident 71. These observations raised the 
question whether enrichment of memory T cells reactive to particular antigens in the BM 
are the result of specific accumulation within the CD69+ cell subset or whether they are 
equally distributed between both cell CD69+ and CD69- memory T cells. The distribution of 
measles and TT-specific CD4+ memory T cells between the CD69+ and CD69- CD4+ 
memory T cell subsets was investigated in order to test it for both, a long-passed 
(measles) and a recurring (TT) antigen. Measles-specific memory T cells were equally 
distributed among the CD69+ and CD69- cells. TT-specific memory T cells were also 
present in both cell subsets, suggesting a similar array of antigen specificities in both 
CD69+ and CD69- memory CD4+ T cells.  
These results show that both BM memory T cell subsets are generated from the same 
immune responses, and suggest that in humans the CD69- BM memory CD4+ T cells are 
not recirculating. Despite the presumed capacity of BM CD69- memory T cells to re-
circulate (due to their lack of expression of CD69 and therefore expression of S1PR1), 
these cells seem to resemble to the BM CD69+ cell population and reside preferentially in 
the tissue, separated from the circulating pool. It is not clear whether the expression of 
CD69 distinguishes two distinct BM populations, or if BM memory T cells are able to up- 
and down-regulate the expression of CD69.  
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Finally, these findings also suggest that CD69+ and CD69- memory T cells are capable to 
provide systemic immunological protection, as they both maintain specificities for different 
antigens. In order to provide systemic immunity, CD69+ memory T cells should be able to 
down-regulate CD69 to leave the BM and enter blood circulation or to divide in the BM 
after antigen encounter generating a progeny of CD69- daughter cells which could be able 
to enter blood circulation and confer fast immune protection.  
 
4.2.2 Differences in TCRβ repertoire demonstrates compartmentalization of 
PB circulating and BM resident memory T cells 
While assessing antigen specificities provides a measure of how the TCR repertoire is 
distributed in different sites, TCR sequencing provides a direct measure of individual T cell 
clone distribution, expansion and diversity. The TCR repertoire reflects the multiplicity of   
T lymphocytes, which are able to recognize a multitude of different antigens through highly 
variable αβ heterodimeric surface receptors. It has been estimated that over 2.5 x 107 
unique TCRs are present in periphery 10,227. Applying deep sequencing approaches, it is 
possible to survey all possible TCR rearrangements228 and quantitatively assess the tissue 
compartmentalization of T cells. TCR analysis of TEM cell sorted from spleen and two 
peripheral lymph nodes from individual donors revealed that the majority of CD4+ TEM in 
lymphoid tissue Ire unique to each site, with only some overlap between sites, while CD8+ 
TEM in lymphoid tissue showed increased sharing of clonally expanded populations 
between sites102. TCR analyses from tissue samples from patients afflicted with different 
diseases also revealed distinct repertoires in circulation and in different tissues. For 
example, T cells infiltrating colorectal tumors contained a distinct, non-overlapping 
repertoire compared to T cells in the neighboring mucosal tissue229. Together, these data 
suggest specific recruitment and/or retention of clonally expanded populations in different 
tissues. To further corroborate that PB and BM memory T cells also represent different 
populations strictly compartmentalized in their respective tissue, I compared the CDR3 
TCRβ repertoire of PB and BM memory T cells by flow cytometric analysis and NGS.  
Flow cytometric analysis of 24 TCR V clones showed a highly diversified T cell repertoire 
in both PB and BM cell populations, containing all TCR V families analyzed. The 
composition of TCR V-chain families was very similar between CD69+ and CD69- BM cell 
subsets, further suggesting that both memory T cell subsets are closely related. On the 
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other hand, differences in enrichment of some clones were detected when comparing BM 
to PB memory CD4+ T cells, further suggesting that cells from different compartments (PB 
circulating and BM resident) are preferentially enriched for different specificities. This flow 
cytometric approach using antibodies against 24 V families identified in humans (which 
represent up to 70% of the whole Vβ families181) gives only a quick overview of the 
proportional TCR Vβ usage on a per-cell basis. However, this did not account for the 
plethora of individual clones within each family. NGS approaches allowed us to identify 
and quantitate each unique TCR clone in each sample. For this reason, I performed NGS 
of the TCR region and analyzed the individual CDR3 sequences of memory T cells from 
PB and BM.  
First of all, analysis of technical replicates from the same sample showed low overlap in 
CD4+ (~35%), but was high for CD8+ memory T cells (>90%). Previous studies had shown 
that that the TCRβ estimated diversity among CD4+ T cells is ~5 times greater than in 
CD8+ T cells 230. Therefore, the broad CDR3 TCRβ diversity present in all CD4+ memory   
T cell subsets and the limitations of the starting material (25000 sorted cells for each cell 
population) made it difficult to directly assess the complete repertoire. Based on 
simulations performed by Pawel Durek, I could estimate the overlap expected between 
technical replicates based on the Shannon Evenness Index (SEI) of the samples, which 
gives a direct measurement of the diversity found in each sample. Figure S6.1 from the 
appendices shows the relationship between the SEI and the percentage of overlap 
expected. CD4+ memory T cells presented a SEI of 0.96-0.98, which would correspond to 
an overlap of approximately 30%, whereas the overlap expected from memory CD8+         
T cells (with and SEI of 0.18-0.43) would be of ~90%. These results indicate that low 
overlaps found between technical replicates of CD4+ memory T cells was not due to lack of 
robustness and reproducibility on the library preparation and sequencing processes, but 
due to other technical limitations present in our study. The determination of the sample 
size needed to assess a representative amount of TCRβ sequences would be of great 
importance in order to perform detailed analysis of the differences between circulating and 
tissue resident memory T cell populations. 
Although it was difficult to know the exact numbers and frequencies of clonotypes shared 
between PB and BM memory T cells, I could make some conclusions using the available 
data. The analysis of similarities on the TCRβ repertoire between all samples showed no 
shared TCRβ chains between CD4+ and CD8+ memory T cells, as previously postulated230. 
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When comparing frequencies of clones shared between the different CD4+ memory T cell 
subsets I found low overlap between all three cell subsets (more than 70% of the 
sequences were unique for each cell subset). However, I found higher overlap of TCR 
clones between CD69+ and CD69- BM memory T cells not found in their PB counterparts, 
suggesting that CD69+ and CD69- memory T cells present in the BM come from same 
immune responses. On the other hand, CD8+ memory T cells showed 50-70% overlap 
between the different T cell subsets, showing a closer relation of BM resident and PB 
circulating T cells. In contrast to CD4+ memory T cells, I did not find major similarities 
between BM memory T cell subsets compared to their PB counterparts, suggesting that 
different specificities for CD8+ memory T cells are maintained in a similar way between PB 
and BM cell subsets. So far, I have data showing that BM and PB memory CD4+ T cell 
contain a different array of antigen specificities, with differences in frequencies and total 
numbers of antigen-specific memory T cells in both compartments59. However, the array of 
specificities of human PB and BM memory CD8+ T cells has not been determined so far, 
leaving opened the possibility that both PB circulating and BM resident memory CD8+       
T cells share the same array of antigen specificities. 
In order to perform a more specific analysis, I investigated the CDR3 TCRβ repertoire of 
TT-specific memory T cells isolated from PB and BM. Possibly due to repeated TT 
vaccinations throughout the adult life; TT-specific memory T cells are present in PB and 
BM, reason why I chose this antigen for our analysis. Results obtained showed low 
overlap (less than 25%) among TT-specific memory CD4+ T cells from PB and BM,  further 
indicating that PB and BM memory T cells are different populations separated and 
maintained in their respective compartment, with no or low interchange between them. 
Even when looking at cells specific to a same antigen, I could find differences in their 
TCRβ repertoire, suggesting that cells from the different compartments may react to 
different epitopes and may present differences in their affinity and potential response to 
the pathogens. Previous studies from our group showed higher frequencies and numbers 
of polyfunctional TT-specific memory T cells in the human BM compared to the PB 
counterparts59, which could be related to the differences found on the TCRβ repertoire. 
Moreover, it would be interesting to perform further experiments using different dilutions of 
the antigens in order to see whether differences in the TCRβ repertoire are also 
associated with higher affinity in any of the two tissue compartments. One possibility could 
be that clonotypes found in the BM are the ones generated during the first infection or 
vaccination, which would be first recruited to the tissue to remain there for long periods, 
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whereas the ones in circulation are more recent clones generated during later vaccinations 
or infections. That could explain the fact that I only find antigen-specific memory CD4+       
T cells against childhood antigens in the BM of elderly donors but not in blood circulation, 
because cells generated with the vaccine would be recruited and maintained in the BM 
and slowly disappear from the blood circulation38. 
Until now, TCRβ repertoire analysis of humans has mostly been performed using blood 
samples, other organs and tissues being mostly neglected. However, recent studies have 
shown that TRM cells seem to reside in their respective tissues without exchange with 
circulating cells, resulting in different pools of memory T cells stored in different parts of 
the human body. It would be interesting to determine the TCR repertoire in different 
tissues like BM, skin, gut, lungs, liver and also lymph nodes in order to cover the full TCR 
repertoire present in the human body and establish the differences between circulating 
and TRM cells. This analysis would allow to determining whether specific clonotypes are 
preferentially enriched in particular tissues. Moreover, functional analysis of TRM cells 
regarding their capacity to respond to different antigens compared with PB memory T cells 
would provide a better understanding of the significance of TRM cells and T cell responses 
before, during and after infection or vaccination 231. 
 
4.3 Mobilization of tissue resident memory CD4+ T cells to blood 
circulation after systemic immune re-challenge 
In humans, T cell responses (especially by memory CD4+ T cells) after boost vaccination 
are poorly understood. In this study, I performed a longitudinal analysis of MMR-reactive 
memory CD4+ T cell kinetics in donors in which pre-existing MMR-specific memory CD4+  
T cells was very reduced.  
Measles, mumps and rubella viruses, are a highly infectious RNA virus that infects 
humans through the respiratory tract, resulting in a systemic immune response in the host 
and long-life antiviral immunity187,188. However, the mechanism underlying the protective 
immunity is not fully understood. Besides humoral immunity, it is believed that strong T-cell 
responses are important for antiviral immunity39. Memory CD4+ T cells are pivotal in 
controlling humoral and cellular responses, therefore their longevity and response to 
vaccination are critical for the maintenance of protective immunity.  
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Previous work of our group and others have demonstrated that memory T cells are 
compartmentalized in tissues as TRM cells with regard to their distinct functional properties. 
For example, it has been shown in both mice and man that, BM is home to memory T cells 
that are non-proliferative and sessile, have globally down regulated gene expression, and 
maintain functional long-term systemic memory59,90,209. In humans, CD4+ memory T cells 
specific for viral childhood antigens, like measles, mumps or rubella have been found in 
the bone marrow of elderly, but not among circulating memory T cells59. These initial 
findings provoked the questions of whether and how TRM cells respond to antigenic re-
challenges. 
Recent studies have shown that TRM can respond rapidly to pathogen challenge at their 
local sites and mount local secondary immune reactions to provide faster protection at the 
site of infection 82,232. Moreover, even though TRM and TCM seem to be generated from 
common clonal progenitors, TRM cells of the skin mediated faster and more efficient 
responses after antigen re-challenge after intradermal immunization233. Most investigations 
performed on TRM cells are focused on responses to local antigens at the site of infections, 
without looking at the responses that those cells could generate in the periphery. In 
contrast to the role of TRM cells in other tissues -to provide local protection at sites of 
pathogen entry- BM memory T cells are thought to contribute to systemic memory59. 
However, the contribution of those cells to secondary immune response remains to be 
elucidated. 
Early (i.e. before day 7) secondary CD4+ cellular immune responses have never been 
investigated in detail before. I performed a study in which I analyzed the dynamics of 
antigen-reactive memory CD4+ T cells at early time-points after immunization (16h as the 
earliest). I started with the assumption that, even when there are not circulating antigen-
reactive memory T cells in blood; TRM cells, such as the ones present in the BM, could be 
rapidly recruited into blood circulation and contribute to the secondary immune response. 
For our study, I performed a screening of healthy volunteers in order to find those ones 
that had been in previous contact with at least one of the antigens (being positive for 
measles, mumps or rubella IgG-specific antibodies) but had low numbers of MMR-reactive 
memory CD4+ T cells in blood circulation (because they have been vaccinated more than 
30 years ago). From our screening of 24 healthy adults ranging from 24 to 43 years, I 
could only incorporate 11 suitable donors in our study. Moreover, due to strict regimens on 
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MMR vaccination in Germany, I could only find one donor which was naive for one of the 
antigens present in the vaccine.  
 
4.3.1 Rapid and transient mobilization of antigen-reactive memory CD4+ T 
cells after MMR systemic immune re-challenge 
Addressing MMR-reactive CD4+ T cells by stimulation assay and ICS revealed a typical 
anti-viral response 234, dominated by TH1 cells expressing mostly IFNγ and TNFα 235. After 
MMR vaccination, I found a rapid increase of MMR-reactive memory T cells in blood 
circulation, followed by a decrease at days 2-3 and a greater increase at days 7 and 14 
after immunization. The rapid increase of non-proliferating MMR-reactive memory CD4+    
T cells after vaccination (compared to the pre-existing circulating ones), suggest their 
mobilization from other tissues, such as the BM. In all cases analyzed, measles, mumps or 
rubella memory T cells were low in blood circulation before MMR vaccination, suggesting 
their preferential maintenance in other parts of the human body. The enrichment of 
measles, mumps and rubella (MMR)-specific memory CD4+ T cells in the BM 59 leads us to 
the assumption that the mobilized cells appearing in the blood circulation may have their 
origins from the quiescent pool previously found in BM. However, so far no other tissues 
have been analyzed for the presence of memory CD4+ T cells holding these specificities, 
so it is not possible to assure that the cells are uniquely coming from this tissue.  
Interestingly, early appearing antigen-reactive memory T cells were mostly polyfunctional, 
expressing 2 or 3 cytokines at the same time. Previous studies from our group had shown 
that BM memory CD4+ T cells are mainly polyfunctional, further suggesting that mobilized 
cells may come from this tissue59. Polyfunctionality is proposed to be associated with 
protective immunity against various pathogens 189–191, producing more cytokine per cell 
compared to the single-producing ones and showing higher expression of CD154, which 
provides a better co-stimulation to CD8+ T and B cells60. Therefore, mobilized CD4+ 
memory T cells show high protective potential. 
Moreover, early mobilized CD4+ memory T cells show a TRM/ TEM phenotype, with 
decreased expression of CCR7 on their surface. Non-lymphoid TEM cells have more robust 
IFNγ production than TCM cells, providing a mechanism to rapidly respond to re-infections. 
Similarly, CD4+ T cells that express CCR7 produce high amounts of IL-2 but low levels of 
other effector cytokines236. This effector memory phenotype goes along with the kinetics of 
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cytokine-producing memory T cells, suggesting that after vaccination, there is a transient 
mobilization of antigen-specific memory CD4+ T cells resembling TRM/TEM phenotype, 
which are able to produce high amounts of effector-cytokines.  
More importantly, early mobilized MMR-reactive memory CD4+ T cells show no signs of 
proliferation, indicating that the increase of antigen-reactive memory CD4+ T cells in blood 
after MMR vaccination is not due to proliferation of pre-existing memory T cells, but 
because of the mobilization of those cells from their site of residence. In support to our 
findings, a study analyzing the antigen responsiveness of naive and memory T cells using 
traceable TCR-transgenic T cells showed that memory T cells are quicker to respond but 
divide slow like naive cells. Both naive and memory T cells showed an approximate time 
delay of 3 days after infection, before they initiate cell division237. Altogether, these results 
indicate that antigen-reactive CD4+ T cells can be reactivated in the tissue238 and 
mobilized into the blood, from where they could migrate to secondary lymphoid organs or 
inflamed tissues. 
After the early peak, the numbers of antigen-reactive memory CD4+ T cells in blood 
circulation declined in the following 24-48 h, suggesting they may be already heading to 
the site of inflammation or to the secondary lymphoid organs. 7 and 14 days after 
vaccination, the frequencies and numbers of antigen-reactive memory CD4+ T cells 
increased again in blood, probably reflecting the termination of the immune reaction and 
the egress of previously mobilized and newly formed memory T cells into the blood. This 
later influx of antigen-reactive CD4+ T cells may be a mixture of pre-existing and newly 
generated effector memory CD4+ T cells as a consequence of vaccination. As shown 
before for the early mobilized cells, late appearing antigen-reactive memory CD4+ T cells 
are also mainly polyfunctional, suggesting their high protective potential, and show an 
effector memory phenotype. In contrast, the later accumulation of antigen-reactive memory 
CD4+ T cells contains a high percentage of Ki-67+ cells, suggesting they have undergone 
clonal expansion. Newly recruited cells might contribute to the heterogeneity and survival 
of the memory T cell pool. Ultimately, those memory T cells generated as a result of the 
MMR vaccination would remain in blood circulation for some time 239, but also relocate 
again in the BM, as evident from the previous analysis performed in elderly donors 59.  
In contrast to the cellular kinetics of a secondary immune response observed in 
experienced donors, the analysis of a measles-naive donor showed a complete different 
scenario. No antigen-reactive memory T cells were detectable until day 14 after 
DISCUSSION 
 
 
111 
vaccination, when both cytokine-producing and Ki-67+ antigen-reactive CD4+ T cells 
appeared in the bloodstream. In addition, antigen-reactive cells appearing at day 14 were 
mostly single-producers (~70%), which goes in line with reduced protective capacity of 
newly generated antigen-reactive T cells240. Interestingly, the measles-naive donor´s 
responses to mumps and rubella after MMR vaccination followed typical secondary 
immune responses, demonstrating a singular and specific immune response to each of the 
antigens present in the triple vaccine. The analysis of a primary response to the MMR 
vaccine provided us with information about the specificity of the system, but further naive 
subjects should be studied in order to verify the obtained results. 
Altogether, results obtained from this analysis show that TRM cells can be reactivated in the 
tissue238 and mobilized into the blood, from where they could migrate to secondary 
lymphoid organs or inflamed tissues. Mobilized cells have high protective potential, mainly 
expressing 2 or 3 of the analyzed cytokines, and may contribute to create an effective 
response to the infectious agents. It is thought, that recall immune responses are mainly 
mediated by TCM cells that patrol the T cell areas of secondary lymphoid organs where they 
can rapidly proliferate in response to antigens presented by dendritic cells (DC) 240. 
However, here I show that TRM cells mobilized from tissues can also mediate rapid and 
enhanced secondary immune responses.  
 
4.3.2 Significant fraction of early mobilized antigen-reactive memory CD4+ T 
cells present a TRM/TEM phenotype, with high expression of CD127 
In order to better characterize the mobilized antigen-reactive memory T cells, I determined 
the expression of several cell lineage markers in antigen-reactive memory CD4+ T cells.  
The expression of CD137, CXCR5 and PD-1 expression on antigen-specific memory CD4+ 
T cells showed no hint of mobilization of regulatory or follicular T cells. In concordance with 
the analysis of expression of CCR7 and cytokines in antigen-reactive memory CD4+          
T cells, mobilized cells show mainly a TRM/TEM phenotype, suggesting mainly cells with 
effector functions are mobilized in response to the antigen re-challenge.  
Moreover, I determined the expression of the IL-7Rα (CD127) in antigen-reactive memory 
CD4+ T cells. High expression of the IL-7α receptor (CD127) and the anti-apoptotic BCL-2 
have been associated to enhanced survival capacities, and tend to decrease in recently 
generated effector CD4+ T cells 198. In our case, I found that early appearing MMR-specific 
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memory CD4+ T cells maintained high levels of CD127 expression, whereas there was a 
reduction on the expression at days 7 and 14 after MMR vaccination. This data suggests 
that early appearing antigen-reactive memory CD4+ T cells are most likely pre-existing 
memory T cells mobilized from their tissue of residence, and that they maintain high 
survival capacities. However, a fraction of antigen-reactive cells appearing at later time-
points (days 7 and 14) would be generated as a result of activation and generation of new 
effector cells, thus having decreased expression of CD127.  
Finally, in order analyze whether MMR-specific memory CD4+ T cells were mobilized from 
the site of vaccine injection, I analyzed the expression of the skin homing marker CLA in 
the antigen-reactive cells. MMR-vaccination is administered subcutaneously, so it could be 
possible that after immunization, a pool of memory T cells are maintained as skin resident 
memory T cells at the site of injection. Those cells could then be the ones mobilized into 
blood circulation. I did not observe any drastic increase in CLA expression on antigen-
reactive memory CD4+ T cells, suggesting they are not mobilized from there. However, I 
only had the chance to perform this analysis in one subject, so further analysis should be 
done in order to verify this initial finding. 
It remains to be clarified where early mobilized antigen-reactive memory CD4+ T cells 
come from and where they are heading after they are firstly mobilized to the bloodstream. 
The lack of markers to identify BM memory T cells makes it impossible to determine from 
where they are coming from and where are they going. In order to address this question, a 
defined phenotype of TRM cells from each tissue would be needed. However, TRM cells 
could change their phenotype during the egress into the bloodstream, so it would be 
required to define those cells based in more stable characteristics like their DNA 
methylation status.  
 
4.3.3 Bystander mobilization of TT-specific memory CD4+ T cells in 
response to MMR vaccination 
Human studies analyzing the dynamics of memory T cell responses to TT booster 
vaccination have observed that the expected expansion of TT-specific memory T cells was 
accompanied by an increase of memory T cells specific for two unrelated and not cross-
reactive antigens: purified protein derivative from tuberculin (PPD) and Candida albicans, 
with similar kinetics to the specific response199. These bystander responses could result 
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from TCR-independent activation, most likely cytokine-mediated, occurring in a shared 
microenvironment during the vaccine-specific secondary immune response. In these 
studies, the CD4+ memory T cell response was analyzed at later time after boost (1-2 
weeks after vaccination) and followed until 16 weeks after. In this case, I was mainly 
interested in knowing whether early bystander mobilization also occurs as a result of MMR 
vaccination. Similar to the results obtained looking at the later response; I could also 
detect an early bystander mobilization of unrelated antigen-specific memory T cells in the 
blood, with similar kinetics to the ones observed in MMR-specific responses. Bystander 
mobilized TT-reactive memory CD4+ T were also polyfunctional in terms of cytokine 
secretion, mainly producing TNFα and IL-2. In terms of immune protection, the ability of 
the mobilized bystander population to secrete pro-inflammatory cytokines at the site of 
infection would enhance the effectiveness of the specific response. 
In order to clarify the nature of the bystander activated cells and the mechanisms driving 
their increase in peripheral blood, I addressed their phenotypic and functional features, 
comparing them with those of MMR-specific memory CD4+ T cells. Previous studies have 
shown that vaccine-specific and bystander activated memory CD4+ T cells differ in their 
proliferative status, as well as their expression of markers such as CCR7 and CD127 1-2 
weeks after boost vaccination200. In our analysis, I wanted to study whether I could confirm 
these differences by looking at the MMR vaccine response, phenotypically characterizing 
vaccine-reactive and bystander mobilized memory CD4+ T cells. Analysis of MMR-reactive 
memory T cells at days 7 and 14 after MMR vaccination showed similar results to the ones 
obtained in the TT vaccination study, mainly presenting an effector memory phenotype 
(CCR7-), decreased CD127 expression and proliferating status (Ki-67+). Bystander 
mobilized memory CD4+ T cells maintained the frequencies of TCM phenotype compared to 
before vaccination (40-50%), retained high expression of CD127 (80-90%) and were not 
proliferating, suggesting they are not recently activated effector cells, but they seem to 
derive from a central memory compartment200. Looking at the early mobilized cells (16 h 
and day 1), I did not detect any significant differences between vaccine-specific and 
bystander mobilized memory CD4+ T cells. Both of them were non-proliferating cells with 
high expression of CD127. I could only detect an increase on the TRM/TEM memory T cell 
phenotype among MMR-reactive memory CD4+ T cells, which was not observed among 
bystander-mobilized TT-specific memory CD4+ T cells. Altogether, these results suggest 
that vaccination results in early mobilization and migration into the bloodstream of both, 
vaccine-specific and unrelated memory CD4+ T cells. The contribution of the bystander 
DISCUSSION 
 
 
114 
mobilized cells to the secondary immune response, as well as the reason for it remains to 
be elucidated.  
 
4.3.4 MMR vaccine induces specific cellular and humoral responses 
To verify whether early mobilized antigen-reactive memory CD4+ T cells were specific for 
the vaccine antigens or cross-reactive to other antigens (present or not present in the 
vaccine), I isolated measles- and TT-specific CD4+CD54RA-CD154+CD69+ at day 1 after 
MMR vaccination, expanded them for 14 days 202 and re-stimulated them with vaccine-
related and –unrelated antigens. Measles-reactive expanded cells reacted only to re-
stimulation with measles antigen by up-regulating CD154 and producing several cytokines. 
Interestingly, cytokine producing cells maintained their polyfunctional capacities, with 
higher expression of IFNγ and TNFα. On the other hand, TT-specific memory CD4+ T cells 
responded to TT re-stimulation but also reacted to other antigens such as measles or 
CMV, suggesting they were cross-reactive to other antigens.  
Moreover, I followed the kinetics of the humoral immune response by analyzing the levels 
of IgG and IgM-specific antibodies. In all donors and specificities analyzed, I found an 
increase on IgG-specific antibodies at day 14 after vaccination, with no changes on the 
IgM levels. This response is the typical for a secondary immune response and shows a 
clear relation between the T and B cell immune responses. The maintenance of the levels 
of TT-specific neutralizing IgG antibodies during the time of the study, demonstrated that 
the antibody response generated by the MMR vaccination is specific for the vaccine 
antigens. While bystander CD4+ memory T cells can secrete cytokines, and could 
potentially influence B cells, no increase in bystander antibody was evident in any of the 
vaccinees. These results suggest that antibody responses could be only generated in the 
presence of the antigen, and that in contrast to memory CD4+ T cells, there is no 
bystander activation of B cells. 
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4.3.5 Mobilization of CD4+ TRM cells provides new functional TCR CDR3 
clonotypes, which contribute to the immune response 
The lack of proper cell surface markers identifying cells from a given compartment makes 
it very difficult to identify from where are mobilized antigen-reactive CD4+ memory T cells. 
As the TCR is a unique identifier for specific T cell clones, I tracked specific T cells by their 
CDR3 TCRβ sequences. The TCR formation is not submitted to somatic hypermutation, so 
after the recombination process a unique CDR3 sequence is created and transmitted to 
the progeny through all its lifetime. Taking into account this information and previous 
results showing that different tissue compartments (PB and BM) show different TCR family 
repertoires in a global view and also at the level of antigen-specific CD4+ memory T cells, I 
aimed to determine whether the early mobilized antigen-reactive memory T cells contained 
different CDR3 TCRβ clonotypes compared to the ones present in blood circulation before 
vaccination. Moreover; I aimed to know whether the newly appearing clonotypes as a 
result of vaccination would contribute to the immune response by being also present in 
blood at day 14 after immunization. 
In our experiment, I used RNA rather than DNA since it allows straightforward introduction 
of Unique Molecular Identifiers (UMI), and also because it detects only the functional TCR 
molecules that are transcribed in memory CD4+ T cells. Moreover, the use of RNA 
increases the likely coverage of the repertoire, since each cell can contain several 
molecules of messenger RNA. Even though this method is potentially sensitive to changes 
in RNA content associated with T cell activation and differentiation, several studies have 
demonstrated that such changes are small and transitory, and are unlikely to have a major 
impact in the repertoire241,242. Therefore, I could discard this bias of differential RNA 
expression upon activation via MMR vaccination. 
MMR vaccination resulted in an influx of new clonal diversities, shown by the increase of 
the number of different clonotypes found among the same number of analyzed cells (2500 
measles-reactive memory CD4+ T cells). I aimed to know whether newly appearing CDR3 
clonotypes at day 1 (not present in blood before MMR vaccination), further contributed to 
the immune response by being also present at day 14. Performing this analysis in 2 
different donnors, I detected 6 and 5 abundant clonotypes respectively, which appeared at 
day 1 after vaccination and were still present at day 14. Of these, 3 clonotypes were 
expanded at day 14, whereas the rest were maintained at similar frequencies. On the 
other hand, none of the clones present before and at days 1 and 14 after vaccination were 
DISCUSSION 
 
 
116 
expanded at day 14 compared with day 0 and 1. This data suggests that TRM CD4+ cells 
rapidly mobilized after MMR vaccination play a role in the generation of the secondary 
immune response, even to a greater extent than pre-existing memory CD4+ T cells in 
circulation.  
In order to determine whether the newly appearing cells are coming from the BM, it would 
be really informative to have sequences from the TCRβ clonotypes present in the antigen-
specific memory CD4+ T cells from paired PB and BM prior to vaccination. However, 
patients undergoing hip replacement operations (source of our samples) are mainly elderly 
donors, so it would be not permitted to perform the MMR vaccination after the operation. 
Moreover, I do not know if other tissues share the same clonotype diversity than the one 
found in the BM, so it would not be possible to confirm that cells are coming from the BM. 
 
4.4 Concluding remarks 
For a long time, maintenance of long-term T cell memory has been a matter of extensive 
investigations and debate. After demonstrating that the human BM hosts long-lived 
memory T cells capable of providing systemic immunological protection, and resting in 
terms of activation, transcription and proliferation59, a central question has been whether 
circulating and BM resident memory T cells differ in their maintenance, 
compartmentalization and function.  
BM memory T cells are maintained in specific survival niches, where they are subjected to 
the tissue conditions and receiving signals needed for their long-term maintenance. In 
contrast, memory T cells present in blood are in constant circulation through blood, 
secondary lymphoid organs and tissues, fact that makes them more likely to adapt to 
different environmental conditions. Maintenance of BM memory T cells in a resting state 
would result in the requirement of fewer resources compared to the long-term 
maintenance of actively circulating memory T cells, and may be a mechanism of the 
human body to sustain a huge array of antigen specificities, even when the antigen is long 
past. Cytokines such as IL-7 and IL-15 as well as direct contact with stromal cells are 
required for memory T cells to be sustained in a resting state in the BM, while retaining 
their capacities to respond to reactivation signals an confer us with protection after 
systemic immune re-challenges. After systemic immune re-challenges with long-past 
antigens, such as MMR, BM memory CD4+ T cells have the capacity to respond and be 
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mobilized into blood circulation in order to contribute to the generation of a highly 
protective secondary immune response  
The knowledge obtained from this doctoral thesis provide a better understanding of the 
maintenance and function of immunological memory in humans, and could be used for the 
development of new vaccines and immunotherapies. Induction of a more prominent 
population of BM memory T cells could be an advantage for the prolonged maintenance of 
highly protective systemic memory. The enhancement of protective memory as well as 
depletion of pathological memory could be achieved by knowing the mechanisms involved 
in memory T cell survival.  
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6 Appendices 
 
 
Table 6-1: TCRβ repertoire usage of PB, BM CD69- and BM CD69+ CD4+ (A) and CD8+ (B) memory T 
cells. Data presented as mean, standard deviation (SD), minimum and maximum values of each TCR Vβ 
family (n=8). 
 
 
 
memory CD4
+
 CD69
+
 BM
mean (%) SD min (%) max (%) mean (%) SD min (%) max (%) mean (%) SD min (%) max (%)
V 2.923 0.494 2.370 3.810 3.205 0.879 2.160 5.140 3.414 1.161 1.720 5.410
V 8.461 1.543 6.000 10.200 8.174 1.212 6.600 9.510 7.865 1.416 4.870 9.540
V 4.274 2.637 1.050 8.030 4.033 2.404 1.330 7.320 4.008 2.470 1.050 7.340
V 2.448 0.744 1.390 3.690 2.579 0.505 2.080 3.380 2.624 0.747 2.010 4.350
V 5.404 2.419 1.690 9.970 5.063 2.583 1.290 9.980 8.206 7.847 1.020 26.200
V 0.738 0.419 0.251 1.500 0.869 0.679 0.302 2.380 0.844 0.459 0.340 1.880
V 0.950 0.875 0.314 3.060 1.158 1.137 0.286 3.860 1.113 1.033 0.498 3.640
V 1.530 0.893 0.301 3.270 1.376 0.896 0.250 3.280 1.755 0.834 1.040 3.470
V 1.983 1.654 0.870 5.520 1.725 1.812 0.589 5.740 1.884 2.224 0.540 6.830
V 7.119 5.204 2.790 19.300 5.889 4.188 2.920 14.500 8.848 12.100 2.450 38.500
V 2.530 1.805 0.922 6.680 2.455 1.774 1.070 6.680 1.684 0.779 0.565 3.070
V 0.932 1.192 0.220 3.820 1.037 1.233 0.160 3.930 0.779 0.613 0.274 2.220
V 2.426 1.721 1.280 5.680 1.990 1.319 0.946 5.150 1.445 0.490 0.834 1.990
V 2.993 1.931 1.180 7.120 3.456 2.601 1.990 9.780 3.076 2.198 1.310 8.350
V 2.011 0.740 0.730 3.100 1.779 0.714 0.460 2.740 2.085 0.966 0.720 3.680
V 1.843 0.694 1.140 3.290 1.651 0.536 1.020 2.330 1.667 0.733 0.840 3.120
V 2.596 1.476 1.030 5.840 2.496 1.320 0.940 5.260 2.193 1.309 0.720 4.640
V 1.211 0.656 0.760 2.780 1.073 0.763 0.560 2.920 1.181 0.868 0.580 3.270
V 5.178 1.136 3.450 6.750 4.940 1.243 3.220 6.650 4.628 1.189 2.760 6.490
V 1.180 0.587 0.282 2.310 1.385 0.880 0.480 3.000 0.907 0.431 0.162 1.700
V 2.378 0.863 1.150 3.690 2.651 1.639 0.869 4.920 2.106 1.045 0.705 3.660
V 2.463 1.548 1.190 5.890 2.658 2.628 0.570 8.600 1.293 0.652 0.421 2.310
V 3.301 0.553 2.250 3.920 3.328 0.909 2.310 4.840 3.266 0.827 1.930 4.100
V 0.381 0.239 0.102 0.820 0.394 0.255 0.156 0.940 0.404 0.187 0.193 0.656
memory CD4
+
 CD69
-
 BM memory CD4
+
 CD69
-
 PB
mean (%) SD min (%) max (%) mean (%) SD min (%) max (%) mean (%) SD min (%) max (%)
V 3.444 1.559 1.280 5.790 3.376 0.655 2.430 4.130 4.153 1.516 2.400 7.550
V 8.916 8.811 1.910 29.100 6.395 4.412 1.300 16.000 6.936 5.762 1.430 18.600
V 4.103 4.735 0.123 14.900 4.279 3.391 0.560 10.600 3.899 3.198 0.203 9.770
V 1.873 1.053 0.720 3.660 2.071 1.089 0.390 3.780 3.069 1.319 1.000 5.030
V 3.429 3.585 0.341 11.400 2.818 1.696 0.566 5.420 3.761 3.472 0.247 10.600
V 0.639 0.728 0.069 2.340 0.875 0.825 0.349 2.820 0.747 0.705 0.150 2.400
V 1.410 1.108 0.174 3.380 1.494 1.914 0.246 6.070 1.459 1.785 0.087 5.380
V 1.497 0.779 0.747 3.270 2.211 0.524 1.370 2.770 2.335 0.780 1.500 4.040
V 2.067 0.801 1.370 3.830 2.216 1.339 0.940 4.700 3.075 4.534 0.790 13.300
V 3.284 4.527 0.680 14.300 4.910 5.346 1.550 17.700 10.820 20.710 1.440 61.800
V 1.176 0.636 0.259 2.230 1.300 0.588 0.386 2.270 0.779 0.421 0.253 1.370
V 0.775 1.248 0.124 3.790 1.141 1.552 0.177 4.760 0.933 1.260 0.186 3.890
V 1.395 1.394 0.526 4.670 2.007 1.695 0.930 6.030 1.987 1.961 0.561 6.600
V 4.055 3.796 0.668 11.600 2.903 1.899 0.677 5.910 3.018 2.289 0.450 7.620
V 2.620 2.010 0.604 5.150 3.098 2.677 0.785 8.090 4.160 5.196 0.670 13.500
V 3.295 5.378 0.460 16.300 2.655 2.680 0.830 8.690 1.838 1.799 0.613 6.050
V 6.019 6.537 1.410 21.600 5.258 2.474 1.780 8.970 5.405 2.417 2.080 9.060
V 1.313 0.582 0.435 1.980 1.329 0.530 0.580 2.270 0.850 0.280 0.490 1.330
V 4.715 3.343 0.970 11.400 4.303 1.936 2.590 8.520 4.459 2.246 2.790 9.720
V 0.868 1.442 0.077 4.070 0.605 0.739 0.017 2.010 0.553 0.547 0.098 1.720
V 1.066 0.428 0.649 2.000 1.897 0.770 0.868 3.170 1.783 1.727 0.675 5.860
V 1.651 1.083 0.671 3.610 1.615 0.643 0.767 2.510 1.137 0.511 0.351 1.950
V 1.846 1.238 0.791 4.760 2.738 0.906 1.280 3.900 3.435 1.920 1.190 6.080
V 3.136 4.193 0.062 11.000 1.960 1.848 0.223 5.500 1.298 0.704 0.320 2.560
memory CD8
+
 CD69
+
 BM memory CD8
+
 CD69
-
 BM memory CD8
+
 CD69
-
 PBB 
A 
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Sample N°cells Replicates UMI counts Clonotypes SEI 
  A B A B A B A B 
CD4
+
CD45RA
-
CD69
-
_PB 25000 ½ RNA ½ RNA 5692 5396 4035 3911 0.9820 0.9834 
CD4
+
CD45RA
-
CD69
-
_BM 25000 ½ RNA ½ RNA 2166 1830 1094 913 0.9604 0.9571 
CD4
+
CD45RA
-
CD69
+
_BM 25000 ½ RNA ½ RNA 8017 4080 5293 2955 0.9789 0.9794 
CD8
+
CD45RA
-
CD69
-
_PB 25000 ½ RNA ½ RNA 11644 12605 725 851 0.4093 0.4371 
CD8
+
CD45RA
-
CD69
-
_BM 25000 ½ RNA ½ RNA 28887 31851 500 514 0.1874 0.2313 
CD8
+
CD45RA
-
CD69
+
_BM 25000 ½ RNA ½ RNA 18307 16287 1070 988 0.3672 0.3608 
 
Table 6-2: Number of cells sorted, UMI counts, clonotypes found and SEI among samples from 
which technical replicates were performed. Raw data is shown for both technical replicates of each 
sample analyzed. 
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Figure 6-1: Simulations of the relationship between diversity and overlap between technical 
replicates. (A) Representation of the clonal distribution of the top 100 clones regarding the Shanon 
Eveness Index (SEI). Each line represents an established SEI, resulting in different clonal distributions. (B) 
Relationship between SEI and percentages of overlap expected between samples.  
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Figure 6-2: Clonal space shared between memory T cell subsets from PB and BM samples of additional 
donors. Sequencing libraries were performed as mentioned before. CDR3 sequences obtained from replicates 
were pooled (in cases were replicates were performed) and down-sampled in order to compare the same amount of 
sequences. Frequencies of the clonal space shared between different memory T cell subsets are represented as 
circular graphs (A) Frequencies of overlap between memory CD4+ T cell subsets from PB and BM samples,
regarding CD69 expression (n=3) (B) Frequencies of overlap between memory CD8+ T cell subsets from PB and 
BM samples, regarding CD69 expression (n=3). (C) Frequencies of overlap between TT-specific memory CD4+ T 
cell subsets from PB and BM samples (n=2). 
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Donor Gender Age First Ag. encounter Analysis 
MMR2 Female 34 MMR vaccination Cellular analysis 
MMR3 Female 32 MMR vaccination Cellular analysis 
MMR4 Female 29 Naïve measles  Cellular analysis 
MMR5 Female 26 MMR vaccination Cellular analysis 
MMR7 Male 42 Natural infection Cellular analysis 
MMR8 Male 31 MMR vaccination Cellular analysis 
MMR10 Male 37 MMR vaccination TCRβ sequencing 
MMR11 Female 34 MMR vaccination TCRβ sequencing 
 
Table 6-3: Information of healthy volunteers re-vaccinated with the MMR vaccine. Gender, age, first 
antigen encounter and analysis performed is depicted in the table 
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Figure 6-3: (A) Gating strategy used for analyzing antigen-reactive memory CD4+ T cells. (B) Technical 
replication of antigen-reactive memory CD4+ T cells. PBMCs were separated in 3 different wells and stimulated 
in vitro with measles and anti-CD28 for 7 h, adding Brefeldin A for the last two hours of stimulation. After in vitro 
antigen stimulation and ICS, we analyzed the expression of CD154, IFNγ, TNFα and IL-2 in all 3 replicates in order 
to establish limit of detection and the variance between measurements. 
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Figure 6-4. Phenotypic analysis of antigen-reactive CD4+CD45RA-CD154+ T cells. Using ex vivo stimulation 
with the indicated antigens we performed a phenotypic analysis of CD154+ memory CD4+ T cells present in blood 
circulation. CD127, CLA, CD137, CXCR5 and PD-1 expression was analyzed by surface staining in antigen-
memory CD4+ T cells. Representative dot plots of marker expression in a representative donor at different time-
points are shown.  
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Sample N°cells Replicates UMI counts Clonotypes Efron Thisted 
  A B A B A B A B 
MMR10 d0 2500 ½ RNA ½ RNA 175 269 106 150 265 393 
MMR10 d1 2500 ½ RNA ½ RNA 638 523 360 282 1034 815 
MMR10 d14 2500 ½ RNA ½ RNA 783 763 395 393 1096 1350 
MMR11 d0 2500 ½ RNA ½ RNA 376 399 302 314 976 967 
MMR11 d1 2500 ½ RNA ½ RNA 773 835 558 602 1688 1902 
MMR11 d14 2500 ½ RNA ½ RNA 404 463 306 343 893 958 
 
Table 6-4: Number of cells sorted, UMI counts, clonotypes found and Efron Thisted index among 
MMR samples sequenced. Raw data is shown for both technical replicates of each sample analyzed.
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Abbreviations and acronyms 
Abbreviation / Acronym Definition 
A405... A647 Alexa Fluor™ 405... 647 
Ab serum Human male Ab serum 
ANNV Annexin V 
APC Allophycocyanin 
BCL-2  B Cell Lymphoma 2 
BIM  BCL-2-like protein 11 
BM Bone marrow 
BMMCs Bone marrow mononuclear cells 
BSA Bovine Serum Albumin 
BV Brilliant Violet 
CCR CC chemokine receptor 
CD Cluster of differentiation 
CFSE Caroxyfluorescein Succinimidyl Ester 
CM Central memory 
CMV Cytomegalovirus 
Cy Cyanine 
DAPI 4',6-Diamidino-2-phenylindole 
DC Dendritic cell 
DNA Deoxyribonucleic Acid 
EDTA Ethylenediaminetetraacetic acid 
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eF670 Cell Proliferation Dye eFluor 670 
EL Erytrocyte Lysis 
ELISA Enzyme-Linked ImmunoSorbent Assay 
EM Effector memory 
FACS Fluorescence-activated cell sorting 
FCS Fetal calf serum 
FITC Fluoresceine isothiocyanate 
HEPES Hidroxyethylpiperazinoethanesulfonate 
h hour 
ICS Intracellular cytokine staining 
IFN Interferon 
Ig Immunoglobulin 
IL Interleukin 
LN Lymph node 
MACS Magnetic cell sorting 
MCL-1 Myeloid cell leukemia sequence 1 
MFI mean fluorescence intensity 
MMR Measles, mumps and rubella 
N naïve 
NK cells Natural killer cells 
NOXA  NADPH oxidase activator 1 
PacB Pacific Blue™ 
PB Peripheral blood 
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PBMCs Peripheral blood mononuclear cells 
PBS Phosphate Buffered Saline 
PBE PBS/BSA/EDTA 
PCR Polymerase Chain Reaction 
PE Phycoerythrine 
Pen/Strep 100 U/ml penicillin, 100 μg/ml streptomycin 
PerCP Peridinin chlorophyll complex 
PI Propidium Iodide 
PO Pacific Orange 
pp65 Human cytomegalovirus phosphoprotein 65 
RNA Ribonucleic Acid 
RPMI Roswell Park Memorial Institute 
RT Room Temperature 
SEB Staphylococcus enterotoxin B 
TCR T cell receptor 
Tfh T folicular helper cells 
TGFβ Tumour growth factor beta 
TE Trypsin + EDTA 
TNFα Tumor necrosis factor alpha 
Treg T regulatory cells 
TT Tetanus Toxoid 
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